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INTRODUCTION
The diffuse endocrine system is composed of neuroendocrine cells dispersed throughout the 
whole body [1]. These cells, which may be found in isolation or in small aggregates, can give 
rise to neuroendocrine tumors (NETs) [1, 2]. NETs represent a heterogeneous group of rare, 
slow-growing neoplasms [3, 4], and comprise 1-2% of all gastrointestinal and pulmonary 
malignancies [5, 6].
According to the last National Cancer Institute’s Surveillance, Epidemiology, and End 
Results (SEER), the incidence of NETs has increased substantially (1.09/100,000 persons in 
1973 to 6.98/100,000 in 2012) [7]. It is not known whether this is a true increase in NET 
incidence, the result of increased use of (improved) diagnostic procedures, or a combination 
of both [4, 8]. According to the SEER database, 27.4% of NETs have distant metastasis at 
diagnosis and 20% have regional infiltration [7]. Other series describe increased metastasis 
rates (localized and distant metastasis) when NETs are diagnosed (60–80%) [9]. Five to ten 
percent of metastasized tumors have an unknown primary tumor [10]. Despite the increase 
in incidence, survival in NET patients has improved, especially for patients with advanced 
gastroenteropancreatic- (GEP-) NETs [7].
This group of neoplasms displays a wide range of biological behavior ranging from benign 
to highly malignant growth [11]. In NETs, the overall 5-year survival rate ranges between 
57-65% [12, 13], but depends on several parameters including the localization of the pri-
mary tumor (75.0% for jejunoileal, 42.9% for pancreatic NETs), the presence of metastasis 
(51.7% in presence vs 80% in absence of metastasis at initial diagnosis), tumor size, grade 
and stage of disease [12, 14].
1. Clinical features
NETs may produce specific clinical syndromes due to overproduction of hormones and 
bioactive peptides. The incidence of functioning NETs ranges from 0.01-8.4 cases per 
100,000 habitants per year, depending on the secreted hormone. Carcinoid syndrome (CS) 
is the most frequent hormone-related syndrome (2-8.4 new cases/100,000 habitants/year) 
and is predominantly encountered in patients with metastasized midgut NETs [15]. The 
syndrome is mediated by several active hormones, especially serotonin, and comprises several 
symptoms, including flushing (94%), diarrhea (78%) and abdominal pain (51%), which is 
usually related to mesenteric fibrosis [16, 17]. Additionally, patients may present with car-
cinoid heart disease (CHD), which consists in the deposition of plaques on the endocardial 
surfaces of valve leaflets, subvalvular apparatus and cardiac chambers. CHD affects especially 
the right side of the heart and is observed in about 60% of patients with CS [18].
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Pancreatic NETs (PNETs) are able to produce pancreatic peptides which can lead to specific 
hormone syndromes. Among these, the most common is the endogenous hyperinsulinism-
related hypoglycemia caused by insulinomas [19]. The glucagonoma syndrome should be 
also mentioned and is characterized by necrolytic migratory erythema (NME), diabetes 
mellitus and weight loss [20]. Furthermore, multiple peptide ulcers may be related to gastric 
hypersecretion, specifically the Zollinger-Ellison syndrome in patients with gastrinomas 
[21]. Watery diarrhea may be related to functioning NETs that release vasoactive intestinal 
polypeptide (VIP) or calcitonin, while somatostatinomas may be asymptomatic or pres-
ent with diabetes mellitus, cholelithiasis, weight loss, steatorrhea and diarrhea [89-91]. 
In addition, ectopic hormone production (EHP) may also be observed in NETs. In EHP, 
adrenocorticotropic hormone (ACTH) producing tumors are most commonly observed, 
but ectopic release of peptides including corticotropin-releasing hormone (CRH), growth 
hormone-releasing hormone (GHRH), antidiuretic hormone, parathyroid hormone-related 
peptide (PTHrP) and gonadotropins by NETs has also been described [96-98].
The proportion of non-functional NETs is larger than functioning tumors. Non-functional 
NETs may be discovered incidentally during diagnostic procedures, or present with me-
chanical symptoms (e.g. bowel obstruction, cough, hemoptisis)[22, 23]. Due to their silent 
clinical presentation, patients with non-functioning NETs generally present late with large 
primary tumors and advanced disease [24].
2. Diagnosis
NETs may be diagnosed following symptoms-directed evaluation (in case of functioning 
tumors), due to non-specific symptoms or incidentally during endoscopic/cross-sectional 
imaging procedures [23]. Diagnosis should be ideally confirmed by histological evalua-
tion, in which immunohistochemical markers are key points, particularly synaptophysin 
and chromogranin A [25]. Tumor grade is defined using the Ki67 index and the mitotic 
index according to the World Health Organization (WHO) grading system. For lung NETs, 
necrosis is also considered [26, 27].
2.1. Currently available markers for NETs
Currently used biochemical markers in NETs are usually hormones or amines secreted by 
the enterochromaffin cells, which can be influenced by several factors, including co-existent 
disease(s) and drugs. These biomarkers add to diagnosis, but are insufficient to accurately 
diagnose, to identify the primary tumor site or to differentiate tumor grading, especially due 
to limited sensitivity and specificity [28]. Despite this, some of them are considered for the 
diagnosis and follow-up of NETs according to several clinical guidelines [29-31]. In Table 1, 
a summary of the sensitivity and specificity of currently used and novel biomarkers in NETs 
is depicted.
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Chromogranin A (CgA): is a protein present in the secretory granules of normal and 
neoplastic neuroendocrine cell types,which is released with peptide hormones and biogenic 
amines, and is also the precursor for functional neuroendocrine peptides [50, 51]. Several 
guidelines recommend plasma CgA measurement during diagnosis, treatment and follow up 
in GEP-NETs. Baseline and serial CgA may predict clinical outcome, prognosis and tumor 
response [52], and may be indicative for local progression in patients with liver involvement 
[32]. Additionally, a progressive decrease in CgA levels may be observed in patients with 
extensive metastatic spread and loss of neuroendocrine differentiation [53]. However, CgA 
is elevated in only 60–80% of patients with NETs, has a limited sensitivity of 60-83% and 
also specificity is relatively low, i.e. 72-85% (Table 1) [32-36, 38, 54-56]. Moreover, proton 
pump inhibitors, atrophic gastritis and impaired kidney function can induce a rise in CgA 
levels [38, 57]. The combination of CgA with other diagnostic methods, e.g. somatostatin 
receptor scintigraphy, may increase its sensitivity (93%) and specificity (81%) [58-60]. 
Importantly, the sensitivity of CgA depends further on the threshold cut-off [37, 38, 53], 
NET primary location [37, 61, 62], endocrine associated syndrome [9], disease spread, liver 
metastases [37, 53, 56, 63] and the used assay [64]. Importantly, different analytical proper-
ties of the CgA kits give different performances, a fact that must be taken into consideration 
when comparing results from different clinical studies.
Neuro-specific enolase (NSE): is a soluble cerebral protein which provides information on 
neural, neuroendocrine and paraneuronal cells [65]. An increase in NSE levels is thought 
to be related to a high death rate of cells with neuroendocrine differentiation [32]. NSE is 
probably the most reliable tumor marker in diagnosis, prognosis and follow-up of small cell 
lung cancer (SCLC) [66]. This marker may be elevated in 38-40% of GEP-NETs patients, in 
Table 1: Sensitivity and specificity of current and novel neuroendocrine biomarkers
Tumor marker Primary tumor location Sensitivity Specificity
Chromogranin A [32-38] Non-specific 60-83% 72-85%
Urinary5-HIAA [32, 38, 39] Midgut 35-68% 90-100%
Pancreatic polypeptide [28, 40, 41] Pancreas, midgut 31–63% ~67%
Neuron-specific enolase [28, 32, 42] Non-specific 33% 73%
N-terminal brain natriuretic peptide [28, 43] Midgut (non-specific for CHD) 87% 80%
Progastrin-releasing peptide [44] Lung 43% 99%
Paraneoplastic Ma antigen 2 [45] SB-NETs 46-50%
DCR [46] SB-NETs AUC: 0.74
TFF3 [46] SB-NETS AUC: 0.72
Midkine [46] SB-NETS AUC: 0.71
Multritranscript genes [47-49] GEP-NETs 75-98%
Legend: CHD: carcinoid heart disease; SB: small-bowel, AUC area under the curve.
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particular in those with high grade tumors [42, 67]. The specificity of NSE is similar to CgA 
but with lower sensitivity (Table 1) [42, 68, 69]. NSE levels have been directly associated 
with tumor differentiation, aggressiveness and size [42, 67]. Despite its limited sensitivity, 
NSE is inversely correlated to overall survival (OS) in ENETS TNM stage IV [67] and with 
shorter progression-free survival (PFS), even if CgA levels are normal [70].
N-terminal brain natriuretic peptide (NT-BNP): is a peptide produced by myocardial 
cells in response to electrolyte and fluid balance; its serum concentration is usually elevated 
in mid-gut NETs with a sensitivity of 87% and a specificity of 80% [28, 43]. NT-BNP 
is in particular used for evaluating CHD and it has been reported that a cut-off value of 
260 pg/ml has a sensitivity of 92% and specificity of 91% [71]. Interestingly, it has been 
suggested that patients with elevated NT-BNP levels combined with increased CgA levels 
have worse OS when compared to CgA alone [28, 72]. Importantly, NT-BNP is not disease 
specific, thus further studies for evaluating its applicability in the progression of CHD are 
still required [71].
5-hydroxyindoleacetic acid (5HIAA): Serotonin, produced by (midgut) NETs, is the most 
prominent hormone associated with diarrhea and flushes in carcinoid syndrome. Its me-
tabolite, 5-hydroxyindoleacetic acid (5HIAA), measured in 24 h urine is used as a diagnostic 
and follow up marker [73]. Urinary 5HIAA levels are not directly related to the severity of 
symptoms and large fluctuations within an individual patient have been described [74]. The 
specificity of 5HIAA is around 90%, but the reported sensitivity is 35-68% in patients with 
NETs [32, 38, 39]. 5HIAA is mainly used as an indicator of hypersecretory activity in pa-
tients with NETs, especially in midgut NETs [32]. Its prognostic value, however, is limited, 
some studies have related higher urinary 5HIAA levels with mortality [75], but these results 
were not reproduced by other studies [39, 73]. Its combination with other markers also 
failed to predict OS, for this reason, 5HIAA determination is only recommended to assess 
carcinoid syndrome [71].
Pancreatic Peptide (PP): is a non-specific marker in NETs [76]. Around 63% of PNETs and 
18-53% of primary gastrointestinal NETs show increased PP levels [41]. Its determination 
does not seem to increase the diagnostic performance of other markers like CgA, but changes 
above 50% in PP serum levels seem to correlate with tumor increase on imaging [56].
Despite the above-mentioned limitations, current biomarkers are regularly used in clinical 
practice and their accuracy increases when combined. Importantly, specific comparisons 
between markers are difficult since several publications are based on short heterogeneous 
cohorts and retrospective analysis. Additionally, the differences between assays limit com-
parisons and solid conclusions.
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2.2 Potential novel diagnostic biomarkers
To improve early diagnosis and follow-up of NETs, several new prognostic and treatment-
related biomarkers have been developed in the last years (Figure 1).
Most of these biomarkers are still under study and not available yet for use in clinical prac-
tice. It is aimed to develop high-specific and sensitive circulating biomarkers using DNA, 
RNA and a metabolomic approach. Combination markers and multianalyte analysis seem 
to be more effective than the current use of monoanalytes because of a higher sensitivity 
[28, 49, 77]. A summary of potential novel circulating and tissue biomarkers for diagnosis, 
prognosis, and therapy response prediction, as well as their relation with tumor localization, 
is shown in Figure 2.
Figure 1: Timeline of the publication of potential novel biochemical and therapeutic markers in 
neuroendocrine tumors. Monoanalytes, transcripts, DNA-, RNA- , immune- markers are shown. 
They are still mostly under study and not available for use in clinical practice. Image-based modalities 
are represented in purple.
Legend: EGFR: epidermal growth factor receptor; proGRP: progastrin-releasing peptide; MT: mul-
titranscript; CCN2: connective tissue growth factor for carcinoid heart disease; IL-8: interleukin 8; 
miRNA: microRNA; XIAP: X-linked Inhibitor of Apoptosis; GLUT-1: glucose transporters type 1; 
VEGFR: vascular endothelial growth factor receptor; MGMT: O-6-methylguanine-DNA methyl-
transferase; 18F—FDG PET: 18-fluorodeoxyglucose positron emission tomography; PNMA2: para-
neoplastic Ma antigen 2; CTCs: circulating tumor cells; TSC: Tuberous sclerosis complex; PlGF: Pla-
cental growth factor; ALT: alternative lengthening of telomeres; cftDNA: circulating cell free tumor 
DNA; SDF-1α: stromal cell-derived factor 1α; PD-L1: programmed death ligand-1; CECs: circulat-
ing endothelial cells. Imaging techniques, as reference, are presented in purple.
a. Peptides and growth factors:
Several peptides and growth factors (Table 2) have been studied for a (potential) role as 
biomarkers in NETs and may: (1) help to localize primary tumors (e.g. progastrin-releasing 
peptide in lung NETs, connective tissue growth factor (CCN2), paraneoplastic Ma antigen 
2 , DcR3, TFF3, and midkine in small intestine NETs [28, 44, 46, 78]); (2) predict the 
outcome in functioning NETS (e.g. α-Internexin in insulinomas [79, 80]) or predict early 
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complications in patients with carcinoid heart disease [78]; and (3) add information to that 
provided by other circulating/tissue markers for treatment response evaluation and outcome 
prediction (e.g. pro-GRP and CgA for predicting outcome/therapeutic response in lung 
carcinoids; α-Internexin and Ki67 in insulinomas [44, 81-83] or as part of multianalyte 
tests [46]). Additionally, some peptides may be useful to correlate with imaging techniques. 
For instance, glucose transporter 1 (GLUT1) expression in NETs is associated with the Ki67 
index and 18-fluorodeoxyglucose (FDG) uptake at FDG-positron emission tomography 
Plasma/serum samples:
• Pro-GRP**
• CCN2 *
• PNMA2
• XIAP
• DcR3, TFF3, Midkine***
Gastrointestinal NETs
• CCN2 *
• PNMA2
• Survivin
• XIAP
• GLUT-1
Pancreatic NETs
• αInternexin
• Survivin
• GLUT-1
• ALT
• MGMT
• MT genes
• microRNA
Lung NETs
• SSTs expression
• EGFR expression
• PD-L1
• Survivin
• GLUT-1
• SSTs expression
• EGFR expression
• IL-8
• SDF-1α  
• PlGF
• VEGFR
• TSC
• PD-L1
• αInternexin
• MGMT
• MT genes
• SSTs expression
• EGFR expression
• VEGFR expression
• cftDNA
• IL-8
• SDF-1α  
• CECs
• White Blood Cell Subtypes
• PlGF
Figure 2: Summary of potential novel diagnostic and therapeutic markers in neuroendocrine 
tumors
Several tumor or plasma/serum biomarkers seem to play a role in the diagnosis or follow-up in lung 
and GEP-NETs. Its presence may be determined in serum or tissue samples.
Legend: * specific for carcinoid heart disease; ** only for lung-NETs; *** only for small intestine 
NETs; proGRP: progastrin-releasing peptide; CCN2: connective tissue growth factor for carcinoid 
heart disease; PNMA2: paraneoplastic Ma antigen 2; XIAP: X-linked Inhibitor of Apoptosis; GLUT-1: 
glucose transporters type 1; ALT: alternative lengthening of telomeres; MGMT: O-6-methylguanine-
DNA methyltransferase; MT: multitranscript; cftDNA: circulating cell free tumor DNA; EGFR: epi-
dermal growth factor receptor; SDF-1α: stromal cell-derived factor 1α; CECs: circulating endothelial 
cells; PlGF: Placental growth factor; VEGFR: vascular endothelial growth factor receptor; TSC: tuber-
ous sclerosis complex; SSTs: somatostatin receptor; PD-L: programmed death ligand-1.
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(PET) scans [84]. GLUT-1 expression may serve as an additional marker for aggressiveness 
of NETs and may add to a more accurate grading [84]. Although some of these peptides 
have been suggested as promising biomarkers, most of them are non-specific. In addition, 
their applicability is limited, due to their sensitivity and specificity (Table 1) and the absence 
of cut-off levels. In addition, some of them have been described only in single retrospective 
studies, thus further validation in larger and longitudinal cohorts is still required.
Table 2: Peptides and growth factors as novel markers in NETs
Peptide/growth 
factor
Function Potential role as marker in NETs
Progastrin-releasing 
peptide (proGRP)
Precursor of gastrin-releasing peptide, a 
neuropeptide hormone widely distributed 
throughout the gastrointestinal and 
pulmonary tract [85]
Primary tumor localization in patients with a 
metastatic NET of unknown origin.
Complementary marker to CgA in lung 
NET for treatment response evaluation and 
survival [44, 86]
Connective tissue 
growth factor for 
carcinoid heart 
disease (CCN2)
CCN2 is an early gene product of the 
CCN family of matricellular proteins, 
which are involved in cell proliferation, 
angiogenesis, tumourigenesis and wound 
healing. It may be involved in the 
pathogenesis of carcinoid heart disease 
[78, 87]
Independent predictor of both reduced right 
ventricular function and right-sided valve 
regurgitation (its plasma levels are inversely 
related to right ventricular function levels)
Early predictor of cardiac fibrosis [78]
Paraneoplastic Ma 
antigen 2 (PNMA2)
Antineuronal antibodies identified as 
markers of neurological paraneoplastic 
syndromes [88]
Allows the identification of almost 50% of 
small bowel NETs at the primary stage of 
the disease
Correlation with disease progression and 
recurrence free survival [45]
α-Internexin Cytoskeleton protein involved in 
tumorigenesis and disease progression [89]
Association with proliferation, ki67 index 
and malignancy [79]
X-linked Inhibitor 
of Apoptosis (XIAP)
Inhibitor of apoptotic cell death in cancer 
cells [90, 91]
Potential target therapies [92-94]
Glucose transporters 
type 1 (GLUT-1)
Mediate the transport of glucose across 
the cellular membrane and are commonly 
overexpressed in tumors, probably related 
with higher metabolism and cell growth 
[95]
Predictor of risk of death in neuroendocrine 
lung carcinomas and lung carcinoids [96]
Relation with Ki67 index in GEP- and lung 
NETs [84, 97]
Correlation with the uptake in 18-FDG-
PET [84]
DcR3 Regulates cytokines that influence tumor 
growth and reduce apoptotic stimuli [98]
DcR3 correlates to liver metastasis and worse 
survival
Predictor of treatment resistant tumors [46]
TFF3 Protects and repairs epithelial surfaces
Enhances migration, angiogenesis, and 
inhibits apoptosis [99-101]
Higher concentrations have been correlated 
to reduced survival [46]
Midkine Promotes tumor cells migration, 
angiogenesis and reduces apoptosis [102]
Predictive marker to chemotherapy 
response[103, 104]
16
C
ha
pt
er
 1
b. DNA markers:
These markers are expected to improve diagnosis in NETs, especially when the primary tu-
mor is unknown, and to predict drug response. They include the determination of mutations 
which are associated with alternative lengthening of telomeres [105, 106], the expression of 
the DNA repair enzyme O-6-methylguanine-DNA methyltransferase which may predict the 
clinical responses to alkylating agents including temozolamide [107, 108] and the evaluation 
of cell-free DNA in liquid biopsy which contains identical genetic defects as the primary 
tumor [109]. A schematic overview of DNA markers is depicted in Figure 3.
Figure 3: Summary of DNA markers in neuroendocrine tumors: DNA markers are presented 
in green. Tumor cells release small fragments of cftDNA into circulation by multiple mechanisms, 
cftDNA contains identical genetic defects compared to the primary tumor. DNA methylation at the 
O6 position of guanine results in apoptosis and tumor cell death; in GEP-NETs, the methylation of 
MGMT promoter and loss of MGMT protein expression have been reported. Inactivating mutations 
in ATRX and DAXX genes are associated with ALT.
Legend: cftDNA: cell free tumor DNA; O-6-MGMT: O-6-methylguanidine-DNA methyltransfer-
ase; O6MG: DNA methylation at the O6 position of guanine; ALT: alternative lengthening of telo-
meres; ATRX X linked transcriptional regulator; DAXX: death domain-associated protein 6
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c. RNA markers:
These are novel and potentially promising minimally invasive markers used for diagnostic 
purpose and/or to identify therapeutic targets for NETs. Specifically, the identification of 
circulating target genes using PCR-amplification has been used for determining stage, prog-
nosis, recurrence or new metastasis in several cancers [110-112]. Modlin and co-workers 
have developed a PCR-based molecular test using 51 genes for identifying GEP-NETs [49]. 
For this so-called NETtest, a score, based on tissue and peripheral blood transcriptomes, 
was developed [49] as a diagnostic and follow-up tool for NETs [48, 49, 77, 113]. NETtest 
results were shown to differentiate progressive disease [48] and to predict tumor response to 
somatostatin analogs (SSAs) [114] and peptide receptor radionuclide therapy (PRRT) [47]. 
Despite these promising results, prospective independent validation is desirable in order to 
establish the reproducibility of the results and their interpretation.
Additionally, dysregulated microRNAs (miRNA) have been correlated with diagnosis, 
staging, progression, prognosis and therapeutic response in several tumors, including NETs 
[115]. Their up- and down-regulation has been described and associated with histological 
characteristics (e.g. Ki-67, degree of malignancy) and prognosis characteristics, including 
OS [116, 117]. The therapeutic strategy for miRNAs includes the oncogenic miRNA in-
hibition or the introduction of a tumor suppressor miRNA [118]. However, the currently 
available technology is not robust enough to support its clinical use yet [119]. Furthermore, 
dysregulation of miRNAs is not tumor specific and the absence of cut-off levels for differen-
tiating tissue and tumor subtypes, the lack of reproducibility in other NET cohorts and the 
difficulties in their interpretation, limit the clinical application of miRNAs. Further studies 
are required to evaluate the application of miRNAs as clinical and therapeutic markers in 
NETs.
d. Therapeutic/prognostic biomarkers:
Somatostatin/cortistatin system components (ligands and receptors) are widely expressed in 
tissues, including the gastrointestinal tract, where they inhibit endocrine secretions, motility 
and absorption, in a paracrine and endocrine manner [120, 121]. Somatostatin acts through 
the binding and activation of a family of five G-protein-coupled somatostatin receptor sub-
types (SST1-5), which are widely distributed in the organism [122-124]. SSTs are a family of 
5 G-protein-coupled, 7 transmembrane domains receptors that trigger different intracellular 
signaling pathways. Through their activation, in addition to secretion processes, prolifera-
tion, differentiation and angiogenesis are regulated [124]. The complexity of somatostatin/
cortistatin system has increased in recent years after the identification of SSTs splicing vari-
ants of the SST5 gene (SST5TMD4 and SST5TMD5) [125-131], which may be dysregulated 
in tumor pathologies where they may be associated with aggressive features [128, 132].
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SSAs are considered to be the preferred first-line treatment option in functionally active 
NETs, including those associated with the carcinoid syndrome and functional PNETs 
[133, 134]. Additionally, monthly administered long-acting preparations of octreotide and 
lanreotide are usually used for disease stabilization in NETs [135, 136]. The effects of SSAs 
depends on the presence of SSTs in the tumor (octreotide and lanreotide bind preferably to 
SST2 and pasireotide has high binding affinity to multiple SSTs, particularly SST5; see also 
figure 5) [137].
Tightly related with the somatostatin system, the ghrelin system is involved in the regulation 
of multiple (patho)-physiological functions, including hormonal secretion, β-cell survival, 
as well as appetite and gastric motility [138-141]. The acylation of the third serine residue 
in ghrelin molecule is necessary for its activation, which is catalyzed by the ghrelin-O-acyl-
transferase (GOAT) enzyme [141, 142]. Acylated ghrelin binds and activates its canoni-
cal ghrelin receptor, GHSR1a. Additionally, some ghrelin system variants resulting from 
post-transcriptional modifications or alternative splicing have been identified, including 
the In1-ghrelin [138, 143] and a truncated receptor GHSR1b, with unknown ligand and 
function [138, 143, 144].
In recent years, there is increasing interest in somatostatin/cortistatin and ghrelin systems, 
since alterations in some of their components seems associated with the development/
progression of various cancers [143, 145-148]. Both, ghrelin [132, 149] and somatostatin 
systems [22, 122, 150] have been described in NETs, but the clinical-molecular correlations 
have not been fully elucidated [149, 151]. Their use as tissue markers may provide informa-
tion about clinical evolution and outcome [132, 149]. The molecular expression and clinical 
relations of both systems are described in chapter 2, 3 and 4 of this thesis. In particular, SSTs 
expression in NETs is considered to have therapeutic implications for treatment with SSAs 
and for PRRT.
In recent years, the use of molecular targeted therapies has been approved in NETs. The 
possibility to peripherally measure monoanalytes directly related to the drug mechanism 
of action represents an important approach to predict treatment response. In this sense, 
some molecular biomarkers could play a role as prognostic markers for treatment response 
to tyrosine kinase- and mTOR inhibitors. For sunitinib, such biomarkers include: the 
epidermal growth factor receptor [152-155], vascular endothelial growth factor (VEGF) 
and its transmembrane receptors (VEFGR-1, VEFGR-2, VEFGR-3) [156], interleukin-8 
[157], stromal cell-derived factor-1α [157] and circulating tumor, endothelial and white 
cells [158, 159]]. For everolimus, circulating levels of placental growth factor [160] and 
tuberous sclerosis complex mutations [161] have been described. Additionally, some 
relations were shown between these markers, tumor response, PFS and OS [158, 159]. 
119
G
en
er
al
 In
tro
du
ct
io
n

 



	








 ­






 


 


 
 


­

	

 
	
 

	

 	 
  




	




	
Figure 4: Therapeutic markers: molecular biomarkers for tyrosine kinase and mTOR inhibitors.
Blue arrows represent the effect of the mTOR inhibitor everolimus and red arrows the effect of the 
tyrosine kinase inhibitor sunitinib. Molecular markers are presented in blue. Sunitinib has been related 
to decreased SDF1, IL-8, VEGFR 2-3, CD14 monocytes expressing VEGFR, decreased circulating 
endothelial precursors (CEPs), increased circulating endothelial cells (CECs) and probably decreased 
PlGF. Everolimus has been related to decreased PlGF and VEGFR2; additionally, mTOR directed 
therapies may be more effective in tumors with tuberous sclerosis complex 1 (TSC1) somatic muta-
tion. Factors related to PFS and OS are also shown.
Legend: SDF-1α: Stromal cell-derived factor 1α; IL-8: interleukin-8; PlGF: placental growth factor; 
CXCR 1,2,4: chemokine family receptor 1,2,4; VEGF: vascular endothelial growth factor; VEGFR 
1-3: vascular endothelial growth factor receptor 1-3; TSC 1-2: Tuberous sclerosis complex 1-2; CECs: 
circulating endothelial cells; CPECs: circulating endothelial precursors derived from the bone marrow.
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Their use may identify patients with increased drug sensitivity and higher possibilities of 
drug responsiveness [161]. However, currently there is no consensus for supporting their 
use. Further multicenter, longitudinal studies in this field are required. A summary of the 
current potential tumor biomarkers for tyrosine kinase and mTOR inhibitors is shown in 
Figure 4.
2.3 Imaging
Tumor staging using imaging techniques should be performed in all NETs. Specifically, 
endoscopic evaluation in small (<1 cm) low-grade gastric- or rectal NETs is recommended 
[23, 162]. Most cases require evaluation with conventional imaging techniques, usually 
computed tomography (CT) or magnetic resonance imaging [30, 163]. SSTs-based imaging 
techniques help to localize primary tumor and metastasis for disease staging [164, 165]. 
Additionally, they help to make therapeutic decisions and are used to evaluate prognosis in 
NETs [165, 166]. Initially 111In-DTPA-octreotide (Octreoscan®) was used. In recent years, 
the positron emitter 68Gallium, which labels several somatostatin analogs, combined with 
positron emission tomography CT (68Ga PET/CT), probably represents the gold standard 
for SSTs imaging of NETs [163, 167]. Other functional imaging techniques such as 18-fluo-
rodeoxiglucose PET/CT (18-FDG PET/CT) have higher accuracy for poorly differentiated 
NETs and may be useful for evaluating atypical carcinoids. Importantly, images of 18-FDG 
PET/CT should be analyzed in combination with 68Ga-PET/CT [163, 166, 168]. Addition-
ally, a radiolabelled glucagon-related peptide 1 receptor agonist [Lys40(Ahx-HYNIC-99mTc/
EDDA)NH2]-exendin-4, has been reported as a promising imaging technique for the 
localization of insulinomas [169].
3. Treatment
3.1 Surgery
Surgery with margin-negative resection and, in some cases, adequate lymphadenectomy is 
the only curative treatment for localized NETs [170]. Unfortunately, patients often present 
with extended or metastatic disease at diagnosis [7]. Despite this, surgical management may 
still be an option with tumor debulking and resection of limited liver/lymph node metastasis 
with the subsequent use of liver-directed therapies [171-173]. Surgery is also useful for 
symptom control, specifically primary tumor resection/enucleation in localized functioning 
NETs is indicated. In some metastasized functioning NETs, decreased tumor load after 
surgery improves the associated symptoms. Additionally, in patients with recurrent/severe 
abdominal pain due to mesenteric fibrosis, surgery may improve clinical symptoms and 
obstruction [171-173]. Finally, bilateral adrenalectomy in patients with ectopic ACTH syn-
drome should be considered in cases of uncontrollable hypercortisolism, unknown primary 
tumor or extended disease [174].
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3.2 Medical treatment
Hormone excess symptom control
SSAs are first-line therapy in functionally active NETs, including those associated with the 
carcinoid syndrome and functional PNETs [133]. The mechanisms of action of current 
medical options for functioning NETs are depicted in Figure 5.
Medical options for functioning NETs are summarized in Table 3. Chemotherapy may also 
be used in some aggressive cases [133, 175]; this therapeutic option is not discussed in this 
thesis. Since in Part II of this thesis novel therapeutic options for ACTH and serotonin 
overproduction are evaluated, only carcinoid syndrome and ectopic ACTH syndrome are 
described in more detail.
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Figure 5: Current medical treatment for symptoms control in neuroendocrine tumors. Short-, 
long-acting and radiolabeled- somatostatin analogs bind to G-protein linked receptors on the cell 
surface with variable affinity. The inhibition of the cAMP and the decrease in intracellular calcium 
levels inhibit hormone release. Somatostatin influences hormone secretion and motility in the whole 
gastrointestinal tract. Serotonin production may be also decreased by telotristat, which inhibits the rate 
limiting step in the serotonin secretion (the enzyme tryptophan hydroxylase).
Legend: SSTs: somatostatin receptor; SSAs: somatostatin analog; PRRT: peptide receptor radionuclide 
therapy; cAMP: cyclic adenosine monophosphate; VIP: vasoactive intestinal peptide; PP: pancreatic 
polypeptide.
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Table 3: Medical Treatment for functioning NETs
Functioning NET Medical treatment Mechanism of action/clinical relevance
Carcinoid 
syndrome
-SSAs, pasireotide, 
telotristat.
Please refer to the text for explanation of the medical 
options.
Insulinoma: - Diazoxide 
(benzothiadiazine derivative)
- Octreotide LAR and 
lanreotide autogel
- Pasireotide
- Everolimus
- PRRT
- Inhibits insulin secretion, increases the hepatic glucose 
production and inhibits tissue glucose uptake [206-210].
- Decrease insulin release if SSTRs are expressed [209], 
otherwise, paradoxical decrease in blood glucose by 
suppressing glucagon release [208].
- Mediates insulin secretion by binding SSTR5 [211]
- Decreases insulin release (AMP-activated protein kinase 
(AMPK)/c-Jun N-terminal kinase (JNK)/FoxO pathway); 
induce peripheral insulin resistance (glucose transporter 1 
downregulation) [212-215].
- Decreases insulin secretion, antitumor effect [208].
Glucagonoma: - Octreotide LAR and 
lanreotide autogel
- Pasireotide
- Everolimus, sunitinib
- PRRT with 90Yttrium-
DOTATOC or 177Lu-
DOTATATE
- The necrolytic migratory erythema improves despite the 
persistence of elevated serum glucagon levels [216]
- Clinical response in octreotide-resistant tumors [20, 217].
- Clinical response after SSAs failure [218, 219].
- Disease stabilization or tumor regression with subsequent 
symptoms control [220].
Gastrinoma: - H+-K+-ATPase proton-
pump inhibitors (PPIs)
- SSAs
- IFN-α
-Control gastric hypersecretion [21]
- Suppress gastrin secretion and normalizes gastric acid 
secretion [26–34]. Prevent the enterochromaffin-like cell 
hyperplasia or the development of gastric type 2 NETs [221].
- Improves clinical symptoms caused by hypergastrinemia 
only in stabilized tumors (41).
VIPoma, 
somatostatinoma:
- SSAs (Octreotide LAR and 
lanreotide autogel)
- Glucocorticoids
- Molecular targeted therapy 
and PRRT
- Control symptoms in the majority of patients [29, 222, 
223]
- In SSAs refractory cases [223].
-In metastasized cases [218-220, 224-226].
Ectopic hormone 
producing 
syndromes:
• ACTH:
• GHRH:
-SSAs (octreotide and 
lanreotide)
• PTH related protein:
Includes hypercalcemia 
control
- Intravenous isotonic saline
- Bisphosphonates
- Denosumab
- SSAs
- PRRT with 177Lu-
DOTATATE.
- Please refer to the text for explanation of the medical 
options.
- Low ectopic tumoral production of GHRH, with a 
subsequent decrease in circulating GH and insulin-like 
growth factor-1 (IGF-1) levels [227, 228].
- Corrects volume depletion
- Interfere with the osteoclast-mediated bone resorption
- Reduces the formation, function, and survival of osteoclasts 
via the nuclear factor κB (RANK) pathway [190, 229, 230]
- Improve symptoms control but might be insufficient in 
patients with tumor progression [190, 231].
- Tumor stabilization with parallel calcium control [190].
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Carcinoid syndrome (CS)
CS is mediated by several active hormones, especially serotonin [16, 17]. The role of SSAs 
for improving secretory diarrhea and flushes in NETs was initially described in 1978 [176, 
177]. Since then, short-acting octreotide was considered as a treatment option for carcinoid 
syndrome. The efficacy of short- and long-acting octreotide is similar once circulating oc-
treotide steady-state concentrations are achieved [178, 179]. Long-acting preparations of 
SSAs are widely used, as these improve flushes and diarrhea in 53-75% and 45-80% of cases, 
respectively [180, 181]. Octreotide and long-acting lanreotide similarly reduce u5-HIAA 
acid and improve quality of life in NET patients [180]. Both octreotide and lanreotide are 
well tolerated and side effects are observed only in 14-29% of patients [180]. In addition, a 
favorable clinical response of carcinoid syndrome-related symptoms has also been reported 
in patients after treatment with PRRT [182, 183].
Pasireotide, a SSA with affinity to multiple somatostatin receptors, has been also tested in 
patients with octreotide-LAR resistant tumors. Here, pasireotide showed efficacy in 33% of 
patients when administered 150 µg twice daily, escalated to a maximum dose of 1200 µg 
per day [184]. α-interferon in combination with octreotide was suggested as an effective 
treatment for symptom control, but unfortunately the use of this combination is limited 
due to the high rate of adverse effects (attributed to α-interferon in 5-76% of cases) [185].
Recently, telotristat etiprate, a novel inhibitor of tryptophan hydroxylase, the rate-limiting 
enzyme in the biosynthesis of serotonin, has been developed. Telotristat etiprate decreases 
u5-HIAA and improves CS symptoms [186]. Remarkable, published data of its in vitro 
effects is lacking. This novel drug will be extensively described in chapter 7 of this thesis.
Importantly, SSAs and/or tumor debulking techniques may improve the hemodynamic 
impact of tumor vasoactive agents on CHD [178, 187, 188] but there is no concluding 
evidence suggesting that these treatment options can stop the progression of CHD [189].
Ectopic hormone producing syndromes
Ectopic hormone production is rare in NETs. The treatment aims in these patients include 
symptomatic long-term control, tumor stabilization or reduction, and prolongation of 
(progression-free) survival [190].
Ectopic ACTH syndrome
The ectopic ACTH syndrome (EAS) causes approximately 10% of all cases of Cushing syn-
drome [191, 192]. Clinical evolution is usually faster and characterized by mineralocorticoid 
effects (hypertension, hypokalemia, and edema), thromboembolic disease and opportunistic 
infections [193]. Curative surgery is the primary treatment option but is often not possible 
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Figure 6: Current and future medical options for tumor control in neuroendocrine tumors. Cur-
rent therapeutic options are presented in blue, possible novel therapeutic options are presented in red. 
SSAs and PRRT: increase apoptosis by activating the protein tyrosine phosphatase SHP1; decrease 
cell proliferation and survival through the mitogen-activated protein kinase and cyclic adenosine mo-
nophosphate; and inhibit the signaling of the insulin-like growth factor receptor type 1; additionally, 
PRRT produces DNA double stand breaks induced by β-irradiation, leading consequently to apopto-
sis. Sunitinib is a multikinase inhibitor that modulates the phosphoinositate-3-kinase/Akt pathway (it 
blocks the vascular endothelial growth factor receptors 1-3, the platelet-derived growth factor receptors 
α and β, and the epidermal growth factor receptor). Everolimus decreases tumor cell proliferation, 
metabolism, survival and angiogenesis through the mammalian target of rapamycin complex-1. The 
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[191, 194]. EAS can result in a critical condition for which aggressive medical therapy or 
life-saving bilateral adrenalectomy is necessary [193]. Medical treatment options for EAS 
include: (1) tumor-directed drugs including somatostatin analogs (octreotide, pasireotide) 
and dopamine agonists that decrease tumoral ACTH secretion [193, 195-198]. The identi-
fication of SSTs expression in the tumor using radiolabeled somatostatin analogs, may also 
help to identify suitable patients that might benefit from PRRT [195, 199, 200]. In addi-
tion, the tyrosine kinase inhibitors vandetanib and sorafenib may have antisecretory effects 
in selected cases with EAS [201, 202]; (2) steroid synthesis inhibitors which directly suppress 
adrenal cortisol production. In this sense, a combination of ketoconazole, metyrapone and 
mitotane was shown to be effective in critically ill patients with EAS [203]. Additionally, the 
anaesthetic drug etomidate can also rapidly suppress cortisol levels in an ICU setting [204]; 
and (3) glucocorticoid receptor antagonists. Mifepristone has a short onset of action and was 
shown to reverse morbidity of EAS in several cases [205].
Tumor growth control
According to the latest analysis of the SEER database, 27.4% of NETs have distant metasta-
sis at diagnosis and 20% have regional infiltration [7]. Survival in NETs is related to tumor 
localization, tumor load and grading and these factors should be considered when selecting 
the appropriate medical treatment that would allow tumor stabilization and/or shrinkage. 
Current and promising novel medical options for tumor growth control in NETs (excluding 
chemotherapy) are described in this chapter and presented in Figure 6.
The current registered clinical trials of novel and combination therapies in NETs are depicted 
in Table 4.
indirect inhibition of mTOR through the phosphoinositate-3-kinase/Akt produced by the SSAs seems 
to increase sensitivity to mTOR inhibition. Multi-receptor chimeras may bind SSTs and D2R, and 
may enhance the signaling of the cAMP and JNK pathways; induced SST2 internalization and SST2 
heterodimerisation interference have been also hypothesized. The interaction between some receptors 
expressed on the surface of cytotoxic T-cells (PD-1, CTLA-4) with ligands expressed on the tumor 
cells (PD-L1, B7-1/B7-2) downregulates the immune response to tumor cells; novel drugs that target 
these specific immune checkpoints inhibit this interaction allowing the immune system to maximize 
an efficient antitumor response.
Legend: SSAs: somatostatin analogs, PRRT: peptide receptor radionuclide therapy; IGF-1R: insulin-
growth factor receptor type 1; VEGFR: vascular endothelial growth factor; EGFR: epidermal growth 
factor receptor; PDGFR: platelet-derived growth factor receptors; TSC: tuberous sclerosis complex; 
mTOR: mammalian Target of Rapamycin; CTL4: cytotoxic T-lymphocyte antigen-4; PD-L1: Pro-
grammed death-ligand 1.
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Somatostatin analogs
The antiproliferative effect of SSAs depends on the level of expression of SSTs in the tumor, 
although indirect antitumor effects have been described as well [232]. SSAs may inhibit the 
cell cycle and increase apoptosis, and indirect effects may include immuno-modulation, 
antiangiogenic effects, and growth factor inhibition [135, 222, 233]. Long-acting prepara-
tions of octreotide and lanreotide are usually used for disease stabilization in NETs [135, 
136]. The anti-proliferative effect of SSAs in NETs was initially evaluated in the PROMID 
study [234]. In this phase III B study, 85 well-differentiated metastatic midgut NETs were 
included. Patients randomly received placebo or octreotide-LAR 30 mg every four weeks. A 
difference of 8.3 months in tumor progression was observed after comparing the octreotide 
and the placebo group. Stable disease after six months was observed in 66.7% of patients 
treated with octreotide-LAR, compared to 37.2% in the placebo group [234]. Despite the 
initial good response to octreotide LAR, the results from the long-term survival analysis 
revealed that the overall survival (OS) was not significantly different in the placebo and in 
the octreotide group [235]. Similar to the PROMID study, the CLARINET study revealed 
that lanreotide Autogel (120 mg every 28 days) increased progression free survival (PFS) 
of patients with metastatic well- and moderate-differentiated gastroenteropancreatic NETs 
when compared to placebo [(PFS rate of 65.1% in the lanreotide group and 33% in the 
placebo group) [236]]. Usually SSAs induce tumor stabilization but in selected cases SSAs 
can cause tumor shrinkage, possibly due to their effects on the perfusion of liver metastases 
[237]. Currently, the CLARINET FORTE study is evaluating the safety and anti-tumor 
efficacy of lanreotide autogel 120 mg every 14 days in patients with pancreatic- or midgut 
NETs with progressive disease under regular dose of long-acting SSAs (NCT02651987). 
Pasireotide has been also studied in NETs, in which pasireotide concentrations correlated 
with tumor shrinkage in a non-significant manner [238]. Other studies have reported pre-
dominantly disease stabilization (60%) in treatment-naïve patients with grade 1-2 NETs, 
but also partial response (4%) and disease progression (36%) have been reported [239]. 
Additionally, pasireotide-LAR has been compared to octreotide-LAR in patients with 
metastatic NETs and carcinoid symptoms. In these patients, pasireotide tended to increase 
the tumor control rate after six months and was associated with a longer PFS [240]. In the 
phase 2 prospective LUNA study in advanced (unresectable or metastatic), progressive, well 
differentiated carcinoid tumors of the lung or thymus, pasireotide LAR treatment resulted in 
an objective tumor response in 39% of patients [241]. In a randomized, open-label, phase 2 
study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, 
well-differentiated, progressive pancreatic neuroendocrine tumors (COOPERATE-2 trial), 
the addition of pasireotide to everolimus was not associated with the improvement in PFS 
compared with everolimus alone [242]. Further investigation to evaluate the applicability of 
pasireotide alone or in combination with other therapies is required.
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Interpheron-alpha
Interferon-alpha has antiproliferative, pro-apoptotic, cytotoxic/cytostatic and immuno-
modulatory effects in NETs [243, 244]. It has been considered as a second-line therapeutic 
option in progressive NETs under SSAs [133, 245]. Tumor response rates of about 10% 
have been reported [246] and its efficacy is similar to other agents, including bevacizumab, 
when combined with SSAs [247]. Unfortunately, several adverse effects have been described; 
a pegylated formulation seems to be associated with fewer side effects, and its combination 
with octreotide seems to be better tolerated [246, 248]. Despite this, the availability of novel 
therapeutic options with higher efficacy and lower side effects, limits the applicability of this 
drug for tumor control [249].
Peptide receptor radionuclide therapy
PRRT with SSAs allows targeted delivery of radionuclides to tumor cells expressing high 
levels of SSTs. Treatment response is directly related to the expression of SSTs in the tumor, 
making it a predictive marker of response [165]. Tumor response may also differ according 
to the primary tumor localization and tumor load [250]; OS is also different in NETs of 
different localization [pancreas: 71 months, CI 56-86), midgut: 60 months (95% CI52-68) 
[251]]. In contrast, response rates are decreased in patients with larger tumor load and higher 
liver infiltration [252]. The pivotal phase III NETTER-1 trial for the first time evaluated 
the efficacy of PRRT with 177Lu-DOTATATE in a multi-center, randomized clinical trial. 
This study included 229 patients with well-differentiated, metastatic midgut NETs that were 
progressive on a standard dose of long-acting SSA. Patients were randomized to receive 4 
cycles of PRRT with 177Lu-DOTATATE or a double dose of octreotide LAR. The primary 
outcome was an increase in PFS (median not reached vs 8.4 months) in favor of patients 
treated PRRT. This study also reported a 79% reduction in risk of progression or death 
compared to octreotide and an increased overall response ratio (ORR) in the PRRT group 
(18%) compared to 3% in the control group [253]. In those cases with tumor progression 
after an initial good response, retreatment with PRRT represents an alternative. In this sense, 
disease control rates of 70-85% have been reported, but tumor response is limited [254, 
255]. 177Lu-DOTATATE has been also evaluated with radiosensitizing agents; its use in 
combination with 5-fluorouracil, capecitabine or temozolamide may increase the response 
rate (ORR 24-38%), but toxicity should still be evaluated [256-258]. Similar ORR has been 
reported when combined to everolimus [259]. Some case reports and series have suggested 
the use of pre-operative PRRT for downstaging NETs [260-262], but further investigation 
is still required on the efficacy of neoadjuvant PRRT in patients with initially unresectable 
NETs. Soon the results of the COMPETE study will be available. The aim of this multi-
centre phase III study is to evaluate the efficacy and safety of PRRT (177Lu-Edotreotide) 
compared to everolimus in progressive gastroenteropancreatic- (GEP-) NETs with positive 
expression of SSTs (NCT03049189). Hopefully this comparison will provide information 
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about the treatment sequence that should be followed in progressive NETs under SSAs. A 
representative example of tumor response to PRRT is depicted in Figure 7.
Molecular Targeted Therapy
- Everolimus: The mammalian target of rapamycin (mTOR1) pathway plays an important 
role in the regulation of cell proliferation in NETs [263]. The efficacy of the PI3K/AKT/
mTOR inhibitor everolimus in well-differentiated NETs has been shown in several clinical 
trials [133]. In the phase III RADIANT 3 trial PFS was longer in the everolimus group 
compared to placebo [264], and its effect on PFS and OS was independent of the prior use 
of chemotherapy or SSAs [264-266]. Increased PFS and higher disease control rate were 
also reported in the RADIANT 4 study [267]. However, although everolimus is considered 
A B
C D
Figure 7: Peptide receptor radionuclide therapy in NETs. (A) CT imaging of a pancreas neuroen-
docrine tumor grade 2 with lymphatic and liver metastasis (segment 6); in this case, 4 cycles of peptide 
receptor radionuclide therapy (cumulative dosis 30 Gbq) was administered resulting in decreased size 
of the primary tumor (B). After 6 years, of partial response and stable disease, the primary tumor in-
creased in size accompanied by new liver and mesenteric metastasis (C). Due to a first good treatment 
response, 2 cycles of PRRT (14.9 GBq) were administered, decreased size of primary tumor and liver 
metastasis were observed (D).
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a safe drug, treatment can be accompanied by grade 3 and 4 drug-related adverse events 
(diarrhea, infections, anemia, fatigue, hyperglycemia) [267], which may limit the treatment 
tolerance and consequently the patient adherence. Importantly, the RADIANT 4 study, 
as the previous ones, failed to demonstrate statistically significant improvements in OS 
[267], which should be considered especially in those patients with poor treatment toler-
ance. The combination of everolimus and octreotide LAR improved PFS in lung [268] and 
colorectal NETs [269]. Everolimus is considered as first-line therapy in progressive atypical 
lung carcinoids, SSTs-negative lung NETs, and in well-differentiated midgut SSTs-negative 
NETs [133]. Currently, several studies are evaluating the combination of everolimus with 
other therapies including, chemotherapeutic agents, SSAs, molecular targeted therapies, 
radiotherapy and PRRT.
-Sunitinib: Sunitinib is as an oral multi-targeted tyrosine kinase inhibitor (TKI) that in-
hibits multiple angiogenic factors, including the vascular endothelial growth factor receptors 
1-3 (VEGFR), the stem-cell factor receptor, and the platelet-derived growth factor receptors 
[270]. Increased PFS in progressive PNETs compared to placebo has been reported in those 
patients treated with sunitinib (SUN 1111 trial) [218], but as for everolimus, significant 
improvement in OS has not been reported yet.
Other therapeutic targets
The comprehensive evaluation of signaling pathways regulating cell proliferation involved in 
NET development and progression has opened new perspectives for the medical treatment 
of these tumors. mTOR inhibitors and TKIs are the most representative examples, but other 
novel pathway-directed therapeutic compounds are also currently evaluated in (pre-)clinical 
studies [271]. Other examples of potential new treatment options include immunotherapy 
and somatostatin-dopamine multi-receptor chimeras. The mechanisms of action of immune 
checkpoint inhibitors and multi-receptor chimeras are depicted in Figure 6.
Immune checkpoint inhibitors have rapidly advanced and improved the management of 
several tumors in the last years [272, 273]. Programmed death-ligand 1 (PD-L1) is expressed 
on several cancer cells and interacts with PD1, which is expressed on T cells. This ligand-
receptor interaction inhibits T cells and blocks the antitumor immune response [274, 275]. 
The expression of PD-L1 was demonstrated in GEP- and lung (large cell neuroendocrine 
carcinoma) NETs [274, 276], and has been associated with clinical variables including, 
histological type, tumor grade, and survival [274, 277]. The expression of PD-1 and PD-L1 
has also been suggested as an independent survival prognostic factor in NETs [277]. Despite 
immunotherapy has an important role in the management of other types of cancer, the effect 
on well-differentiated NETs, according to preliminary data, seems to be limited although it 
may represent an option for G3NETs/NECs which needs further investigation [278].
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Furthermore, multi-receptor interaction has been suggested as an efficacious and selec-
tive therapeutic strategy for enhancing the effects of somatostatin [279]. The presence 
of hetero-dimers has been described among SSTs and between SSTs and other receptor 
families, including dopamine receptors, especially the dopamine receptor subtype 2 (D2R) 
[280, 281]. Based on this, some structural chimeric molecules that combine elements of 
SSAs and dopamine analogs (DA) were developed [279]. In vitro studies using GEP-NET 
primary cultures, revealed inhibitory properties of chimeras on hormone secretion [282]. 
Importantly, BIM-23A760, a chimeric compound that activates SST2 and D2R, acutely 
decreased growth hormone and prolactin secretion in pituitary tumors, but long-term effects 
disappeared due to a dopaminergic metabolite that may interfere with the activity of the par-
ent molecule [279]. Multi-receptor targeting drugs are described in chapter 6 of this thesis.
Finally, other therapeutic options may have additional effects on cell proliferation and secre-
tion in NETs. In this sense, ketoconazole is a steroidogenesis inhibitor which is widely used 
for medical treatment of Cushing Syndrome, since it improves clinical signs, symptoms and 
comorbidities [205]. Ketoconazole impairs adrenal and gonadal steroidogenesis by inhibiting 
side-chain cleavage, 17,20-lyase, and 11-β hydroxylase enzymes [283]. This drug could exert 
additive effects in the control of patients with severe hypercortisolemia [283]. Specifically, a 
direct effect ketoconazole on tumoral ACTH secretion has been suggested [284, 285] due to 
prolonged remission of hypercortisolemia in EAS patients [284-286] and reduced ACTH in 
vitro secretion [287]. Additionally, cytotoxic effects [288], ketoconazole-induced apoptosis 
[289] and changes in cell cycle phases have been described [290].
A putative association between treatment with metformin and cancer prevention/treatment 
is suggested [291]. Epidemiological studies have suggested a decreased risk for pancreas, liver, 
colon, lung, and breast cancer in patients with diabetes treated with metformin [292-295]. 
This protective effect of metformin has been also described in several meta-analysis [295-
297]. Moreover, biguanides can inhibit cell proliferation in vitro in several cancer cell lines, 
including pancreatic and neuroendocrine tumor cells [298, 299]. Metformin stimulates the 
AMP-activated protein kinase (AMPK), which reduces hepatic gluconeogenesis/glycoge-
nolysis and increases glucose uptake in the muscle [300, 301]. Additionally, it suppresses 
the mTOR1 pathway, reduces the insulin/insulin like growth factor 1 (IGF-1) signaling 
[302, 303] and mediates cell cycle arrest and apoptosis [304, 305]. Some of these actions 
may be also exerted in an AMPK-independent manner [306]. Closely related to metformin, 
statins are also commonly used in patients with metabolic syndrome or T2DM. Statins not 
only affect the rate limiting step in cholesterol synthesis, they also exert other clinical effects 
related with immunomodulatory mechanisms [307]. Additionally, some antitumor effects 
have been described in several tumor types, including melanoma, colon and breast cancer 
[308-311]. The antitumor mechanisms of statins may include induced cell-cycle arrest, 
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apoptosis induction, decreased invasion/metastasis capacity and decreased Ki67 expression 
[310-314]. In this context, these drugs are described in chapters 5 (ketoconazole) and 8 
(metformin and statins).
3.3 Liver directed therapies
Non-surgical liver directed therapies may represent a primary treatment option, especially in 
functioning metastasized NETs. Radiofrequency ablation, cryoablation and microwave abla-
tion are some options for small liver lesions [315]. Ablation is useful in cases of intrahepatic 
disease recurrence with limited liver surgical options, and as an adjuvant therapy to surgical 
resection in metastatic disease [316].
Since metastasis in NETs are highly vascular, and the hepatic artery supplies the majority 
of their blood, endovascular procedures are useful in several NETs with liver metastasis 
[317]. Bland embolization, chemoembolization, or radioembolization are recognized as a 
palliative treatment in hepatic-predominant metastatic NET patients who are not candi-
dates for surgical resection [318]. Arterial directed interventions produce local effects and 
could deliver high chemotherapy doses or selective internal radiotherapy for symptomatic 
control of hormone release and tumor size [319]. Currently no modality has demonstrated 
to be superior to the others, but unfortunately, prospective, randomized, placebo-controlled 
studies are not available yet [319].
AIMS AND OUTLINE OF THIS THESIS
The general aims of the studies presented in this thesis are:
1. To identify potential novel tissue biomarkers for lung carcinoids and GEP-NETs
2. To evaluate the antitumor effect of registered drugs (for other medical purposes) in NETs
3. To evaluate the effects of novel drugs on NET hormone release and cell proliferation
Specifically, we studied the potential applicability of ghrelin and somatostatin systems as 
biomarkers in tissue samples of lung carcinoids and GEP-NETs. As registered drugs for 
other medical purposes, we evaluated the antitumor effects of ketoconazole, metformin and 
statins. Finally, somatostatin-dopamine receptor chimeras and telotristat were studied as 
novel drugs for hormone release and cell growth control.
Chapter 1 gives an overview of the current literature on epidemiological and clinical char-
acteristics of NETs, diagnostic strategies and therapeutic options. Diagnosis is especially 
focused on novel circulating and (some) tissue biomarkers. Part I is focused on potential 
novel tissue biomarkers in NETs. Chapter 2 describes the molecular and immunohisto-
logical presence of somatostatin/cortistatin, and ghrelin system components in human 
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lung carcinoids, as well as their clinical and histological relations. In chapter 3 the mRNA 
expression of somatostatin/cortistatin, system components in GEP-NETs is described and 
correlated with clinical features, histology and immunohistochemistry. Additionally, the in 
vitro evaluation of the observed clinical relation is also included. Finally, chapter 4 describes 
the potential role of ghrelin O-acyltransferase (GOAT) and ghrelin receptor (GHSR1a) as 
tissue markers in GEP-NETs. Part II is focused on novel therapeutic options in NETs. To 
this aim, in chapter 5 the in vitro direct and indirect effects of ketoconazole in ACTH- and 
non-ACTH producing tumor cells are studied. Additionally, an in vitro pancreas model of 
NETs using two-dimensional and three-dimensional culture systems is extensively evaluated 
in chapter 6, and in the same chapter the in vitro effect of somatostatin/dopamine agonists 
and somatostatin-dopamine multi-receptor targeting drugs is described. Furthermore, 
the first report of the in vitro effects of the novel serotonin syntesis inhibitor telotristat is 
described in chapter 7. The clinical relation between metabolic syndrome and NETs is 
described in chapter 8, as well as some clinical data and in vitro effects of biguanides and 
statins in NETs. Finally, chapter 9 and 10 provide a general discussion and summary of the 
presented data.
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ABSTRACT
Background: Lung carcinoids (LCs) are rare tumors that comprise 1-5% of lung malignancies 
but represent 20-30% of neuroendocrine tumors. Their incidence is progressively increasing 
and a better characterization of these tumors is required. Alterations in somatostatin (SST)/
cortistatin (CORT) and ghrelin systems have been associated to development/progression of 
various endocrine-related cancers, wherein they may become useful diagnostic, prognostic 
and therapeutic biomarkers.
Objectives: We aimed to evaluate the expression levels of ghrelin and SST/CORT system 
components in LCs, as well as to explore their putative relationship with histological/clinical 
characteristics.
Patients and methods: An observational retrospective study was performed; 75 LC patients 
with clinical/histological characteristics were included. Samples from 46 patients were pro-
cessed to isolate mRNA from tumoral and adjacent non-tumoral region, and the expression 
levels of SST/CORT and ghrelin systems components, determined by quantitative-PCR, 
were compared to those of 7 normal lung tissues.
Results: Patient cohort was characterized by mean age 53 ±15 years, 48% males, 34% with 
tobacco exposure; 71.4/28.6% typical/atypical carcinoids, 21.7% incidental tumors, 4.3% 
functioning tumors, 17.7% with metastasis. SST/CORT and ghrelin system components 
were expressed at variable levels in a high proportion of tumors, as well as in adjacent 
non-tumor tissues, while a lower proportion of normal lung samples also expressed these 
molecules. A gradation was observed from normal non-neoplastic lung tissues, non-tumoral 
adjacent tissue and LCs, being SST, sst4, sst5, GHS-R1a and GHS-R1b overexpressed 
in tumor tissue compared to normal tissue. Importantly, several SST/CORT and ghrelin 
system components displayed significant correlations with relevant clinical parameters, such 
as necrosis, peritumoral and vascular invasion, or metastasis.
Conclusion: Altogether, these data reveal a prominent, widespread expression of key SST/
CORT/ghrelin system components in LCs, where they display clinical-histological correla-
tions, which could provide novel, valuable markers for NET patient management.
Key Words: lung carcinoids; somatostatin system; ghrelin system; clinical-histological 
features
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INTRODUCTION
Lung neuroendocrine tumors (LNETs) represent 20-30% of all neuroendocrine tumors 
[1-3]. The 2015 World Health Organization (WHO) classifies lung neuroendocrine tumors 
in low-grade typical carcinoid (TC), intermediate-grade atypical carcinoid (AC) and high-
grade large cell neuroendocrine carcinomas (LCNEC) and small cell carcinoma (SCLC)[4]. 
Although these neoplasms share morphological, immunohistochemical and ultrastructural 
features, there are significant clinical, prognostic and therapeutic differences between sub-
types. Indeed, high-grade tumors are very aggressive and display poor prognosis, while lung 
carcinoids (LCs, including TCs and ACs) have been less characterized, with a less standard-
ized clinical management, apart from surgical resection or chemoradiotherapy [5, 6].
LCs display an incidence of 5-10 cases per million population/year [7, 8], and 5-15% of 
multiple neuroendocrine neoplasia 1 (MEN1) patients [9, 10]. Compared to other NETs, 
a lower proportion of LCs exhibits hormone hypersecretion, such as vasoactive intestinal 
peptide, adrenocorticotropic hormone (ACTH), and diuretic hormone, wherein the most 
common hormonal syndrome is the ectopic ACTH syndrome [11]. Paraneoplastic syn-
dromes, including inappropriate antidiuretic hormone secretion, are even less frequent [9]. 
Importantly, LCs prognosis is tightly correlated to histotype, as TCs have a 5-year survival 
rate of 87%, presenting regional lymph node metastasis in 10-15% and distant metastases 
in 3-5% of cases. In contrast, ACs are more aggressive, with frequent nodal and distant 
metastases (20–50% respectively) and a 5-year survival of 60% [3, 12, 13]. Anyway, the only 
curative treatment for LCs is radical surgery [14].
The heterogeneity of these neoplasms, their different clinical behavior, and the possibility of 
recurrence or long-term metastasis, emphasize the importance of identifying new diagnostic 
and therapeutic markers, which could improve the diagnosis, prognosis and/or treatment of 
these patients. Accordingly, alterations in the regulatory neuroendocrine systems comprised 
by somatostatin (SST)/cortistatin (CORT), ghrelin and their receptors (ssts and GHSRs, 
respectively) have been associated to the development/ progression of various endocrine-
related cancers. However, their expression has not been systematically characterized in LCs.
SST and CORT are two highly related neuropeptides that exert a plethora of physiological, 
often inhibitory, functions, by acting through their so-called SST receptors (sst1-5) [15-18], 
which regulate, among other activities, cell proliferation, differentiation, and angiogenesis 
[19]. They are widely distributed in normal and tumoral tissues, playing a useful role in 
tumor imaging (sst-scintigraphy or octreotide scan) [20]. More importantly, synthetic SST 
analogues (SSAs) represent a valuable therapeutic tool to treat ssts-positive tumors, to con-
trol hormone hypersecretion and tumor growth [21-24]. Additionally, ghrelin is a peptide 
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hormone with multiple, and generally stimulatory functions, which span from hormone 
release to regulation of tumor cell proliferation [25, 26]. Ghrelin needs to be acylated by the 
enzyme ghrelin-O-acyl transferase (GOAT) [27, 28] to bind its receptor GHSR-1a [29]. The 
complexity of SST/CORT and ghrelin systems has been lately expanded by the identification 
of additional splicing variants of ghrelin (In1-ghrelin) [30-35], ghrelin receptor (GHSR-1b) 
[36, 37] and sst5 (sst5TMD4 and sst5TMD5) [38-44] genes, which are overexpressed in 
tumoral pathologies, including gastroenteropancreatic NETs (GEP-NETs 34, 44), where 
they are associated with aggressive features.
The data collected in a limited number of studies on the presence and clinical implications of 
certain components of these systems [34, 45-54] suggest that a more detailed knowledge of 
the expression pattern of their components could unveil relevant implications in the diagnosis, 
prognosis and medical treatment of LCs. Accordingly, we implemented an exhaustive charac-
terization of the presence/expression of the components of SST/CORT and ghrelin systems in 
well-characterized LCs, compared to non-tumoral adjacent tissues and normal non-neoplastic 
samples, and explored their putative relationship with clinical/histological characteristics.
MATERIALS AND METHODS:
Patients
The Ethics Committee of the Reina Sofia University Hospital (Cordoba, Spain) approved the 
study, which was conducted in accordance with the Declaration of Helsinki and with national 
and international guidelines. A written informed consent was signed by every individual. 
Seventy-five patients with LCs who underwent surgery from 2005 to 2015 were included. 
Clinical records were used to collect full medical history. Endocrine-associated syndromes such 
as MEN or von Hippel-Lindau syndromes were excluded. LCs were evaluated and classified 
according to histopathology features in TC and AC. To confirm the neuroendocrine nature 
of all tumors, different neuroendocrine markers (including chromogranin A, synaptophysin, 
cytokeratin 7, cytokeratin 20, CD56, neuronal specific enolase, AE1AE3, cytokeratin, p53, 
glucagon, insulin, gastrin, SST, intestinal vasoactive peptide, pancreatic polypeptide and/or 
serotonin) were determined by immunohistochemistry following standardized protocols and 
evaluated by two experienced pathologists to confirm that all the included neuroendocrine 
tumors expressed a minimum of two different neuroendocrine markers. In addition, tissue 
samples were obtained from 46 of those patients and from 7 normal tissues from anonymous 
body organ donors. In particular, we obtained 89 formalin-fixed paraffin-embedded (FFPE) 
samples (46 primary tumors and 43 non-tumoral adjacent tissues) and 7 normal tissues. 
To ensure the appropriate identification of tumor and non-tumor adjacent areas for further 
RNA isolation, a comprehensive analysis of hematoxylin/eosin and immunohistochemistry 
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sections was performed by two different experienced pathologists using conventional micros-
copy. Each sample was evaluated twice in order to identify, delineate and manually dissect 
the corresponding tissues, and when tumor and adjacent tissue were appropriately identified, 
5um slides from each paraffin-embedded tissue were cut and tumor and non-tumor adjacent 
regions subsequently separated for further evaluations.
RNA isolation and reverse-transcription
Total RNA from FFPE samples was isolated using the RNeasy FFPE Kit (Qiagen, Limburg, 
Netherlands) according to manufacturer’s instructions. Quantification of the recovered 
RNA was assessed using NanoDrop2000 spectrophotometer (Thermo Scientific, Wilming-
ton, NC, USA). One microgram of total RNA was retrotranscribed to cDNA with the 
First Strand Synthesis kit using random hexamer primers (Thermo Scientific) as previously 
reported [39, 55].
Quantitative real time PCR (qPCR)
cDNAs were amplified with the Brilliant III SYBR Green Master Mix (Stratagene, La Jolla, 
CA, USA) using the Stratagene Mx3000p system and specific primers for each transcript 
of interest, as previously reported. Expression levels (absolute mRNA copy number/50ng 
of sample) of native-ghrelin, In1-ghrelin, GOAT, GHSR-1a, GHSR-1b, SST, CORT, sst1, 
sst2, sst3, sst4, sst5 and sst5TMD4 were measured using previously validated primers [31, 
33, 56, 57]. Samples were run, in the same plate, against a standard curve to estimate mRNA 
copy number and a No-RT sample as negative control. Thermal profile consisted of an initial 
step at 95°C for 30s, followed by 50 cycles of denaturation (95°C for 20s) and annealing/ 
elongation (60°C for 20s), and finally, a dissociation cycle (melting curve: 55°C to 95°C, 
increasing 0.5°C/30s) to verify that only one product was amplified. RNA expression was 
adjusted by the expression of the housekeeping gen beta-actin (ACTB), whose levels were 
not significantly different among groups.
Immunohistochemistry (IHC) analysis
IHC analysis of GHSR-1a and sst4 was implemented in formalin-fixed, paraffin-embedded 
(FFPE) lung tissue samples (n=19), which included tumor and non-tumor regions from 
patients diagnosed with LCs, using standard procedures. The optimum antibody concentra-
tion to perform GHSR-1a and sst4 IHC analyses (1:300) using a commercially available 
human GHSR-1a and sst4 antibodies (Santa Cruz and AVIVA, respectively) was selected 
by performing a series of antibody dilution tests (1:100; 1:200; 1:300 and 1:400) in brain 
samples (a tissue that has been previously reported to express high levels of GHSR-1a and 
sst4). Two independent pathologists performed the IHC analysis of the samples following 
a blinded protocol. In the analysis, 1+, 2+, 3+ stand for low, moderate, and high intensities 
of the tumoral region staining compared to the adjacent region with non-tumor lung tissue.
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Statistical analysis
Paired t-test analysis was used to compare the expression levels between LC samples and 
adjacent non-tumoral tissue. Non-paired t-test analysis was used to compare the expres-
sion levels between normal lung tissue and tumor or adjacent non-tumoral tissue. U-Mann 
Whitney tests were used to evaluate clinical-molecular relations. Chi-squared test compared 
categorical data. Statistical analyses were performed using SPSS statistical software v20 and 
GraphPad Prism v6. Data are expressed as mean±SEM. p-values<0.05 were considered 
statistically significant.
RESULTS
Patient population and clinical correlations
A total of 75 LCs patients were included. Demographic and clinical features are summarized 
in Table 1, while characteristics of the 49 tumor tissues are summarized in Table 2. Demo-
graphic and clinical characteristics were similar between TC and AC subjects. When all LC 
patients were considered together, age was positively correlated to second neoplasm presence 
Table 1: Demographic and clinical characteristics of the patient population
General characteristic Total n=75
(100%)
Typical n=34
(69.4%)
Atypical n=15
(30.6%)
p*
Gender >0.05
Male 48% (36) 44.1% (15) 66.7% (10)
Female 52% (39) 55.9% (19) 33,3% (5)
Age 53.13±15.18 years 49.36±3.45 51.66±4.62 >0.05
Personal history of other tumors 17.4% (12) 22.6% (7) 20% (3) >0.05
Smoke habit >0.05
Active 34% (18) 33.3% (8) 28.6%(4)
Ex-smoker 28.3% (15) 33.3% (8) 28.6% (4)
No habit 37.7% (20) 33.3% (8) 28.6% (4)
Family history of neoplasms 55.6 % (5) 66.7% (2) 33.3 % (1) >0.05
Incidental tumor 21.7% (10) 29.4% (5) 36.4% (4) >0.05
Pre-surgical treatment 6.1% (4) 3.2% (1) 14.3% (2) >0.05
Clinical symptoms** >0.05
Hemoptysis 17.9% (5) 23.5% (4) 9.1% (1)
Cough 10.7% (3) 11.8% (2) 9.1% (1)
Pneumonia 35.7% (10) 35.3% (6) 36.4% (4)
*p value refers to the comparison between typical and atypical carcinoids
** most common clinical symptoms
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(p=0.006) and parenchyma localization (p=0.013), and showed a non-significant trend to 
correlate with vascular invasion (p=0.055). Although all tumors were positive for at least 
one neuroendocrine marker, these markers did not exhibit any apparent association with 
clinical variables. In contrast, tumor diameter was directly correlated to necrosis (p=0.016), 
peritumoral invasion (p=0.006) and metastasis (p=0.026). ACs exhibited significantly 
higher diameter (p=0.022), necrosis (p=0.013), vascular invasion (p=0.005), peritumoral 
tissue invasion (p=0.028), and metastasis (p<0.001) than TCs.
Table 2: Tumor sample characteristics
Tissue samples Total (%)
(46)
Typical n=22
(66.7%)
Atypical n=11
(33.3%)
p*
Primary tumor localization
Right lung 62.2% (28) 72.7% (16) 54.5% (6) >0.05
Left lung 37.8% (17) 27.3% (5) 45.5% (5) >0.05
Upper lobe 25.6% (11) 18.2%(4) 36.4% (4) >0.05
Right middle lobe 27.9% (12) 40.9% (9) 18.2% (2) >0.05
Lower lobe 44.2% (20) 36.4% (8) 36.4% (4) >0.05
Immunohistochemistry
Chromogranin A 39.6% (19) 34,28% (12) 40%(6) >0.05
Synaptophysin 31.3% (15) 28.57%(10) 28.57% (4) >0.05
Cytokeratin 7 4.2% (2) 2.86%(1) 9.1% (1) >0.05
Cytokeratin 20 2.1% (1) 0% (0) 7.14% (1) >0.05
Neuronal specific enolase 22.9% (11) 17.14% (6) 21.43% (3) >0.05
CD56 18.8% (9) 18.2% (4) 18.2% (2) >0.05
Others** 73% (36) 62.85%(22) 71.42% (10) >0.05
Functionality 4.3% (2) 0% (0) 8.3% (1) >0.05
Tumor diameter (cm) 2.72±2.05 2.38±0.21 4.81±1.36 0.013
Multiple tumors 7% (5) 3% (1) 13.3% (2) >0.05
Peri-tumoral invasion 22.5% (9) 6.7% (2) 46.2% (6) 0.028
Vascular invasion 16.7% (4) 0% (0) 50% (4) 0.005
Neural invasion 11.8% (2) 0% (0) 33.2% (2) >0.05
Metastasis 12.5% (5) 0% (0) 46.2% (5) 0,007
Bronchial lumen localization/infiltration 80% (32) 75% (21) 66.7% (8) >0.05
Parenchyma localization/infiltration 32.5% (13) 35.7% (10) 58.3% (7) >0.05
Pleural localization/infiltration 7.5% (3) 10.7% (3) 0% (0) >0.05
*p value refers to the comparison between typical and atypical carcinoids
**Others indicate positive immunohistochemistry for (at least) one of the following neuroendocrine 
markers: AE1AE3, cytokeratin, p53, glucagon, insulin, gastrin, SST, intestinal vasoactive peptide, pan-
creatic polypeptide and/or serotonin
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Histopathological characterization of LCs and non-tumoral adjacent tissue
Representative histological images of TC and ACs, adjacent non-tumor tissues and normal 
lungs are depicted in Figure 1. Remarkably, adjacent non-tumor tissue displayed clear signs 
of pathological transformation (Figure 1C) as they presented diffuse interstitial chronic in-
flammation characterized by lymphocytes, scattered plasma cells and occasional multinucle-
ated giant cells, which was not observed in normal non-neoplastic lung tissues (Figure 1D).
A B
C D
Figure	1
Figure 1: Histopathological evaluation of normal lung, adjacent non-tumoral tissue and LCs 
samples. Representative images of hematoxilin/eosin staining performed on TC (A), AC (B), adjacent 
non-tumoral tissue characterized by diffuse interstitial chronic inflammation with lymphocytes, scat-
tered plasma cells and occasional multinucleated giant cells (narrows) (C) and normal lung controls (D).
Expression of SST/CORT system components in control and LC samples
SST/CORT system components were expressed in a modest proportion of normal lung 
samples, as determined by qPCR. Only SST and sst3 were expressed in almost 50% (3 
out of 7) of normal samples, whereas other SST/CORT components were only detected in 
1 or 2 samples (Figure 2A). In contrast, a high proportion of tumoral and, also, adjacent 
non-tumoral tissues expressed most of the SST/CORT system components (Figure 2A). 
Specifically, SST, sst1, sst2, sst3, sst5, and sst5TMD4 were expressed in at least 75% of 
adjacent non-tumoral and tumoral samples, with only sst4 being present in less than 25% 
of the adjacent and tumoral tissues (Figure 2A). Of note, the percentage of tumoral tissues 
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Figure 2: Presence and mRNA expression of SST/CORT system components in normal lung, 
adjacent non-tumoral tissue and LCs. A: The graphs indicate the percentage of samples (normal 
lung control, adjacent non-tumoral tissue and tumoral tissue) positive for each of the SST/CORT 
system components. B: The absolute mRNA expression of the different components of the SST/
CORT system was determined by qPCR in normal lung controls, adjacent non-tumoral tissue and 
LC samples (values are adjusted by ACTB expression). Data represent the mean±SEM. Asterisks (*, 
p<0.05; **, p<0.01; ***,p<0.001) indicate significant differences by paired analysis between adjacent 
non-tumoral and LCs and non-paired analysis between normal lung tissue and adjacent non-tumoral 
or tumoral tissues.
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expressing the components of SST/CORT system was similar between AC and TC (p>0,05) 
(Suppl. Figure 1).
Expression levels of the SST/CORT system components were largely variable. In this 
analysis, only cases that showed detectable expression were included. SST expression levels 
were 100-fold higher than those of CORT, whose mRNA levels were close to the detection 
limits (Figure 2B). SST levels were higher in non-tumoral adjacent and tumoral tissues 
compared to control tissue, being this increase more pronounced in tumoral tissue (Figure 
2B). In the case of the receptors, sst1 and sst2 were highly expressed, followed by sst3, while 
sst5, sst5TMD4 and sst4 showed lower levels. Expression of all ssts, except sst3, displayed a 
similar tendency, increasing progressively from control tissues to non-tumoral adjacent tis-
sue and being apparently higher in the tumoral regions (Figure 2B). Interestingly, in tumor 
samples, SST expression was correlated to sst1, sst2, sst3 and sst5 expression; CORT levels 
were correlated to sst5 expression and, finally, sst1, sst2 and sst3 expression levels showed 
significant correlations (Suppl. table 1).
Expression of ghrelin system components in control and LC samples.
Ghrelin system components were also expressed in <25% of normal lung samples, as deter-
mined by qPCR (Figure 3A). In contrast, ghrelin, In1-ghrelin, GHSR-1a and GHSR-1b 
were expressed in at least 75% of tumoral and adjacent non-tumor tissues; while GOAT 
was present in less than 50% of the adjacent non-tumoral samples but in more than 75% of 
tumoral samples (Figure 3A). The proportion of tumoral tissues expressing ghrelin system 
components was not statistically significant different between AC and TC (Suppl. Figure 2). 
In contrast, GHSR-1a and GHSR-1b were overexpressed in tumor tissue and adjacent-non 
tumoral tissue compared to normal lung tissue (Figure 3B). No significant correlation was 
observed among the expression levels of the ghrelin system components in tumor samples 
(data not shown).
Immunohistochemistry (IHC) analysis
Although qPCR is a sensitive method of assaying for gene expression, we subsequently 
performed IHC analysis in a set of selected samples in order to validate the observed changes 
at the protein level, and to determine which particular cells are expressing those markers. 
To this end, we selected sst4 and GHSR-1a due to their clear overexpression in tumor 
samples. Specifically, GHSR-1a and sst4 IHC was performed on FFPE-lung carcinoids, 
which revealed stronger staining in tumor samples compared to non-tumor adjacent tissue 
(Suppl. Figure 3B, 4B). In general, IHC analysis of non-tumol adjacent tissue revealed that 
only few cells from pulmonary parenchyma and glandular tissue were specifically stained 
(Suppl. Figure 3A, 4A). However, it is worth noting that infiltrated immune cells and espe-
cially alveolar macrophages presented an intense staining in these samples. In contrast, IHC 
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analysis of tumor tissue revealed that GHSR-1a and sst4 were present in the vast majority 
of tumor cells. Interestingly, tumor samples presented variable levels of both molecules, 
although most samples were classified as having an intensity of 2+ or 3+ by the pathologists. 
Therefore, these data confirm the contention that the expression of certain components 
of the SST/CORT/ssts and ghrelin/GHSRs systems, and especially GHSR-1a and sst4, is 
clearly dysregulated in LC samples compared to non-tumor adjacent tissue.
Expression of SST/CORT and ghrelin systems components and clinical-
histological characteristics in tumoral LC samples.
Correlation analyses revealed that sst3 was overexpressed in LCs of patients with tobacco 
smoke exposure (p<0.05), that sst5 was higher in incidental tumors, and that disease-free 
patients exhibited higher sst5TMD4 expression (Figure 4). Regarding the ghrelin system, 
ghrelin expression was correlated to vascular invasion (p=0.042) and tended to associate with 
bronchial localization (p=0.057) (Figure 4). Interestingly, necrotic tumors overexpressed 
GOAT (p<0.05) and GHSR-1a was overexpressed in tumors with parenchyma localization 
and in non-functional and metastatic tumors (p<0.05) (Figure 4).
Figure	3
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Figure 3: Presence and mRNA expression of ghrelin system components in normal lung, adjacent 
non-tumoral tissue and LCs. 3A: The graphs indicate the percentage of samples (normal lung control, 
adjacent non-tumoral tissue and tumoral tissue) positive for each of the ghrelin system components. 
3B: The absolute mRNA expression of the different components of the ghrelin system was determined 
by qPCR in normal lung controls, adjacent non-tumoral tissue and LC samples (values are adjusted 
by ACTB expression). Data represent the mean±SEM. Asterisks (*, p<0.05; **,p<0.01; ***,p<0.001) 
indicate significant changes by paired analysis between adjacent non-tumoral and LCs and non-paired 
analysis between normal lung tissue and adjacent non-tumoral or tumoral tissues.
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DISCUSSION
In this study, we have comprehensively evaluated by qPCR the expression of SST/CORT 
and ghrelin system components in a large series of well-characterized TCs and ACs, and 
compared with the expression in adjacent non-tumoral and normal lung tissues. To the 
best of our knowledge, this study represents the first systematic characterization of the 
components of these regulatory systems in samples from LCs, in comparison with adjacent 
non-tumoral regions and normal lungs, and may therefore provide a useful overall picture 
of the landscape of changes associated to LCs pathology. Although several studies have ex-
plored the presence of certain SST/CORT and ghrelin systems components in LCs [45-52], 
their presence had never been compared to that found in adjacent non-tumoral regions or 
Figure	4
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Figure 4: Correlations between epidemiological, clinical, histological and molecular parameters 
in LCs. The putative correlations between epidemiological, clinical, histological and molecular param-
eters within LC samples were assessed by U-Mann Whitney tests and asterisks (*, p<0.05; **, p<0.01) 
indicate significant associations.
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normal lungs. In addition, specific SST/CORT and ghrelin system components displayed 
clinical-histological correlations in tumoral tissues, suggesting that they could provide novel, 
valuable markers for LC-patient management.
Consistent with previous reports showing that 75% of LCs are central (bronchial) and 
25% are peripheral tumors [3], our tumor series presented a similar distribution. In ad-
dition, previous studies have reported that LCs diameter is not correlated to survival or 
recurrence [13]. Consistently, in our series, no direct correlation with clinical outcome was 
observed, although tumors >2.4cm showed higher rate of peritumoral invasion, vascular 
invasion and distant metastasis. In fact, no correlations between clinical, histological or im-
munohistochemical characteristics and survival or mortality were found herein, which is in 
contrast with previous reports describing some independent predictors of survival [mitotic 
rate, tumor size, sex [58], typical histology and lymphatic invasion [59]]. Nevertheless, our 
analysis revealed that age correlated directly to the presence of parenchyma localization, a 
second neoplasm and vascular invasion, which have not been previously reported and could 
suggest age as a risk factor for more aggressive tumors.
Remarkably, tumoral characteristics of TCs and ACs were markedly different. ACs exhibited 
significantly higher diameter, necrosis, peri-tumoral and vascular invasion and metastasis, 
which is consistent with higher ACs malignancy compared to TCs [60]. Similar to other 
reports, adjacent non-tumoral tissues exhibited signs of pathological alteration compared to 
normal lung samples [61-64]. Consequently, to comprehensively characterize SST/CORT 
and ghrelin system components expression in a large series of well-characterized TCs and 
ACs, and compare with their expression in adjacent non-tumoral tissues and normal lungs, 
we applied a qPCR-based approach as previous studies have demonstrated that mRNA levels 
of the components of these systems correlate well with their respective protein levels [46, 48, 
49, 65, 66]. Moreover, qPCR is a more sensitive detecting method than IHC [67].
NETs are known to overexpress stss [46, 53, 54], which is important in their diagnosis 
and management [20, 46, 68, 69]. However, to date, only a limited number of studies 
have reported the expression of ssts other than sst2, with variable results, likely due to the 
application of different experimental approaches [19, 70, 71]. Particularly, just few studies 
have explored a small number of cases or only single receptor subtypes [50, 65, 67, 70, 72]. 
Recently, additional studies have more comprehensively characterized ssts presence on LCs 
[46, 48, 73]. Interestingly, the data presented in the current study reveal the prominent and 
widespread expression of ssts in LCs, being sst1 the most abundant, followed by sst2, sst3 
and sst5, with sst4 and the truncated sst5TMD4 being the least expressed. These data agree 
with the majority of the previous studies [48-52, 65, 67]. Moreover, this is the first study 
reporting the presence of sst5TMD4 in LCs and sst5 in symptomatic patients. Although 
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initial studies suggested that ssts presence in LNETs could exhibit a progressive decrease 
from low- to high-grade forms [45]; however, our work and other studies [46] indicate that 
there are no major differences, suggesting that ssts could be a common hallmark of low 
and intermediate grade LNETs. Moreover, our results revealed, for first time, a prominent 
expression of SST in LCs, whereas CORT expression was comparatively negligible. Of note, 
expression of SST directly correlated with that of sst1, sst2, sst3 and sst5, which suggests 
an autocrine/paracrine SST/ssts loop capable to modulate in situ the progression of LCs. 
In addition, SST and ssts expressions displayed herein a gradation in normal lungs, non-
tumoral adjacent tissue, and LCs. Of special interest is our observation that non-tumoral 
adjacent tissues also present a notable expression of SST and ssts, and in fact, a similar 
proportion of non-tumoral adjacent tissues presented ssts compared to LCs, although, in 
general, at lower expression levels. To further explore this notion, we selected sst4 (due to 
its differential distribution), to perform an IHC analysis, as it has been previously reported 
that specific antibodies against SST receptors allow an appropriate immunolocalization of 
receptor subtypes in tumor tissue with a comparable, although not quantitatively superior 
quality than that of qPCR [65]. Results from this analysis enabled visualization of sst4 in 
specific cells of tumor tissue and demonstrated that non-tumor adjacent cell type (in airway 
epithelium and associated neuroendocrine cells, as well as in pulmonary parenchyma and 
associated glandular tissue) are less immunopositive that other tumor cells.
Our results also revealed a differential expression of ghrelin system components in normal 
lung tissues, non-tumoral adjacent tissue, and LCs. In particular, ghrelin system components 
were expressed at low levels in a reduced proportion of normal lungs, which is consistent 
with previous reports showing ghrelin expression in normal and fetal lungs [30, 47, 66, 
74]; while GHSR1a was undetectable [74]. In contrast, our analysis revealed a prominent 
and widespread expression of ghrelin system components in LCs and adjacent non-tumoral 
samples. Interestingly, a higher expression levels of the canonical variants (native ghrelin 
and GHSR1a) is consistent with previous reports showing that ghrelin is expressed in lung 
tumors, regardless of their neuroendocrine phenotype, and that GHSR1a is present in well 
differentiated functioning and non-functioning lung NETs [29, 75]. In contrast, expres-
sion of the alternative splicing variants (In1-ghrelin/GHSR1b) is lower, and had not been 
reported previously. This is also the first study reporting the expression of the GOAT enzyme 
in a high proportion of LCs, wherein the concomitant presence of ghrelin, GOAT and 
GHSR1a on most LCs suggests the existence of a functional regulatory association that 
could be modulating the development and/or progression of this pathology. Unfortunately, 
no studies have yet investigated the direct effect of this in LCs, and the only report in 
SCLC suggests that ghrelin could inhibits cell proliferation and increases apoptosis [29], 
in agreement with the negative association between ghrelin and vascular invasion in our 
cohort. However, GOAT levels were higher in tumors with necrosis, which were the ones 
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with a larger size and higher capacity of peritumoral invasion and distant metastasis; this, 
together with the direct relationship between metastasis, requirements of post-surgical treat-
ments, and GHSR1a expression, reinforces the idea that this system could be associated 
to the pathogenesis of the disease and might therefore provide novel potential diagnostic, 
prognostic and/or therapeutic tools in LCs.
In summary, this study provides a comprehensive primary mapping of the expression of SST/
CORT and ghrelin system components (including their most relevant splicing variants), in 
LCs, as compared with their respective adjacent non-tumoral tissues, and with normal, non-
neoplastic tissues. Our results indicate a prominent and widespread overexpression of SST/
CORT and ghrelin system components in LCs and in non-tumoral adjacent tissues, wherein 
they could exert relevant regulatory roles, for they display changes in expression tightly 
linked to the degree of disease, and exhibit associations to fundamental clinical parameters. 
Hitherto, there has been a paucity of studies reporting clinical, biochemical, histological, 
immunohistochemical or molecular tumor markers that could help to accurately predict the 
efficacy of the medical treatment, as well as the cure or relapse rates in NETS. This goal is 
specially difficult and necessary in LCs, due to their rarity, high diversity and heterogeneity 
in terms of malignant capacity, localization, and growth pattern. In this context, our present 
findings may help to identify new potential diagnostic and prognostic factors, which could 
help to devise and implement improved therapeutic strategies, aimed at attaining a better 
quality of life and survival for this patients. Hence, our data provide novel information on 
the presence of both SST/CORT and ghrelin systems in LCs, and invite to suggest that 
their role in this pathology as putative molecular biomarkers and therapeutic targets for LC 
patients deserves further investigation.
70
C
ha
pt
er
 2
REFERENCES
 1. Gustafsson, B.I., et al., Bronchopulmonary neuroendocrine tumors. Cancer, 2008. 113(1): p. 
5-21.
 2. Travis, W.D., Advances in neuroendocrine lung tumors. Ann Oncol, 2010. 21 Suppl 7: p. 
vii65-71.
 3. Rekhtman, N., Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med, 2010. 
134(11): p. 1628-38.
 4. Travis, W.D., et al., The 2015 World Health Organization Classification of Lung Tumors: Impact 
of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol, 2015. 
10(9): p. 1243-60.
 5. McMullan, D.M. and D.E. Wood, Pulmonary carcinoid tumors. Semin Thorac Cardiovasc Surg, 
2003. 15(3): p. 289-300.
 6. Kosmidis, P.A., Treatment of carcinoid of the lung. Curr Opin Oncol, 2004. 16(2): p. 146-9.
 7. Modlin, I.M., K.D. Lye, and M. Kidd, A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 
2003. 97(4): p. 934-59.
 8. Travis, W.D., Lung tumours with neuroendocrine differentiation. Eur J Cancer, 2009. 45 Suppl 
1: p. 251-66.
 9. Sachithanandan, N., R.A. Harle, and J.R. Burgess, Bronchopulmonary carcinoid in multiple 
endocrine neoplasia type 1. Cancer, 2005. 103(3): p. 509-15.
 10. Oberg, K., et al., Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guide-
lines for diagnosis, treatment and follow-up. Ann Oncol, 2012. 23 Suppl 7: p. vii120-3.
 11. Isidori, A.M., G.A. Kaltsas, and A.B. Grossman, Ectopic ACTH syndrome. Front Horm Res, 
2006. 35: p. 143-56.
 12. Thomas, C.F., Jr., H.D. Tazelaar, and J.R. Jett, Typical and atypical pulmonary carcinoids : 
outcome in patients presenting with regional lymph node involvement. Chest, 2001. 119(4): p. 
1143-50.
 13. Ferolla, P., et al., Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behav-
ior in bronchial carcinoids. J Thorac Oncol, 2009. 4(3): p. 383-7.
 14. Swarts, D.R., F.C. Ramaekers, and E.J. Speel, Molecular and cellular biology of neuroendocrine 
lung tumors: evidence for separate biological entities. Biochim Biophys Acta, 2012. 1826(2): p. 
255-71.
 15. Cordoba-Chacon, J., et al., Truncated somatostatin receptors as new players in somatostatin-
cortistatin pathophysiology. Ann N Y Acad Sci, 2011. 1220: p. 6-15.
 16. Gahete, M.D., et al., Somatostatin and its receptors from fish to mammals. Ann N Y Acad Sci, 
2010. 1200: p. 43-52.
 17. Gahete, M.D., et al., Are somatostatin and cortistatin two siblings in regulating endocrine secre-
tions? In vitro work ahead. Mol Cell Endocrinol, 2008. 286(1-2): p. 128-34.
 18. Moller, L.N., et al., Somatostatin receptors. Biochim Biophys Acta, 2003. 1616(1): p. 1-84.
 19. Volante, M., F. Bozzalla-Cassione, and M. Papotti, Somatostatin receptors and their interest in 
diagnostic pathology. Endocr Pathol, 2004. 15(4): p. 275-91.
 20. Kwekkeboom, D.J., et al., ENETS Consensus Guidelines for the Standards of Care in Neuroen-
docrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology, 
2009. 90(2): p. 184-9.
 21. Kwekkeboom, D.J., et al., Overview of results of peptide receptor radionuclide therapy with 3 
radiolabeled somatostatin analogs. J Nucl Med, 2005. 46 Suppl 1: p. 62S-6S.
271
C
om
po
ne
nt
s o
f s
om
at
os
ta
tin
 a
nd
 g
hr
el
in
 sy
ste
m
s
 22. Theodoropoulou, M. and G.K. Stalla, Somatostatin receptors: from signaling to clinical practice. 
Front Neuroendocrinol, 2013. 34(3): p. 228-52.
 23. Ruscica, M., et al., Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the 
biology of cancer progression. Curr Mol Med, 2013. 13(4): p. 555-71.
 24. Culler, M.D., et al., Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer 
Metastasis Rev, 2011. 30 Suppl 1: p. 9-17.
 25. Chopin, L.K., et al., The ghrelin axis--does it have an appetite for cancer progression? Endocr Rev, 
2012. 33(6): p. 849-91.
 26. Gahete, M.D., et al., Ghrelin gene products, receptors, and GOAT enzyme: biological and patho-
physiological insight. J Endocrinol, 2014. 220(1): p. R1-R24.
 27. Gutierrez, J.A., et al., Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl 
Acad Sci U S A, 2008. 105(17): p. 6320-5.
 28. Yang, J., et al., Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating 
peptide hormone. Cell, 2008. 132(3): p. 387-96.
 29. Cassoni, P., et al., Ghrelin and cortistatin in lung cancer: expression of peptides and related recep-
tors in human primary tumors and in vitro effect on the H345 small cell carcinoma cell line. J 
Endocrinol Invest, 2006. 29(9): p. 781-90.
 30. Gahete, M.D., et al., A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase 
are overexpressed in breast cancer: potential pathophysiological relevance. PLoS One, 2011. 6(8): p. 
e23302.
 31. Gahete, M.D., et al., Role of ghrelin system in neuroprotection and cognitive functions: implications 
in Alzheimer’s disease. Peptides, 2011. 32(11): p. 2225-8.
 32. Gahete, M.D., et al., Dietary fat alters the expression of cortistatin and ghrelin systems in the 
PBMCs of elderly subjects: putative implications in the postprandial inflammatory response. Mol 
Nutr Food Res, 2014. 58(9): p. 1897-906.
 33. Ibanez-Costa, A., et al., In1-ghrelin splicing variant is overexpressed in pituitary adenomas and 
increases their aggressive features. Sci Rep, 2015. 5: p. 8714.
 34. Luque, R.M., et al., In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution 
and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular 
parameters. Oncotarget, 2015. 6(23): p. 19619-33.
 35. Gahete, M.D., et al., Expression of the ghrelin and neurotensin systems is altered in the temporal 
lobe of Alzheimer’s disease patients. J Alzheimers Dis, 2010. 22(3): p. 819-28.
 36. Korbonits, M., et al., The expression of the growth hormone secretagogue receptor ligand ghrelin 
in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol 
Metab, 2001. 86(2): p. 881-7.
 37. Jeffery, P.L., A.C. Herington, and L.K. Chopin, Expression and action of the growth hormone 
releasing peptide ghrelin and its receptor in prostate cancer cell lines. J Endocrinol, 2002. 172(3): 
p. R7-11.
 38. Duran-Prado, M., et al., The new truncated somatostatin receptor variant sst5TMD4 is associated 
to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene, 2012. 
31(16): p. 2049-61.
 39. Duran-Prado, M., et al., Identification and characterization of two novel truncated but functional 
isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin 
Endocrinol Metab, 2009. 94(7): p. 2634-43.
72
C
ha
pt
er
 2
 40. Durán-Prado, M., et al., A potential inhibitory role for the new truncated variant of somatostatin 
receptor 5 (sst5TMD4) in pituitary adenomas poorly responsive to somatostatin analogs. J Clin 
Endocrinol Metab, 2010. 95(5): p. 2497-502.
 41. Luque, R.M., et al., Truncated somatostatin receptor variant sst5TMD4 confers aggressive features 
(proliferation, invasion and reduced octreotide response) to somatotropinomas. Cancer Lett, 2015. 
359(2): p. 299-306.
 42. Mole, D., et al., The expression of the truncated isoform of somatostatin receptor subtype 5 associates 
with aggressiveness in medullary thyroid carcinoma cells. Endocrine, 2015. 50(2): p. 442-52.
 43. Puig-Domingo, M., et al., The Truncated Isoform of Somatostatin Receptor5 (sst5TMD4) Is As-
sociated with Poorly Differentiated Thyroid Cancer. PLoS One, 2014. 9(1): p. e85527.
 44. Sampedro-Nunez, M., et al., Presence of sst5TMD4, a truncated splice variant of the somatostatin 
receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine 
tumors. Oncotarget, 2015. 7(6): p. 6593-608.
 45. Righi, L., et al., Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clini-
copathologic and immunohistochemical study of 218 ‘clinically aggressive’ cases. Ann Oncol, 2010. 
21(3): p. 548-55.
 46. Kanakis, G., et al., Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung 
Carcinoids: Implications for a Therapeutic Role. Neuroendocrinology, 2015. 101(3): p. 211-22.
 47. Volante, M., et al., Ghrelin expression in fetal, infant, and adult human lung. J Histochem 
Cytochem, 2002. 50(8): p. 1013-21.
 48. Tsuta, K., Wistuba, II, and C.A. Moran, Differential expression of somatostatin receptors 1-5 in 
neuroendocrine carcinoma of the lung. Pathol Res Pract, 2012. 208(8): p. 470-4.
 49. Kaemmerer, D., et al., Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: 
new diagnostic, prognostic, and therapeutic markers. J Clin Endocrinol Metab, 2015. 100(3): p. 
831-40.
 50. Lupp, A., et al., Reassessment of sst(5) somatostatin receptor expression in normal and neoplastic 
human tissues using the novel rabbit monoclonal antibody UMB-4. Neuroendocrinology, 2011. 
94(3): p. 255-64.
 51. Lupp, A., et al., Reassessment of sst3 somatostatin receptor expression in human normal and neoplas-
tic tissues using the novel rabbit monoclonal antibody UMB-5. Neuroendocrinology, 2012. 96(4): 
p. 301-10.
 52. Lupp, A., F. Nagel, and S. Schulz, Reevaluation of sst(1) somatostatin receptor expression in human 
normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7. Regul Pept, 
2013. 183: p. 1-6.
 53. Castano, J.P., et al., Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeu-
tic challenges. Cancer Metastasis Rev, 2014.
 54. Oberg, K., et al., Molecular pathogenesis of neuroendocrine tumors: implications for current and 
future therapeutic approaches. Clin Cancer Res, 2013. 19(11): p. 2842-9.
 55. Martinez-Fuentes, A.J., et al., Ghrelin is produced by and directly activates corticotrope cells from 
adrenocorticotropin-secreting adenomas. J Clin Endocrinol Metab, 2006. 91(6): p. 2225-31.
 56. Gahete, M.D., et al., Expression of Somatostatin, cortistatin, and their receptors, as well as dopa-
mine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer’s disease patients. 
J Alzheimers Dis, 2010. 20(2): p. 465-75.
 57. Taboada, G.F., et al., Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expres-
sion levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol, 2007. 
156(1): p. 65-74.
273
C
om
po
ne
nt
s o
f s
om
at
os
ta
tin
 a
nd
 g
hr
el
in
 sy
ste
m
s
 58. Beasley, M.B., et al., Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum 
Pathol, 2000. 31(10): p. 1255-65.
 59. Rea, F., et al., Outcome and surgical strategy in bronchial carcinoid tumors: single institution 
experience with 252 patients. Eur J Cardiothorac Surg, 2007. 31(2): p. 186-91.
 60. Fisseler-Eckhoff, A. and M. Demes, Neuroendocrine tumors of the lung. Cancers (Basel), 2012. 
4(3): p. 777-98.
 61. Korner, M.U., et al., Wild-type and splice-variant secretin receptors in lung cancer: overexpression 
in carcinoid tumors and peritumoral lung tissue. Mod Pathol, 2008. 21(4): p. 387-95.
 62. Koomagi, R., et al., Expression of resistance-related proteins in tumoral and peritumoral tissues of 
patients with lung cancer. Cancer Lett, 1996. 110(1-2): p. 129-36.
 63. Li, S.X., et al., Expression of survivin and caspase 3 in oral squamous cell carcinoma and peritu-
moral tissue. Asian Pac J Cancer Prev, 2012. 13(10): p. 5027-31.
 64. Haybaeck, J., et al., STAT-1 expression in human glioblastoma and peritumoral tissue. Anticancer 
Res, 2007. 27(6B): p. 3829-35.
 65. Mizutani, G., et al., Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 
5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry. Acta 
Histochem Cytochem, 2012. 45(3): p. 167-76.
 66. Ghelardoni, S., et al., Ghrelin tissue distribution: comparison between gene and protein expression. 
J Endocrinol Invest, 2006. 29(2): p. 115-21.
 67. Papotti, M., et al., Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical 
specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows 
Arch, 2001. 439(6): p. 787-97.
 68. Lamberts, S.W., J.C. Reubi, and E.P. Krenning, Somatostatin receptor imaging in the diagnosis 
and treatment of neuroendocrine tumors. J Steroid Biochem Mol Biol, 1992. 43(1-3): p. 185-8.
 69. Eriksson, B., et al., The use of new somatostatin analogues, lanreotide and octastatin, in neuroen-
docrine gastro-intestinal tumours. Digestion, 1996. 57 Suppl 1: p. 77-80.
 70. Kimura, N., et al., Immunohistochemical expression of somatostatin type 2A receptor in neuroendo-
crine tumors. Clin Cancer Res, 1999. 5(11): p. 3483-7.
 71. Janson, E.T., et al., Somatostatin receptor scintigraphy during treatment with lanreotide in patients 
with neuroendocrine tumors. Nucl Med Biol, 1999. 26(8): p. 877-82.
 72. Reubi, J.C., et al., Subcellular distribution of somatostatin sst2A receptors in human tumors of the 
nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol 
Metab, 2000. 85(10): p. 3882-91.
 73. Kaemmerer, D., et al., Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies 
in pancreatic neuroendocrine tumors. Int J Clin Exp Pathol, 2013. 6(1): p. 49-54.
 74. Gnanapavan, S., et al., The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, 
GHS-R, in humans. J Clin Endocrinol Metab, 2002. 87(6): p. 2988.
 75. Arnaldi, G., et al., Cyclical Cushing’s syndrome in a patient with a bronchial neuroendocrine tumor 
(typical carcinoid) expressing ghrelin and growth hormone secretagogue receptors. J Clin Endocrinol 
Metab, 2003. 88(12): p. 5834-40.
74
C
ha
pt
er
 2
SUPPLEMENTAL DATA
Supplemental Table 1: SST/CORT system components correlations in tumor tissue
sst1 sst2 sst3 sst4 sst5 sst5TMD4
SST 0.522*** 0.613*** 0.364* 0.392*
CORT 0.430**
sst1 0.838*** 0.784***
sst2 0.701***
*p<0.05; **p<0.001; ***p<0.0001
p value refers to the comparison between SST system components
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Supplemental Figure 1: Presence of SST/CORT system components in TC and AC. The graphs 
indicate the percentage of positive samples for each of the SST/CORT system components.
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Supplemental Figure 2: Presence of ghrelin system components in TC and AC. The graphs indicate 
the percentage of positive samples for each of the ghrelin system components.
275
C
om
po
ne
nt
s o
f s
om
at
os
ta
tin
 a
nd
 g
hr
el
in
 sy
ste
m
s
sst4
IH
C	s
ta
in
in
g	(
%)
1+ 2+ 3+
0
20
40
60
A
B
1 2
3 4
Supplemental Figure 3: Presence of sst4 by IHC in TC and AC. The expression of sst4 by immnuno-
histochemistry was determined in adjacent non-tumor tissue and LCs samples. A: Percentage of cases 
with 1+, 2+, 3+ staining, which represent low, moderate, and high intensities of the tumor region 
compared to the adjacent non-tumor tissue. B: Representative images of sst4 staining performed on 
non-tumor adjacent tissue (1), 1+ (2), 2+ (3) and 3+ (4) tumor LCs samples. The arrows represent 
isolated alveolar macrophages with positive IHC staining.
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Supplemental Figure 4: Presence of GHSR1a by IHC in TC and AC. The expression of sst4 by 
immnunohistochemistry was determined in adjacent non-tumor tissue and LCs samples. A: Percent-
age of cases with 1+, 2+, 3+ staining, which represent low, moderate, and high intensities of the 
tumor region compared to the adjacent non-tumor tissue. B: Representative images of sst4 staining 
performed on non-tumor adjacent tissue (1), 1+ (2), 2+ (3) and 3+ (4) tumor LCs samples. The arrows 
represent isolated pneumocytes and alveolar macrophages with positive IHC staining.
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ABSTRACT
Purpose: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) comprise a het-
erogeneous group of malignancies often presenting with metastasis at diagnosis and whose 
clinical outcome is difficult to predict. Somatostatin (SST) analogs (SSAs) provide a valu-
able pharmacological tool to palliate hormonal symptoms, and control progression in some 
NETs. However, many patients do not respond to SSAs or develop resistance, and there 
are many uncertainties regarding pathophysiology of SST and its receptors (sst1-sst5) in 
GEP-NETs.
Methods: The expression of SST system components in GEP-NETs was determined, com-
pared with that of non-tumor adjacent and normal tissues and correlated with clinical and 
histological characteristics. Specifically, 58 patients with GEP-NETs and 14 normal samples 
were included. Cell viability in NET cell lines was determined in response to specific SSAs.
Results: Normal samples and non-tumor adjacent tissues presented a similar expression 
profile, with appreciable expression of sst2 and sst3, and a lower expression of the other 
receptors. In contrast, cortistatin, sst1, sst4 and sst5 were overexpressed in tumors, while sst3 
and sst4 seemed overexpressed in less differentiated tumors. Some SST system components 
were related to vascular/nerve invasion and metastasis. In vitro, sst1 and sst3 agonists reduced 
viability in BON-1 cells, while they, similar to octreotide and pasireotide, increased viability 
in QGP-1 cells.
Conclusions: These results provide novel information on SST system pathophysiology in 
GEP-NETs, including relevant associations with clinical-histological parameters, which 
might help to better understand the intrinsic heterogeneity of NETs and to identify novel 
biomarkers and/or targets with potential prognostic and/or therapeutic value for GEP-NETs 
patients.
Key words: Carcinoids, somatostatin analogs (SSAs), sst1, sst3, prognosis, invasion, 
metastasis.
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INTRODUCTION
Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies arising from 
neuroendocrine cells of the diffuse endocrine system, which present a unique rising inci-
dence in the last decades: from 1.09 (in 1973) to 6.98 (in 2017) new cases per 100,000 
inhabitants annually [1]. Indeed, the Surveillance, Epidemiology and End Results (SEER) 
further support this contention by showing an increase in the incidence of GEP-NETs of all 
origins except to appendix NETs [2]. Gastroenteropancreatic NETs (GEP-NETs) originate 
from the pancreas or the intestinal tract and represent approximately 65% of all NETs and 
2% of all gastroenteropancreatic malignancies [3, 4]. These neoplasms include functioning 
and non-functioning tumors, depending on their capacity to secrete peptide hormones, and 
can occur sporadically or as a result of hereditary predisposition syndromes such as multiple 
endocrine neoplasia type 1 (MEN-1) or Von Hippel–Lindau’s disease (VHL), with clinical 
onset occurring earlier in patients with genetic predisposition [5]. Although some prognostic 
factors include primary tumor localization, histological differentiation, Ki67 index, platelets, 
and lactate dehydrogenase (LDH) levels [6], their clinical outcome is mostly unpredictable, 
in that even well-differentiated low-grade tumors can display an aggressive behavior [3]. Fur-
thermore, in about 30% of NETs the primary tumor cannot be identified [6], and metastatic 
disease is frequently found at diagnosis, especially in non-functioning tumors, ranging from 
27 to 73% depending on the series, with an overall survival rates varying from 30 to 90% 
at 5 years [5, 7, 8]. As a result, most tumors are diagnosed at an advanced stage of disease, 
wherein the only curative therapeutic option is surgery. For this reason, identification of 
novel, early diagnostic biomarkers, and development of new targeted medical treatments has 
gained scientific and clinical interest over the past recent years [9].
Somatostatin (SST), cortistatin (CORT), and their 5 receptors ss1-sst5 (i.e. the SST system) 
are widely expressed in multiple tissues, including the gastrointestinal tract (GIT) [10, 11]. 
In fact, based on their capacity to inhibit endocrine secretions from the GIT, synthetic SST 
analogs (SSAs) have long been used to palliate hormonal symptoms in NETs. Moreover, 
SSAs can also control disease progression in well-differentiated, metastatic midgut NETs 
and in moderately differentiated, metastatic nonfunctioning GEP-NETs [12]. Thus, the 
PROMID study showed that SSAs can delay tumor progression in both functionally ac-
tive and inactive NETs [13], while the CLARINET study reported an increase in median 
progression-free survival in SSA-treated patients [14]. Nevertheless, many tumors, despite 
bearing sst, do not respond or eventually develop resistance to SSA treatments.
The antisecretory and antitumor actions of SSAs are mediated through the SST receptors 
(sst1-5), a family of five G-protein-coupled receptors that are widely distributed through-
out the body and are present in most GEP-NETs [15-17]. Some studies suggest that the 
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antiproliferative effects of SSAs are associated to their affinity for sst2 [18]. SSA treatment 
commonly exhibit a good safety profile [3] but after long-term tachyphylaxis may occur, 
which has been associated to a possible loss of sst2 availability following receptor internaliza-
tion and degradation [19]. In addition, presence of sst5TMD4, a truncated splice variant of 
the sst5 subtype that interacts with sst2 and disrupts its signaling, has been associated with 
increased aggressiveness in pancreatic NETs and other hormone-dependent tumors [20, 21]. 
However, the exact mechanisms by which SST and SSAs exert their effects on NET cells are 
complex and not fully understood [3]. In fact, although various studies have examined the 
presence of SST system components in NETs, the clinical implications of all their members 
are not completely elucidated [22-24].
The intrinsic heterogeneity of NETs coupled to the their unpredictable behavior and prog-
nosis complicates their clinical management, particularly owing to the lack of sufficient and 
reliable biomarkers to predict medical treatment response and patient prognosis. Accord-
ingly, in this study we aimed to systematically and comprehensively determine the precise 
expression of SST system components in GEP-NETs, compare to non-tumor adjacent tissue 
and normal control tissue, and correlate them with clinical, functional and histological 
characteristics.
MATERIALS AND METHODS
Patients and samples
The Ethics Committee of the Reina Sofia University Hospital (Cordoba, Spain) approved the 
study, which was conducted in accordance with the Declaration of Helsinki and according 
to national and international guidelines. Every individual or family member signed a written 
informed consent before inclusion into the study. Data from 58 patients with GEP-NETs 
who underwent surgery at the Hospital from 2005 to 2015 were collected (demographic 
and clinical characteristics of the included patients are summarized in Table 1). As well, 14 
normal control tissues were also included (four whole pancreas, three stomach, four midgut 
and three foregut samples). Patients with neurofibromatosis, multiple endocrine neoplasia 
type 1, Von Hippel-Lindau or any endocrine syndrome were excluded from the present 
study. Clinical records were used to collect full medical history of all patients. GEP-NETs 
were classified according to histopathological features as: well-differentiated NETs (G1), 
well-differentiated neuroendocrine carcinomas (G2), and poorly differentiated neuroendo-
crine carcinomas (G3). Cell survival was determined by counting Ki67 positive cells by 
experienced pathologists [25]. After surgery, if residual disease or relapse was observed, adju-
vant treatment with SSAs or chemotherapy was prescribed; however, only two cases received 
pre-surgery treatment with SSAs. From all these subjects, we obtained 130 formalin-fixed 
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paraffin-embedded samples (58 tumor samples, 58 non-tumor adjacent tissue samples and 
14 normal control tissues). In order to ensure the appropriate identification of relevant areas 
of tumor and non-tumor tissues to carry out the RNA isolation, a comprehensive analysis of 
hematoxylin and eosin (H&E) sections was performed by experienced pathologists.
RNA isolation and reverse-transcription
Total RNA from formalin fixed paraffin-embedded (FFPE) samples was isolated using the 
RNeasy FFPE Kit (Qiagen, Limburg, Netherlands) according to the manufacturer’s instruc-
tions. Quantification of the recovered RNA was assessed using NanoDrop2000 spectropho-
tometer (Thermo Scientific, Wilmington, NC, USA). One microgram of total RNA was 
retrotranscribed to cDNA with the First Strand Synthesis kit using random hexamer primers 
(Thermo Scientific) as previously reported [26, 27].
Quantitative real time PCR (qPCR)
cDNAs were amplified with the Brilliant III SYBR Green Master Mix (Stratagene, La Jolla, 
CA, USA) using the Stratagene Mx3000p system and specific primers for each transcript 
of interest. Specifically, expression levels (absolute mRNA copy number/50 ng of sample) 
of SST, cortistatin (CORT), sst1, sst2, sst3, sst4, sst5 and sst5TMD4 were measured using 
previously validated primers [28, 29]. Briefly, samples derived from human GEP-NET tis-
sues were run, in the same plate, against a standard curve to estimate mRNA copy number 
and a No-RT sample as a negative control. Thermal profile consisted of an initial step at 
95°C for 30 seconds, followed by 50 cycles of denaturation (95°C for 20s) and annealing/ 
Table 1: General characteristics of GEP-NETs patients
General characteristic % (n)
Gender
Male 48,3% (28)
Female 51,7% (30)
Age 56,41±15,6 years
Personal history of other tumors 11,7%
Smoke habit
Active 57,7% (15)
Ex-smoker 15,4% (4)
No habit 26,9% (7)
Family history of neoplasms 45,5% (10)
Incidental tumor 35% (14)
Functionality 43,9% (18)
Pre-surgical treatment 14% (7)
SSA pre-surgical treatment 4% (2)
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elongation (60°C for 20s), and finally, a dissociation cycle (melting curve; 55°C to 95°C, 
increasing 0, 5°C/30 s) to verify that only one product was amplified. RNA expression was 
adjusted by the expression of 18S.
Immunohistochemistry (IHC) analysis
IHC analysis of sst1, sst2 and sst5 was implemented in formalin-fixed, paraffin-embedded 
(FFPE) tissue samples, which included tumor and non-tumor regions from patients diag-
nosed with GEP-NETs, using standard procedures. The optimum antibody concentrations 
to perform the IHC analyses (1:300) using commercially available antibodies against human 
sst1, sst2 and sst5 (respectively, UMB7, UMB1 and UMB4 from Abcam, Cambridge, UK) 
were selected by performing a series of antibody dilution tests (1:100; 1:200; 1:300 and 
1:400) in brain samples (a tissue that has been previously reported to express high levels 
of somatostatin receptors [30, 31]). Independent pathologists performed the IHC analysis 
of the samples following a blinded protocol. In the analysis, negative, 1+, 2+, 3+ stand for 
absent, low, moderate, and high intensities of the tumor region staining compared to the 
adjacent region with non-tumor lung tissue.
Cell cultures
The human NET model cell lines BON-1 and QGP-1 were used in this study [20, 32]. 
Particularly, the human pancreatic neuroendocrine tumor BON-1 cell line was established 
from a lymph node metastasis of a human functional pancreatic NET BON-1 (The Uni-
versity of Texas Medical Branch, Galveston, Tex., USA), while the cell line QGP-1 was 
initially obtained from primary pancreas NET tissue obtained from a 61-year-old male [33]. 
Both cell lines were checked for mycoplasma contamination by PCR as previously reported 
[34]. BON-1 cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM-F12; Life 
Technologies, Barcelona, Spain) supplemented with 10% fetal bovine serum (FBS; Sigma-
Aldrich, Madrid, Spain), 1% glutamine (Sigma-Aldrich) and 0.2% antibiotic (Gentamicin/
Amphotericin B; Life Technologies). QGP-1 cells were cultured in RPMI 1640 (Lonza, 
Basel, Switzerland), supplemented with 10% FBS, 1% glutamine and 0.2% antibiotic. 
Cells were harvested with trypsin (0.05%)–EDTA (0.53 mM) and resuspended in culture 
medium; cell viability always exceeded 85%. Both cell lines were cultured at 37°C in a 5% 
CO2 incubator. All cell line experiments were performed at least four times.
Drugs and reagents
The sst1 agonist (IPSEN Bioscience) was diluted in medium 5% FBS prior to use until ob-
taining final concentration of 10-6 M; sst3 agonist (IPSEN Bioscience), octreotide (Novartis 
Pharmaceuticals Corporation), and pasireotide (Novartis Pharmaceuticals Corporation), 
were diluted in medium 5% FBS prior to use until obtaining final concentration of 10-7 M. 
Paclitaxel 10-7 M (Sigma-Aldrich) was used as positive control. The tested concentrations 
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were chosen based on the reported dose-dependent effects and sst1-5 subtype-binding affini-
ties of somatostatin analogs, according to previously published data [35-41].
Cell viability assay
Cells were plated in 96-well plates at the density necessary to obtain a 65–70% cell conflu-
ence in the control groups at the end of the experiment (5.000 cells/well). Twenty-four h 
later, serum-free medium was added during 24 h. Basal and 24h cell viability was determined 
using Alamar-Blue reagent. Specifically, the day of measurement, cells were incubated for 3 
h in 10% Alamar-Blue/serum-free medium and then, Alamar-Blue reduction was measured 
in a FlexStation3 system (Molecular Devices) plate reader, exciting at 560 nm and reading 
at 590 nm. After this, the appropriate treatments (sst1 and sst3 agonists, octreotide and 
pasireotide) were added to wells in 5% FBS medium. In all instances, cells were seeded per 
quadruplicate and all assays were repeated a minimum of four times.
Statistical analysis
Paired t-test analysis was used to compare the expression levels between GEP-NETs samples 
and adjacent non-tumor tissue. Non-paired t-test analysis was used to compare the expres-
sion levels between normal lung tissue and GEP-NETs samples or adjacent non-tumor tissue. 
Mann-Whitney U test was used to evaluate clinical-molecular relations within GEP-NETs 
samples. Chi-squared test was used to compare categorical data. In functional experiments, 
results are expressed as percentage of control (non-treated cells). Cell survival rate compared 
to control was assessed by multiple comparison tests (One-way ANOVA followed by Dun-
net post-hoc test). All statistical analyses were performed using SPSS statistical software 
version 20 and Graph Pad Prism version 6. Data are expressed as mean ± SEM. P-values < 
0.05 were considered statistically significant.
RESULTS
A total of 58 patients with GEP-NETs and 14 normal control samples were included in the 
study. Clinical features of patients are summarized in Table 1, and tumor characteristics in 
Table 2. Twenty-eight patients (48.3%) had pancreatic NETs and 51.7% had gastrointesti-
nal NETs; 43.9% were functioning tumors. Quantification of Ki-67 and mitotic index was 
available at diagnosis in only 75% of samples, 71% of samples were low or intermediate 
grade tumors. Interestingly, 51.7% of patients had metastasis at diagnosis, relapsed disease 
was observed in 41.2% of patients, and the mortality rate reached 24.5%.
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Table 2: Tumor sample characteristics
Characteristic n (%)
Tissue samples
Primary tumor 58
Non-tumor adjacent tissue 58
Normal tissue 14
Primary tumor localization
Pancreas 48,3% (28)
Stomach 5,2% (3)
Small bowel 22,4% (13)
Colon and rectum 24,1% (14)
Maximal tumor diameter 3,16±2,09 cm
Necrosis <10% 14,3% (1)
10-20% 28,6% (2)
21-30% 42,9% (3)
>30% 14,3% (1)
Depth of infiltration (gastrointestinal NETs)
Submucosa 4% (1)
Mucosa 4% (1)
Muscular 44%(11)
Serosa 48%(12)
Multiple tumors 7,1% (2)
Peri-tumor tissue invasion 66,7% (36)
Vascular invasion 36% (18)
Neural invasion 32,7% (16)
Metastasis 51,7% (30)
Metastasis localization
Liver 10% (3)
Spleen 3,3% (1)
Lymphatic nodules 27,6% (16)
Multiple 29,9% (10)
Grading (WHO 2010 criteria)
Low 32,8% (19)
Intermediate 37,9% (22)
High 5,2% (3)
Unknown 24,1% (14)
Post-surgical treatment 40,4% (19)
Relapsed disease 41,2% (21)
Disease free 61,4% (27)
New surgery requirements 23,1% (9)
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Histopathological characterization of GEP-NETs and non-tumor adjacent tissue
Primary tumor samples were delimited from the non-tumor adjacent tissues after the evalua-
tion of two experienced pathologists using histology and immunohistochemistry (Figure 1).
A
B
C
D
Figure 1: Representative images of pancreatic and intestinal NETs and control tissues. All images 
were taken from hematoxylin-eosin stained specimens at 100X. A) Pancreatic NET and adjacent tis-
sue. B) Normal pancreas. C) Small intestine NET and adjacent tissue. D) Normal intestine. Scale bar 
is included in each image.
Expression of SST system components in control and GEP-NETs samples
Using a yes/no scale, SST system components were expressed in a high percentage of normal 
(control) GEP samples as determined by qPCR, especially SST, sst2, sst3 and sst5TMD4, 
which were expressed in more than 80% of the samples; while CORT was expressed in less than 
30% of samples (Supplemental Figure 1). Consistently, all system components, except sst4, 
were expressed in at least 60% of adjacent non-tumor and tumor tissues. Instead CORT, sst1, 
sst4 and sst5 were present in a higher proportion of GEP-NETs samples compared to adjacent 
tissues, although the differences were not statistically significant (Supplemental Figure 1).
Normal tissue (control) samples and non-tumor adjacent tissues presented a similar profile 
of mRNA expression levels, with a considerable expression of sst2 and sst3 and a lower 
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Figure 2: Presence and expression of SST/CORT system components in normal samples, adjacent 
non-tumor tissue and GEP-NETs. A) The absolute mRNA expression of the different components 
of the SST/CORT system was determined by qPCR in normal control samples, adjacent non-tumor 
tissue and GEP-NETs samples (values are adjusted by 18S expression). Data represent the mean±SEM. 
Asterisks (*, p<0.05; **, p<0.01; ***, p<0.001) indicate significant changes by paired analysis between 
adjacent non-tumor and GEP-NETs and non-paired analysis between normal tissue and adjacent 
non-tumor or tumor tissues. B) Immunohistochemical analysis of somatostatin receptors sst1, sst2 
and sst5 in adjacent non-tumor tissue and GEP-NETs. The presence of sst1, sst2 and sst5 by im-
munohistochemistry using specific antibodies was determined in a subset of samples, which included 
tumor and non-tumor regions from patients diagnosed with GEP-NETs. Representative images from 
pieces stained with sst1, sst2 and sst5 are depicted in B1, B2 and B3, respectively. This analysis revealed 
that somatostatin receptors were present in the vast majority of tumor cells compared with non-tumor 
adjacent tissue, with different grades of staining.
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expression of the rest of receptors (sst1, sst4 and sst5) and the ligands (SST and CORT). 
Interestingly, CORT and the receptors sst1, sst2, and sst5 were clearly overexpressed in 
tumor tissues compared with adjacent non-tumor tissue samples (Figure 2). Expression of 
sst3 and sst4 tended to increase in GEP-NETs according to their grade, while the opposite 
trend (decreasing expression levels with increasing tumor grade) was observed for SST, sst1, 
sst2, sst5, and sst5TMD4 (Supplemental Figure 2). When tumor samples were analyzed 
separately, in pancreatic NETS, sst1, sst2 and sst5 were overexpressed when compared with 
control and adjacent tissue; at the same time, a decreased expression of sst3 and sst5TMD4 
in tumor samples was observed. In contrast, small bowel and colon tumors tended to pro-
gressively increase the expression SST, sst2, sst3, sst5 and sst5TMD4 in adjacent tissue when 
compared to controls and also in tumors when compared to their respective adjacent tissue 
and/or normal controls (Supp. Figure 3). Intriguingly, in tumor samples, SST expression was 
correlated to sst1, sst4 and sst5 and sst5TMD4; in turn, sst5TMD4 was positively correlated 
to the molecular expression of all evaluated SST system components, while CORT was 
correlated to sst1. In addition, sst1 expression was correlated with sst4 (Table 3).
Table 3: SST/CORT system components correlations in tumor tissue
sst1 sst2 sst3 sst4 sst5 sst5TMD4
SST 0.306* 0.324* 0.288* 0.389***
CORT 0.344*** 0.268*
sst1 0.288* 0.377***
sst2 0.902*** 0.455***
sst3 0.460***
*p<0.05; **p<0.01; ***p<0.001
p value refers to the comparison between SST/CORT system components
Immunohistochemistry (IHC) analysis
Although qPCR is a sensitive method to assess gene expression, we subsequently performed 
an IHC analysis in a set of selected samples, in order to validate the observed changes at 
the protein level, and to determine which particular cells are expressing those markers. To 
this end, we selected sst1, sst2, and sst5 due to their clear overexpression in tumor samples. 
Specifically, assays performed on FFPE-samples revealed stronger staining in tumor tissue 
compared to non-tumor adjacent tissue (Fig. 2B). In general, IHC analysis of tumor tis-
sue revealed that somatostatin receptors were present in the vast majority of tumor cells 
compared with non-tumor adjacent tissue, with different grades of staining (Supp. Figure 4). 
These data further suggest a dysregulated presence of somatostatin receptors in GEP-NETs 
samples compared to non-tumor adjacent tissue.
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Figure 3: Correlations between epidemiological, clinical, histological and molecular param-
eters in GEP-NETs. The correlations between epidemiological, clinical, histological and molecular 
parameters within GEP-NETs samples were assessed by U-Mann Whitney tests. Data represent the 
mean±SEM. Asterisks (*, p<0.05; **, p<0.01) indicate significant associations.
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Associations between expression levels of SST system components and clinical-
histological characteristics in GEP-NETS patients
Analysis of the demographic, epidemiological and clinical data revealed that patients with 
tobacco exposure presented GEP-NETs with higher expression of SST and CORT (Figure 
3), while in those cases with family history of tumor disease, a lower expression of CORT 
was observed (Figure 3). Conversely, no correlation was observed with sex, personal history, 
previous neoplasm history, clinical symptoms or diagnostic techniques.
Importantly, the expression of some SST system components was related to aggressiveness 
and prognosis of GEP-NETs. Indeed, tumors with lymph node metastasis overexpressed 
SST while a lower SST and CORT expression was observed in those with liver metastasis. 
In addition, tumors with free surgical borders overexpressed sst2 and sst3, but tumors with 
vascular or nerve invasion overexpressed sst5 (Figure 3).
Effect of SSAs and specific sst agonists on NETs cells survival
To further explore the possible role and potential clinical utility in NET pathophysiology of 
the two less explored SST receptors, sst1 and sst3, we used two commonly accepted NET 
model cell lines, BON-1 and QGP-1 cells. Cells were treated with specific sst1 and sst3 
agonists and compared with the classic multi-receptor compounds octreotide and pasire-
otide (Figure 4). This revealed that BON-1 cells decrease their viability rate after an acute 
treatment (24-h incubation) with sst1 and sst3 analogs (p=0.054 and p<0.05, respectively), 
whereas no such effect was observed in response to octreotide and pasireotide (Figure 4). In 
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Figure 4: Cell survival rate in BON-1 and QGP-1 cell lines in response to sst stimulators. Cell 
survival rate was determined by Alamar-blue technique in BON-1 and QGP-1 cells in response to 
24h incubation with sst1 agonist, sst3 agonist, octreotide and pasireotide compared to vehicle-treated 
control. Paclitaxel (Pcx) was used as inhibitory control. Data represent the mean±SEM from at least 
n=3 independent experiments. Differences were assessed by multiple comparison tests. Asterisks (*, 
p<0.05; **, p<0.01) indicate significant differences with control.
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contrast, QGP-1 cell line exhibited an increased survival rate in response to sst1 and sst3 
agonists, as well as to octreotide and pasireotide after 24-h of treatment.
DISCUSSION
In the present study, we have systematically evaluated the expression of SST system com-
ponents (ligands and receptors) in a large series of clinically well-characterized GEP-NETs, 
including primary tumors of the whole GEP system. Gene expression in tumor tissues was 
compared with that in the corresponding adjacent non-tumor tissues and in normal control 
tissues. Some studies [42, 43], including a recent one from our group [20], have explored 
the presence of certain components of the SST systems in GEP-NETs, but, to the best of our 
knowledge, this study represents the first comprehensive characterization of the components 
of this regulatory system in tumor samples, in comparison not only with their corresponding 
adjacent non-tumor regions but also with normal tissue samples for each analyzed organ. 
In addition, we thoroughly characterized the demographic, epidemiological, and clinical 
characteristics of the patients, and the disease progression and prognosis after 2-10 years, and 
assessed their putative relationship with the expression levels of the components of this SST 
system. Our results revealed a distinctive expression of most SST system components in tu-
mor and peritumoral tissues compared to normal samples. In addition, specific components 
of the SST system displayed clinical-histological correlations in tumor tissues, suggesting 
their potential value as novel markers for GEP-NETs patient management.
The intrinsic variability and heterogeneity that characterize GEP-NETs [44] is further 
confirmed by the results obtained in this particular cohort of samples, which, first of all, 
revealed a marked overexpression of CORT, sst1, sst2 and sst5 in tumor tissues compared to 
non-tumor adjacent samples. The presence of the different ssts in NETs has been analyzed 
previously by various groups [15, 24, 42], including ours, in a different cohort of patients 
[20]. Interestingly, SST system components are expressed not only in tumor tissue but also 
in non-adjacent tissue, although the expression in tumors is consistently increased compared 
to the surrounding tissue [20, 24, 45]. These findings, which have been demonstrated by 
RT-qPCR and IHC, probably relate to their biological regulatory role in secretion and, also, 
cell proliferation [15], suggesting a dysregulation of these system that could be related with 
tumor progression. Although the majority of the alterations found in the expression pat-
terns analyzed herein are in agreement with those reported previously (e.g. of sst1 and sst2 
overexpression in tumor vs. control tissues) [15, 20, 24, 42], certain changes do not seem 
to be completely consistent among the different studies, likely owing to obvious differences 
among the distinct cohorts, but also, to the intrinsic heterogeneity of NETs mentioned 
above, even when comparable experimental approaches are implemented to characterize 
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tumor expression profiles. In this regard, it is remarkable the difference in the expression 
of somatostatin receptors in pancreatic NETs when compared to other localizations, and 
despite the reduced number of samples, our findings underscore the heterogeneity of these 
tumors, and could be related to lower progression free-survival [46, 47] when compared 
with other tumors, for example, small bowel NETs [48]. In spite of these differences, and 
given the emerging relevance of SSAs therapy and peptide receptor radionuclide therapy in 
the management of well-differentiated GEP-NETs [15, 49, 50], it seems worth emphasizing 
the high levels of sst2 expression in these tumors observed in our work, which is consistent 
with previous studies [15, 20, 24, 42], for most currently available SSAs preferentially target 
this receptor subtype. For this same reason, the sst5 overexpression in tumor tissue observed 
in our set of samples would also be a relevant marker supporting the potential benefit of 
SSAs (such as octreotide) as an appropriate treatment for controlling symptoms and tumor 
growth in well-differentiated GEP-NETs. Furthermore, inasmuch as some tumors are (or 
become) resistant to SSAs, and some proposed mechanisms suggest defects in sst2 pres-
ence, activation, or downstream signaling events [51], it is not unreasonable to propose that 
the decreased expression of sst2 in less differentiated GEP-NETs observed herein could be 
related to this phenomenon.
It is also important to note the increased expression of sst2 and sst3 observed in completely 
resected tumors, which may suggest that the presence of this receptor is associated with the 
development of well-defined and localized tumors. In fact, it is well known that sst2 can 
mediates the antiproliferative effects of SST and, as mentioned above, the currently available 
SSAs have high affinity for this receptor, even its presence and uptake imaging techniques 
using labeled somatostatin analogues with positron emitting isotopes, especially Gallium-68 
being necessary for considering the use of peptide receptor radionuclide therapy in these 
patients [35, 52-54]. Around 10% of all hepatic metastases are related to a primary NET 
[55], liver metastatic disease affects between 25 and 90% of NET-patients, and its presence 
decreases the 5-year survival about 35-60% [56-58]. Interestingly, in our cohort, liver me-
tastases were not observed in tumors overexpressing SST despite the presence of lymphatic 
invasion, suggesting a relevant role of SST in tumor behavior. Regarding the expression of 
other receptors, previous reports have described the presence of the truncated variant of 
sst5 (sst5TMD4) in breast cancer and poorly differentiated thyroid carcinomas [59, 60]; 
apparently the balance between this receptor, sst2 and sst5 (full-length) may influence the 
stage of disease [60]. Similarly, sst5TMD4 has been associated with increased tumor aggres-
siveness in somatotropinomas and NETS [20, 21] and its dysregulation may also influence 
the response to SSAs [21, 60]. In the present group of patients, we did not find associations 
between the truncated isoform and tumor aggressiveness, whereas tumors with vascular and 
nerve invasion overexpressed sst5, suggesting that a dysregulation in this receptor could be 
related to aggressive features and the patient outcome.
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Indeed, when there is tumor progression or treatment intolerance in response to SSAs, 
patients require alternative clinical strategies [54, 61, 62], for which novel target treatments 
[e.g. vascular endothelial growth factor (VEGF) inhibitors and inhibitors of mammalian 
target of rapamycin (mTOR)] have shown to improve progression-free survival with a 
low rate of severe adverse events compared with placebo among patients with advanced 
pancreatic NETs [46, 63]. Unfortunately, despite these new therapeutic options, treatment 
strategies are still limited and unsatisfactory and, until now, we lack clinical, histological 
or molecular makers that can satisfactorily predict the evolution of these patients. In this 
scenario, alternative SST receptors other than sst2, such as sst1 and sst3, could represent 
suitable options for the development of novel therapeutic strategies. However, expression 
and functionality of sst1 and sst3 in NETs are hitherto largely unexplored. In our cohort, 
a significant overexpression of sst1 in tumor tissue was observed, which is consistent with 
previous reports [20, 64]. On the other hand, although sst3 was not overexpressed in all 
tumor samples in our cohort, it tended to be overexpressed in less differentiated, more ag-
gressive tumors, and, importantly, it has been found to be overexpressed in other cohorts 
[20]. These findings suggest the interest of exploring the potential utility of sst1 and sst3 
selective agonists in the treatment of NETs. In support of this contention, our present in 
vitro studies demonstrated that treatment with specific sst1 or sst3 agonists was capable to 
reduce cell survival in BON-1 cells, while, in contrast, SSAs mainly targeting sst2 and/or 
sst5 (octreotide and pasireotide) were ineffective in this regard. In contrast, QGP-1 cells 
exhibited an opposite response, wherein treatment with sst1 and sst3 agonists increased cell 
survival. The reason for these unexpected differences is unknown, but it could be related to 
the distinct sst1-sst5 expression in tumor cell lines; according to published results, QGP-1 
cells have lower mRNA expression levels of all somatostatin receptors, specially sst1 and 
sst3 [20, 65]. Moreover, similar stimulatory effects on cell survival were observed with other 
somatostatin analogs (octreotide and pasireotide), in QGP-1 cells but not in BON-1, which 
suggests that it is a cell type-dependent effect, which could be related to a dysregulation in the 
expression, activation or signaling of sst1 and/or sst3, or to their particular interaction with 
other ssts, in this tumor cell line. These findings further emphasize the potential relevance of 
NET heterogeneity in the functional response of these tumors to the SSA treatment.
Earlier studies suggested that sst5 could mediate antiproliferative effects when transfected 
in heterologous cell models [66]. In our cohort, sst5 was overexpressed in tumor tissue 
compared with adjacent non-tumoral tissue, an abundance that appeared to be associated 
to aggressive features, for sst5 expression was higher in tumors with vascular and nerve 
invasion. This suggests that sst5 presence could be related to aggressiveness in NETs, similar 
to that found in other pathologies [29, 67, 68]. The possible mechanisms underlying this 
potential association are still to be elucidated. On the other hand, and at variance with previ-
ous studies from our group reporting an overexpression of the splicing variant sst5TMD4 in 
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various tumor pathologies, including NETs, in the present set of samples sst5TMD4 was not 
overexpressed in tumor samples, [20], an observation that could be explained by intrinsic 
differences in the cohort and would reinforce the idea of the variability and heterogeneity of 
GEP-NETs [69, 70].
In contrast to the SST receptors, the presence of the ligands SST and CORT in NETs has 
received less attention in recent years, and given their potential autocrine actions we sought 
to explore their expression in our cohort. Interestingly, despite its relatively low expression 
levels, we observed that CORT was clearly overexpressed in tumor samples, and that its 
levels were higher in patients without family tumor history, suggesting a potential, distinct 
involvement of this peptide, and its regulation, in NET development and/or progression, 
which has not been described previously and deserves further investigation. On the other 
hand, SST was expressed at higher levels but its expression was not altered in tumor vs. not-
tumor tissues; however, a closer view to key clinical parameters of GEP-NETs (e.g. invasion 
capacity) revealed interesting associations, in that tumors with lymph node metastasis over-
expressed SST, whereas expression of both SST and CORT was decreased in tumors with 
liver metastasis, suggesting that a differential expression of SST and CORT could be related 
to the behavior and aggressiveness in GEP-NETs. In this sense, it has been proposed that 
CORT synthetic analogs may provide potentially valuable tools as diagnostic/therapeutic 
tools in SST and ghrelin expressing tumors [10], although their development is still lacking, 
and should be considered in the future in the field of GEP-NETs.
In summary, this study provides a primary comprehensive mapping of the expression of SST/
CORT system component in GEP-NETs, as compared with their respective adjacent non-
tumor tissues, and with normal, non-neoplastic tissues. Our results indicate a prominent 
and widespread overexpression of SST/CORT system components in tumor tissues, wherein 
they could exert relevant regulatory roles in that the expression levels of some components 
are tightly related to the degree of disease, and exhibit associations to key clinical parameters, 
including invasion and metastasis. Thus, our data provide novel information that might help 
to better understand NETs pathophysiology and its intrinsic heterogeneity and to identify 
novel molecular targets with potential prognostic and/or therapeutic value for GEP-NETs 
patients.
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Supplemental Figure 1: Presence of SST/CORT system components in normal tissues, adjacent 
non-tumor tissue and GEP-NETs. The graphs indicate the percentage of samples (normal control tissue, 
adjacent non-tumor tissue and tumor tissue) positive for each of the SST/CORT system components.
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Supplemental Figure 2: Expression of SST/CORT system components in GEP-NETs of different 
grade. The absolute mRNA expression of the different components of the SST/CORT system was 
determined by qPCR in grade 1, 2 and 3 GEP-NETs samples (values are adjusted by 18S expression). 
Data represent the mean±SEM.
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Supplemental Figure 3: Expression of SST system components in normal samples, adjacent non-
tumor and tumor tissue of stomach, small bowel, colon and pancreatic NETs. The absolute mRNA 
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expression of the different components of the SST/CORT system was determined by qPCR in nor-
mal control samples, adjacent non-tumor tissue and GEP-NETs samples (values are adjusted by 18S 
expression). Data represent the mean±SEM. Asterisks (*, p<0.05; **, p<0.01; ***, p<0.001) indicate 
significant changes by paired analysis between adjacent non-tumor and GEP-NETs and non-paired 
analysis between normal tissue and adjacent non-tumor or tumor tissues.Suppl mental F g re 4
A
B
C
Negative 1+ 2+ 3+
Negative 1+ 3+
1+ 1+ 2+ 3+
Supplemental Figure 4: Presence of sst1, sst2, sst5 by IHC in GEP-NETs. The expression of sst1 
(A), sst2 (B) and sst5 (C) by immunohistochemistry was determined in adjacent non-tumor tissue 
and NET samples. Samples are classified as negative, 1+, 2+, 3+ staining, which represent absent, low, 
moderate, and high intensities of the tumor region compared to the adjacent non-tumor tissue.
Chapter 4
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ABSTRACT
The association between the presence and alterations of the components of the ghrelin 
system and the development and progression of neuroendocrine tumors (NETs) is still 
controversial and remains unclear. Here, we systematically evaluated the expression levels 
(by quantitative-PCR) of key ghrelin system components of in gastroenteropancreatic 
(GEP)-NETs, as compared to non-tumor adjacent (NTA; n=42) and normal tissues (NT; 
n=14). Then, we analyzed their putative associations with clinical-histological characteristics. 
The results indicate that ghrelin and its receptor GHSR1a are present in a high proportion 
of normal tissues, while the enzyme ghrelin-O-acyl transferase (GOAT) and the splicing 
variants In1-ghrelin and GHSR1b were present in a lower proportion of normal tissues. 
In contrast, all ghrelin system components were present in a high proportion of tumor and 
NTA tissues. GOAT was significantly overexpressed (by qPCR) in tumor samples compared 
to NTA, while a trend was found for ghrelin, In1-ghrelin and GHSR1a. In addition, expres-
sion of these components displayed significant correlations with key clinical parameters. The 
marked overexpression of GOAT in tumor samples compared to NTA regions was confirmed 
by IHC, revealing that this enzyme is particularly overexpressed in gastrointestinal NETs, 
where it is directly correlated with tumor diameter. These results provide novel informa-
tion on the presence and potential pathophysiological implications of the ghrelin system 
components in GEP-NETs, wherein GOAT might represent a novel diagnostic biomarker.
Keywords: GEP-NETs, ghrelin, GOAT, GHSRs, In1-ghrelin, prognosis, invasion
Highlights:
- Key components of ghrelin system are markedly dysregulated in GEP-NETs and associ-
ated to key clinical parameters
- Changes in the expression of ghrelin system components are associated with the develop-
ment and/or progression of GEP-NETs
- These molecular targets, especially GOAT, may represent putative diagnosis and/or 
prognostic markers in GEP-NETs.
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INTRODUCTION
Neuroendocrine tumors (NETs) comprise a heterogeneous family of malignancies with 
complex clinical behavior and increasing incidence [1-3]. Primary tumor is identified only 
in 70% of patients [4], while distant metastases are frequently found at diagnosis (27-73%), 
influencing the overall survival [5-7]. Despite that histological differentiation and Ki67 
index are some prognosis factors [4], well-differentiated low-grade tumors may behave ag-
gressively [8]. Unfortunately, surgery is often not applicable since most tumors are diagnosed 
at advanced stage. For these reasons, the development of novel diagnostic markers has gained 
scientific and clinical interest [9, 10].
The ghrelin system is involved in the regulation of multiple (patho)-physiological functions, 
including hormonal secretion, β-cell survival or appetite and gastric motility [11-14]. Ghrelin 
must undergo a unique modification, consisting of the acylation of the third serine residue, 
which is catalyzed by the ghrelin-O-acyl-transferase (GOAT) enzyme [14, 15]. Acylated 
ghrelin (AG) represents the peptide binding and activating its canonical ghrelin receptor, 
GHSR1a. Interestingly, several ghrelin system variants, resulting from post-transcriptional 
modifications or alternative splicing, have been identified, including the In1-ghrelin [11, 16] 
and a truncated receptor GHSR1b, with unknown ligand and function [11, 16, 17].
Alterations in the expression of specific components of this system have been associated with 
the development/progression of various neoplasms [16, 18-21], including NETs, but the 
clinical-molecular correlations have not been elucidated [22, 23]. Accordingly, in this study 
we aimed to: 1) analyze systematically the expression of different components of ghrelin 
system in gastroenteropancreatic-(GEP-)NETs compared to non-tumor adjacent (NTA) tis-
sue and, most importantly, to normal control tissues by quantitative real-time PCR (qPCR); 
2) correlate the expression of these components with clinical/histological characteristics; and 
3) perform in vitro experiments to elucidate the potential pathophysiological role of GOAT 
enzyme as a key component particularly altered in our cohort of NET samples, using BON-
1 and QGP-1 cell lines.
MATERIALS AND METHODS
Patients and samples
This study was approved by the Ethics Committee of the Reina Sofia University Hospital 
(Cordoba, Spain), was performed according to the Declaration of Helsinki, and patients 
were treated following national and international clinical practice guidelines. A written 
informed consent was required before inclusion. Data from 42 patients with GEP-NETs 
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were collected (demographic and clinical characteristics of the cohort are summarized in 
Table 1). Additionally, 14 normal control tissues from healthy donors were also included. 
Patients with hereditary endocrine syndrome were excluded. Clinical records were used to 
collect full medical history. GEP-NETs were classified according to histopathology features 
as well-differentiated NETs (G1), moderately differentiated (G2) and poorly differentiated 
NETs (G3) [24]. Formalin-fixed paraffin-embedded (FFPE) samples were also collected (42 
tumor samples, 42 NTA and 14 normal tissues).
Table 1: General characteristics of the patient population
General characteristic % (n)
Sex
Male 52.4% (22)
Female 47.6% (20)
Age at diagnosis 55.66±17 years
Personal history of other tumors 15.0% (6)
Smoke habit
Active 45.0% (9)
Ex-smoker 20.0% (4)
No habit 35.0% (7)
Family history of neoplasms 52.9% (9)
Incidental tumor 37.9% (11)
Functionality 43.3% (13)
Mortality rate 18.9% (7)
RNA isolation and reverse-transcription
Total RNA from FFPE samples (n=98) was isolated using the RNeasy-FFPE Kit (Qiagen, 
Limburg, Netherlands) according to manufacturer’s instructions. Quantification of the 
recovered RNA was assessed using NanoDrop2000 spectrophotometer (Thermo Scientific, 
Wilmington, NC). Total RNA was retrotranscribed to cDNA with the First-Strand Synthe-
sis kit using random hexamer primers (Thermo Scientific) as previously reported [25-28]
Quantitative real time PCR (qPCR)
cDNAs were amplified with the Brilliant III SYBR-Green Master Mix (Thermo Scientific) 
using the Stratagene Mx3000p system and specific primers for each transcript of interest. 
Specifically, expression levels (absolute mRNA copy number/50ng of sample) of ghrelin, 
In1-ghrelin, GOAT-enzyme, GHSR1a and GHSR1b, were measured using previously vali-
dated primers [21, 29, 30]. RNA expression was adjusted by 18S gene expression[28, 31].
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Immunohistochemistry (IHC) analysis
IHC analysis of GOAT was implemented in all 42 FFPE samples (tumor and NTA regions) 
using standard procedures [32]. Optimum antibody concentration (1:300) using a com-
mercially available antibody against human GOAT (AA257-287, Acris-antibodies, Herford, 
Germany) was selected by performing a series of antibody dilution tests in normal pancreas 
[33]. Two independent pathologists performed the IHC analysis following a blinded pro-
tocol. In the analysis, 0, 1+, 2+, 3+ stand for absent, low, moderate, and high staining 
intensities of GOAT enzyme in the tumor compared to the NTA region.
Cell culture
In vitro experiments were performed using human NET cell lines BON-1 [34] and QGP-
1 [35]. BON-1 cells were cultured in DMEMF12 (Life Technologies, Barcelona, Spain) 
supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, Madrid, Spain), 1% glu-
tamine (Sigma-Aldrich) and 0.2% antibiotic (Gentamicin/Amphotericin-B; Life Technolo-
gies). QGP-1 cells were cultured in RPMI-1640 (Lonza, Basel, Switzerland), supplemented 
with 10% FBS, 1% glutamine and 0.2% antibiotic. Both cells lines were cultured at 37°C 
in a 5% CO2 incubator and monthly checked for mycoplasma contamination by PCR [36].
Cell proliferation assay in response to GOAT inhibitor
The only commercially available GOAT inhibitor (GOATi; GO-CoA-Tat; Ref: 032-37) 
was purchased from Phoenix Pharmaceuticals (Burlingame, CA). The final concentration 
(10-5M) was selected based on dose-response experiments performed in prostate cell-lines 
and on previous reports [37]. Cell proliferation was determined by using Alamar-blue as-
say (basal, 24h, 48h and 72h) as previously reported [21, 22, 32]. Cells were seeded per 
quadruplicate and assays were repeated four times. Paclitaxel (PAX; Sigma-Aldrich) was used 
as control for the inhibition of proliferation [27, 30].
Migration capacity assay
The ability of BON-1 cells to migrate after 24h of treatment was evaluated by wound heal-
ing technique [22, 38-40]. Briefly, stable cells were plated at sub-confluence in 6 well plates. 
The wound was made on confluent cells using a 100 µl sterile pipette tip. Wells were rinsed 
in PBS and treated for 24 h in FBS-free medium. Wound healing was calculated as the area 
of a rectangle centered in the picture 24 h after the wound vs. the area of the rectangle just 
after doing the wound. Three experiments were performed in independent days, in which 
three random pictures per well along the wound were acquired and, the mean area of these 
pictures was used for analysis. Images were analyzed using the ImageJ software [41].
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Statistical analysis
Paired t-test analysis was used to compare the expression levels between GEP-NETs samples 
and NTA tissue. Non-paired t-test analysis was used to compare the expression levels be-
tween normal tissue and GEP-NETs samples or NTA tissue. U-Mann Whitney tests were 
used to evaluate clinical-molecular relations within GEP-NETs samples. Chi-squared test 
was used to compare categorical data. All statistical analyses were performed using SPSS 
and GraphPad Prism. Data are expressed as mean ± SEM. p-values<0.05 were considered 
statistically significant. In functional experiments, results were expressed as percentage vs. 
control (vehicle-treated cells). Cell proliferation rate compared to control was assessed by 
multiple comparison test (Two-way ANOVA followed by Newman-Keuls post-hoc test).
RESULTS
Forty-two patients with GEP-NETs were included. Demographic/clinical features are sum-
marized in Table 1. Specifically, 15 patients presented PNETs and 27 patients presented 
gastrointestinal (GI)-NETs [52.3% males (22/42); mean age 55.6±17 years]. Tumor charac-
teristics are summarized in Table 2. In our cohort, 43.3% (13/30) were functioning tumors; 
63.2% (24/38) had peritumoral invasion [34.3% (12/35) vascular and 35.3% (12/34) 
neural invasion], 52.4% (22/42) had metastasis at diagnosis [multiple localization in 
36.3% (8/22)], 63.2% (24/38) were invasive tumors and the mortality rate reached 18.9% 
(7/37). Relapsed disease was observed in 36% of patients (13/36). Finally, almost 70% of 
samples (29/42) were considered as low/intermediate tumors [38.1% (16/42) grade 1 and 
31% (13/42) grade 2]. PNETs were statistically larger in size compared to those GI-NETs 
(4.0±0.47 vs 2.36±0.34 cm respectively; p<0.01).
Histopathological characterization of GEP-NETs and NTA tissue
Primary tumor samples were delimited from the NTA tissues after the evaluation of two 
experienced pathologists using histology and immunohistochemistry, as previously reported 
[32].
Expression of components of the ghrelin system in control and GEP-NETs samples
Ghrelin system components were present at variable proportions in normal GEP samples, 
as determined by qPCR. Ghrelin and its native receptor GHSR1a were expressed in more 
than 80% of healthy controls (34/42 and 39/42, respectively), while their splicing vari-
ants In1-ghrelin and GHSR1b were expressed in about 40% of the samples (17/42 and 
19/42, respectively). In contrast, expression of GOAT enzyme was only detected in less than 
20% (7/42) of normal samples (Supp. Figure 1). Ghrelin and GHSR1a were also present 
in a high proportion (more than 60%) of the NTA and tumor samples (32/42 and 29/42, 
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Table 2: Tumor sample characteristics
Characteristic % (n)
Tissue samples
Primary tumor 42
Non-tumor adjacent tissue 42
Normal tissue 14
Primary tumor localization
Pancreas 35.7% (15)
Stomach 7.1% (3)
Small bowel 31.0% (13)
Colon and rectum 26.2% (11)
Maximal tumor diameter 2.98±1.86 cm
Pancreas NETs 4.0±0.47 cm
Gastrointestinal NETs 2.36±0.34 cm
Necrosis
<10% 16.7% (1)
10-20% 16.7% (1)
21-30% 50% (3)
>30% 16.7% (1)
Depth of infiltration (gastrointestinal NETs)
Submucosa 4.5% (1)
Mucosa 4.5% (1)
Muscular 40.9%(9)
Serosa 50.0%(11)
Multiple tumors 8.0% (2)
Peri-tumoral tissue invasion 63.2% (24)
Vascular invasion 34.3% (12)
Neural invasion 35.3% (12)
Metastasis 52.4% (22)
Metastasis localization Liver 9.1% (2)
Lymphatic nodules 54.5% (12)
Multiple 36.3% (8)
Grading (WHO 2010 criteria) Low 38.1% (16)
Intermediate 31.0% (13)
High 4.8% (2)
Unknown 26.2% (11)
Post-surgical treatment 43.2% (16)
Relapsed disease 36.1% (13)
Disease free 55.9% (19)
New surgery requirements 18.2% (6)
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respectively); while GOAT enzyme and the splicing variants In1-ghrelin and GHSR1b 
were present in more than 40% of the samples ((25/42, 21/42 and 17/42, respectively; 
Supp. Figure 1). Of note, ghrelin expression levels were decreased in NTA and tumor tissue 
compared with normal samples, with a slightly but not significantly increased expression in 
tumor compared with NTA tissue (Figure 1). A similar observation was found for GHSR1a 
expression, while GOAT enzyme was clearly overexpressed in tumor tissues compared with 
NTA regions and normal tissues, wherein it was virtually absent (Figure 1). Finally, In1-
ghrelin was more expressed in tumor tissues than in control samples but these differences 
were not statistically significant, while no significant changes were found in the case of the 
splicing variant GHSR1b (Figure 1).
In terms of tumor grade, no significant differences in the expression of any of the ghrelin 
system components analyzed were found between differentiated (G1/G2) and non-differen-
tiated (G3) GEP-NET (Supp. Figure 2). However, we found that the expression of GOAT 
enzyme and GHSR1a in GI-NETs was markedly higher than in PNETs, while the expres-
sion of ghrelin was lower in GI-NETs compared to PNETs (Supp. Figure 3). Additionally, 
ghrelin expression levels correlated with those of In1-ghrelin (R2=0.532; p<0.01) and GOAT 
(R2=0.422; p<0.05) in tumor samples, while the expression of GHSR1a was correlated with 
GHSR1b (R2=0.444; p<0.05).
Immunohistochemistry analysis of the presence of GOAT enzyme
Based on the marked overexpression of GOAT enzyme, as well as on previous reports [16, 
18], we also sought to analyze its presence at the protein level. IHC analysis of tumor tissue 
revealed that GOAT enzyme was present in the vast majority of tumor cells compared with 
NTA tissue (Figure 2A), with different grades of staining. Indeed, in our cohort, 86% of the 
tumor samples (36/42) evaluated were positive for the presence of GOAT enzyme by IHC 
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Figure 1: Expression of ghrelin system components in normal GEP, adjacent non-tumor tissue 
and GEP-NETs. The absolute mRNA expression of the different components of the ghrelin system 
was determined by qPCR in normal GEP controls, adjacent non-tumor tissue and GEP-NETs samples 
(values are adjusted by 18S expression). Data represent the mean ± SEM. Asterisks (*, p<0.05; **, 
p<0.01; ***, p<0.001) indicate significant changes by paired analysis between adjacent non-tumor and 
GEP-NETs and non-paired analysis between normal tissue and adjacent non-tumor or tumor tissues.
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Figure 2: Immunohistochemical analysis of GOAT enzyme in adjacent non-tumor tissue and 
GEP-NETs. The presence of GOAT by immunohistochemistry using a specific antibody was deter-
mined in a subset of samples, which included tumor and non-tumor regions from patients diagnosed 
with GEP-NETs. A) Representative images of the IHC analysis of GOAT enzyme in a GEP-NET 
sample compared with the non-tumor adjacent tissue. B) Absolute number of cases according to the 
intensity of GOAT IHC staining (0, 1+, 2+, 3+). C) The graph indicates the percentage of tumor 
samples according to the intensity of GOAT expression by IHC, 0 and 1+ have been grouped as low 
expression while 2+ and 3+ have been grouped as high intensity by IHC. D) Representative images of 
different GOAT staining in GEP-NETs. In the analysis, 0, 1+, 2+, 3+ stand for absent, low, moderate, 
and high intensities of the tumor region staining compared to the adjacent region with non-tumor 
tissue (3C1, 3C2, 3C3, 3C4 respectively). This analysis revealed that GOAT was present in the vast 
majority of tumor cells compared with non-tumor adjacent tissue, with different grades of staining. E) 
Correlation between the absolute mRNA expression of GOAT determined by qPCR in GEP-NETs 
samples (values are adjusted by 18S expression) and the intensity of GOAT staining.
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(Figure 2B), wherein 40% of the tumor cases (17/42) presented a strong staining (2+ or 3+) 
for GOAT compared to NTA tissue (Figure 2C and 2D). Of note, mRNA expression levels 
in tumors samples correlated with GOAT expression by IHC (Figure 2E). Additionally, 
strong staining (2+ or 3+) for GOAT was correlated to increased age at diagnosis (62.5±4 
years) compared to those tumors with absent or lower staining (1+; 51±2 years; p>0.05).
Correlations between the expression levels of ghrelin system components and 
clinical-histological characteristics in GEP-NETs
Epidemiological data revealed that patients with tobacco exposure exhibited higher expres-
sion of ghrelin and In1-ghrelin (Figure 3A). Moreover, patients with family history of tumor 
disease had a lower expression of ghrelin (Figure 3B). Conversely, sex, personal history, 
previous neoplasm history, clinical symptoms, or other histological parameters (vascular/
peritumoral invasion, lymph node metastasis) were not associated with the expression of any 
of the components of the ghrelin system.
Expression of some ghrelin system components was also associated to tumor characteristics, 
invasion capacity and prognosis in GEP-NETs. Specifically, functioning tumors presented 
higher levels of GHSR1a (Figure 3C), while lower expression levels of this receptor were 
associated to the presence of affected surgical borders and mortality (Figure 3C). Tumors 
with necrosis had lower GOAT mRNA levels and those with liver metastasis had decreased 
expression levels of In1-ghrelin (Figure 3D). Interestingly, functionality was also associated 
with increased expression of GHSR1b (Figure 3E). Finally, tumor diameter was directly 
correlated to GOAT expression (R=0.33; p<0.05). Remarkably, no further associations were 
found between expression levels of ghrelin system components and clinical/histological 
characteristics when considering separately PNETs and GI-NETs (data not shown)
In vitro analysis of the role of GOAT in PNETs cell lines
We decided to further investigate the pathophysiological role of GOAT enzyme using the 
only available GOATi in PNETs cell lines. However, GOATi did not affect cell proliferation 
in BON-1 and QGP-1 cells (Figure 4A) or the migration capacity of BON-1 cells (Figure 
4B).
DISCUSSION
This study aimed at evaluating systematically the expression of various components of the 
ghrelin system in an ample series of clinically well-characterized GEP-NETs, and to compare 
these expression levels with those in the corresponding adjacent non-tumor tissues and in 
normal control tissues. Previous studies have reported certain components of the ghrelin 
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system in GEP-NETs [22, 42-44]; however, to our knowledge, this is the first study that 
comprehensively characterizes these components in tumor samples compared to their cor-
responding adjacent non-tumor regions, as well as with normal tissue samples. Moreover, 
we analyzed the demographic, epidemiological, and clinical characteristics as well as the 
disease progression and prognosis after 2–10 years of the patients with GEP-NETs. Overall, 
our results revealed that most of the components of the ghrelin system exhibit a distinctive 
expression in tumor and peritumoral tissues compared to normal tissue samples. Indeed, 
specific components of the ghrelin system, and especially GOAT, displayed remarkable 
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Figure 3: Correlations between epidemiological, clinical, histological and molecular parameters 
in GEP-NETs. The correlations between epidemiological, clinical, histological and molecular param-
eters within GEP-NET samples were assessed by U-Mann Whitney tests. Asterisks indicate significant 
associations (*, p<0.05; **, p<0.01; ***, p<0.001).
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alterations and clinical-histological correlations in tumor tissues, suggesting their potential 
value as novel biomarkers in GEP-NETs.
Also in our cohort, GEP-NETs exhibited a substantial molecular heterogeneity and vari-
ability [22, 32, 45]. Our results are consistent with previous reports showing that different 
components of the ghrelin system are present in tumor and non-adjacent tissues, and that, 
some of these components can be overexpressed in tumor samples compared to the sur-
rounding tissue [22, 42-44]. Differences among these studies may be related to the differ-
ences among patient cohorts.
Ghrelin system regulates key bodily functions, such as hormonal secretion and cell prolifera-
tion, in both normal and tumor cells [11-13, 46, 47]. In this context, our and other studies 
support the notion that the dysregulation of ghrelin system components observed in NETs 
could be pathologically relevant and may participate in tumor progression. The diverse lo-
calization and morphology of ghrelin-producing cells in the GI tract, and their implications 
on metabolic/endocrine functions, might suggest a role of this component in the regulation 
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Figure 4: In vitro analysis of the consequences of GOAT inhibitor (GOATi) treatment in NET 
cell lines. A) Cell proliferation rate in BON-1 and QGP-1 cell lines after 24h, 48h and 72h of GOATi 
treatment determined by Alamar-blue assay. Paclitaxel (PAX) was used as inhibitory control in pro-
liferation assays. B) Cell migration rate in BON-1 after 24h of treatment with GOAT inhibitor by 
wound-healing assay. Cell proliferation rate compared to control was assessed by multiple comparison 
tests while migration was assessed by U-Mann Whitney test. Values represent the mean ± SEM of at 
least three individual experiments. Asterisks indicate significant differences (*,p<0.05; ***,p<0.001) 
compared with control (set at a 100%). Legend: ns means non-significant.
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of GEP-NETs patho-physiology [12, 13, 42], and could also explain the ample molecular 
heterogeneity found herein in the expression of ghrelin in different normal control tissues. 
Moreover, it could also be related to the overall overexpression of ghrelin in normal tissues 
compared to tumor samples. Although expression of canonical ghrelin has been described 
in various tumor types, its potential role in cancer is still controversial [48, 49]. Ghrelin has 
been described in NETs using immunohistochemistry and qPCR [22, 25, 42, 43], in our 
cohort ghrelin was expressed in NET samples, albeit in substantially lower amounts than in 
normal tissues. In addition, in our cohort ghrelin expression levels were higher in PNETs 
than in GI-NETs, which is consistent with previous evidence [43] but differed from other 
reports [44]. At variance with previous studies that did not find any clinical correlation 
between ghrelin expression and clinical features [22, 42], we observed here that ghrelin 
expression was higher in patients without tumor family history. Similarly, the in vitro effects 
of ghrelin on cell proliferation are also controversial [48, 50-56] and some studies have 
reported an association between ghrelin and poor survival in renal cell carcinoma patients 
[57, 58]. Altogether, these data reinforce the notion that NETs are highly heterogeneous 
tumors, wherein the particular ghrelin expression profile and its clinical implications may 
depend on the type of tumor and the particular cohort of patients analyzed.
Expression of the canonical ghrelin receptor GHSR1a has been described in tumors includ-
ing NETs [22, 25, 48]. Here, GHSR1a expression was highly variable in normal control 
samples, but tended to be overexpressed in tumor samples compared to adjacent non-tumor 
tissue, which is consistent with our previous study in a different cohort [22]. The relation 
between GHSR1a, functionality and mortality invites to explore further the potential rela-
tionship of this receptor with tumorigenesis, and its putative value as a molecular prognostic 
marker in NETs.
The pathophysiological implications of the ghrelin system have been recently expanded with 
the discovery of new molecular components [11, 16, 17, 29], which have been found to be 
overexpressed in several tumors [16, 22, 27] and associated to relevant clinical parameters 
[22]. Herein we found comparable tendencies in the expression of these variants; however, 
these differences did not reach statistical significance. Nevertheless, in the present cohort, 
more than 40% of tumor samples presented detectable levels of In1-ghrelin and GHSR1b, 
while in the previous study, more than 80% of the tumor samples exhibited detectable 
levels [22]. These differences could likely reduce the statistical power of the comparisons and 
correlations, and, again, would illustrate the elevated heterogeneity of NETs.
The most novel and relevant finding of this study is the marked overexpression of GOAT in 
NET samples. Whereas the expression of this enzyme was almost absent in control tissues, it 
was present in adjacent non-tumor tissue and notably overexpressed in tumor tissues. These, 
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together with previous results showing a similar, remarkable overexpression of GOAT in 
breast and pituitary tumors [11, 21] provide suggestive evidence for a striking dysregulation 
of this enzyme in endocrine-related tumors. The expression levels GOAT does not always 
correlate with those of ghrelin, whereas they do parallel more consistently the expression 
levels of In1-ghrelin, suggesting the existence of additional targets for GOAT enzyme [11]. 
In NETs, GOAT levels have been correlated with those of In1-ghrelin, and associated with 
worse outcome [22], these findings were not reproducible in our cohort, which may be 
explained by the tumor heterogeneity and the limited number of tumor samples. Despite 
this, in the present study, GOAT expression is associated to larger tumors, especially in 
GI-NETs, reinforcing the notion of a possible association between the dysregulation of 
this enzyme and the pathophysiology of NETs. This is the first study that demonstrates 
an intense overexpression of GOAT enzyme by IHC in GEP-NETs tissues compared to 
non-tumor adjacent tissues; however, its functional implications should be precisely defined. 
Here, a GOAT inhibitor administered on two NET cell lines, BON-1 and QGP-1, did not 
show relevant changes in cell proliferation or migration in vitro. Thus, future studies should 
explore this further, using novel inhibitors or other inhibiting/silencing approaches.
Notwithstanding this, our current and previous [22] studies provide compelling evidence 
that certain components of the ghrelin system, and specially GOAT enzyme, are clearly 
overexpressed in NETs, suggesting their potential value as diagnostic and/or prognostic bio-
markers for this pathology. In support of the present finding in NETs, GOAT has been also 
recently reported as non-invasive plasma biomarker in prostate cancer [18]. Additionally, 
the association between GHSR1a and GHSR1b with the functionally of these tumors and 
the mortality of these patients further supports this notion and emphasizes the importance 
of exploring the modulation of this receptor for improving patient outcome. Therefore, 
although it is difficult to predict the specific clinical impact of these findings, taken together, 
all these results invite to analyze in more detail the putative utility of GOAT overexpression 
as a diagnostic biomarker in NETs.
In summary, we present the first systematic characterization of the components of the 
ghrelin system, including splicing variants, in GEP-NETs tissues in comparison with their 
adjacent non-tumor regions, and also with normal tissue samples. Our results demonstrate 
that key components of this system are markedly dysregulated in GEP-NETs and associated 
to key clinical parameters, suggesting the interest of further studying these molecular targets, 
especially GOAT, as putative diagnosis and/or prognostic markers in GEP-NETs.
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Supplemental Figure 1: Presence of ghrelin system components in normal GEP, adjacent non-
tumor tissue and GEP-NETs. The graphs indicate the percentage of samples (normal GEP control, 
adjacent non-tumor tissue and tumoral tissue) positive for the expression of each of the ghrelin system 
components.
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Supplemental Figure 2: Expression of ghrelin system components in GEP-NETs of different 
grade. The absolute mRNA expression of the different components of the ghrelin system was analyzed 
in grade 1, 2 and 3 GEP-NETs samples (values are adjusted by 18S expression). Data represent the 
mean ± SEM.
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Supplemental Figure 3: Expression of ghrelin system components in pancreas and gastrointes-
tinal NETs. The absolute mRNA expression of the different components of the ghrelin system was 
analyzed in pancreas and gastrointestinal NETs samples. Data represent the mean±SEM. Asterisks 
(**,p<0.01; ***, p<0.001) indicate significant changes by non-paired analysis.
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Novel therapeutic options for neuroendocrine tumors
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ABSTRACT
Background: Biguanides and statins have been reported to exert beneficial effects on various 
cancer types. However, their precise effects and underlying molecular mechanisms are still 
poorly understood. Materials and Methods: We analyzed the relation between metabolic-
syndrome, i.e., presence of type-2 diabetes (T2DM), hyperlipidemia and their treatment, 
with histological, epidemiological, and prognosis variables in two patient cohorts with 
neuroendocrine-tumors [NETs: lung-carcinoids (LCs; n=81) and gastro-entero-pancreatic 
(GEP-NET; n=100)]. Additionally, we investigated the antitumoral effects of different 
biguanides and statins by evaluating proliferation/migration/secretion/gene-expression and 
involved molecular pathways using BON1/QGP1-cell cultures. Results: In T2DM patients, 
pleura invasion was higher (LCs group; p<0.05) and tumor diameter tended to be increased 
(GEP-NET group). mRNA levels of somatostatin and ghrelin systems were different in 
tumor tissue of T2DM patients with and without metformin. Biguanides (metformin/
buformin/phenformin) decreased proliferation rate in BON1/QGP1-cells (24-72h). How-
ever, the effects of statins on proliferation-rate were dependent of the statin-type, cell-type, 
and time. Specifically, only simvastatin/atorvastatin decreased proliferation in BON1-cells 
(48/72h and 72h, respectively), while all statins decreased proliferation rate in QGP1-cells 
(48/72h). Remarkably, metformin and simvastatin decreased migration capacity in BON1-
cells and biguanides decreased serotonin secretion in BON1-cells. Phenformin increased 
apoptosis in BON1/QGP1-cells, and simvastatin in QGP1-cells. These antitumor effects 
likely involved altered expression of key genes related to cancer aggressiveness (i.e. GLUT4, 
INSR). Altogether, our results reveal a clear inhibitory effect of biguanides and statins on 
NET-cell aggressiveness. Conclusion: Given the demonstrated clinical safety of these drugs, 
our results invite to further explore their potential therapeutic role for the treatment of NET 
patients.
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INTRODUCTION
Biguanides comprise a class of drugs with relevant effects as insulin-sensitizing agents, which 
are consequently used to treat type 2 diabetes (T2DM), a severe disease with distinct co-
morbidities and whose incidence is growing worldwide, along with its associated metabolic 
syndrome and their other concomitant diseases [1]. The inflammation and insulin resistance 
present in patients with T2DM or metabolic syndrome have been associated with increased 
incidence of neoplasms [2]; thus, some treatment options targeting related pathways, as 
may be the case of biguanides, could be beneficial in some types of cancer. In this context, 
a putative specific relationship between T2DM-metabolic syndrome and neuroendocrine 
tumors (NETs) has not been established yet.
Among biguanides, only metformin is commercially available for medical use, since it has 
a safe profile and is well tolerated. Phenformin and buformin were withdrawn in the early 
1970s because of an association with lactic acidosis and increased cardiac mortality [3, 4]. 
Interestingly, a putative association between metformin treatment and cancer prevention/
treatment was suggested in 2005 [5], and multiple investigations have been subsequently 
published on this topic. Specifically, some epidemiological studies have suggested a decreased 
risk for pancreas, liver, colon, lung, and breast cancer in patients with diabetes treated with 
metformin [6-9]. This protective effect of metformin for cancer has been also found in 
diabetic patients according to several meta-analysis [9-11]. Moreover, biguanides can inhibit 
cell proliferation in vitro in several cancer cell lines, including pancreatic and neuroendocrine 
tumor cells [12, 13]. In terms of signaling, biguanides stimulate AMP-activated protein ki-
nase (AMPK), reduce hepatic gluconeogenesis/glycogenolysis and increase glucose uptake in 
the muscle [14, 15]. AMPK activation also suppresses the mammalian target of rapamycin 
(mTOR1), which is a key regulator of proliferation in cancer cells. AMPK induces cell 
cycle arrest and reduces the insulin/insulin like growth factor 1 (IGF-1) signaling [16, 17]. 
Metformin-mediated AMPK activation may also result in p53-mediated cell cycle arrest or 
apoptosis [18, 19]. It has been also described that metformin could inhibit cell proliferation 
by G0/G1, G2/M or S phase arrest [20]. However, metformin may also exert antineoplastic 
properties in an AMPK-independent manner [21].
Statins are also commonly used drugs in the therapeutic arsenal for patients with metabolic 
syndrome or T2DM. Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase (HMGCR, HMGCoAR), affecting the rate limiting step in cholesterol synthesis, 
but they also exert other clinical effects related with immunomodulatory mechanisms in 
vascular diseases, autoimmune diseases and organ transplantation [22]. In addition, statins 
also reduce bone marrow stimulation and have been shown to exert anti-proliferative effects 
on smooth muscle cells [23-26]. The antitumor mechanisms of statins may include: induced 
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cell-cycle arrest, apoptosis induction and activation of the signaling of c-Jun N-terminal 
kinases (JNKs), decreased invasion/metastasis capacity and decreased MKI67 expression 
[27-31]. These antitumor effects have been described in several tumor types, including 
melanoma, colon and breast cancer [30-33]. Moreover, statins have been proposed as well as 
an useful treatment option to induce apoptosis and decrease proliferation in pheocromocy-
tomas and paragangliomas [34, 35]; but, to the best of our knowledge, studies with statins 
have not yet been reported in NETs.
Since the anti-neoplastic therapy in advanced NETs is still unsatisfactory, novel drugs for 
tumor growth control are required, especially in progressive and hereditary NETs, which 
are characterized by early onset and multiple lesions [12]. Therefore, based on the potential 
association between T2DM, metabolic syndrome and cancer, we explored this association 
in a well-characterized cohort of lung carcinoids (LCs) and gastroenteropancreatic neuro-
endocrine tumors (GEP-NETs). In addition, we analyzed the use of antidiabetic drugs and 
statins in these cohorts and explored their putative relationship with clinical/histological 
characteristics. Finally, we also investigated , for the first time, the potential in vitro antitu-
moral effects of different biguanides (i.e. metformin, buformin and phenformin) and statins 
(i.e. atorvastatin, lovastatin rosuvastatin and simvastatin) in two different NET-cell models, 
BON1 and QGP1 cell lines.
MATERIALS AND METHODS
Patients and tissue samples
This study was approved by the Ethics Committee of the Reina Sofia University Hospital 
(Córdoba, Spain), and was conducted in accordance with the Declaration of Helsinki, 
and according to national and international guidelines. A written informed consent was 
signed by every individual before inclusion into the study. A total of 181 patients [81 with 
lung carcinoids (LCs), and 100 with gastroenteropancreatic (GEP-NETs)] who underwent 
surgery at the Reina Sofia University Hospital from 2005 to 2015 were included in the 
study. Clinical records were used to collect full medical history. Endocrine-associated syn-
dromes were excluded. Patients with T2DM before the diagnosis of NET (31 patients) were 
analyzed separately: 14 T2DM patients in the LCs group, 6 treated with metformin; and 
17 T2DM patients in the GEP-NETs group, 9 treated with metformin. Similar analysis 
was performed in those patients treated with statins: 4 in the LCs and 6 in the GEP-NETs 
group. Demographic and clinical characteristics of both cohorts are summarized in Tables 
1-4. Patients were managed following the available guidelines and recommendations. After 
surgery, if residual or relapsed disease was observed, adjuvant treatment with or without 
surgery was prescribed. To confirm the neuroendocrine nature of all tumors, chromogranin 
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A, synaptophysin, cytokeratin 7, cytokeratin 20, CD56 and neuronal specific enolase were 
determined by immunohistochemistry, which was performed following the standardized 
diagnosis protocol of our hospital and evaluated by two experienced pathologists. Formalin-
fixed paraffin-embedded samples were available in 46 LCs and 55 GEP-NETs cases, in which 
total RNA was isolated. Tumor samples were re-evaluated by two experienced pathologists 
before RNA isolation. Only primary tumor samples were included. Samples were analyzed 
individually and mRNA expression levels were correlated with the clinical/histological 
characteristics of the corresponding patient.
Culture of cell lines
We used two human pancreatic NET (PNET) cell lines: BON-1 and QGP-1 [36-39]. 
BON-1 cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM-F12; Life 
Technologies, Barcelona, Spain) supplemented with 10% fetal bovine serum (FBS; Sigma-
Aldrich, Madrid, Spain) and 0.2% antibiotic (Gentamicin/Amphotericin B; Life Technolo-
gies). QGP-1cells were cultured in RPMI 1640 (Lonza, Basel, Switzerland), supplemented 
with 10% FBS, 1% glutamine and 0.2% antibiotic. Cells were harvested with trypsin 
(0.05%)–EDTA (0.53 mM) and resuspended in culture medium. Cell viability always 
exceeded 85%. Both cell lines were cultured in 75cm2 flasks at 37°C in a 5% CO2 incubator. 
All experimental procedures in both cell lines were performed at least three times.
Drugs and reagents
Metformin, phenformin, simvastatin, atorvastatin, lovastatin and rosuvastatin were 
purchased from Sigma Aldrich. Buformin was purchased from Santa Cruz Biotechnol-
ogy (Texas, USA). All treatments were dissolved in the respective FBS-free-medium and 
diluted until obtaining final concentrations prior to use (metformin: 10-2M; phenformin 
and buformin: 5 x10-3M; statins: 10-5M). IGF1 and paclitaxel were purchased from Sigma 
Aldrich (Madrid, Spain). Drug doses were selected based on in vitro dose–response curves 
(unpublished results) or in previous studies [40, 41].
Cell viability assay
Cells were plated in 100 µL of medium in 96-well plates at the density necessary to obtain 
a 65–70% cell confluence in the control groups at the end of the experiment. Twenty-four 
hours later, serum free medium was added during 24 h. After this, biguanides and statins 
were added into wells in medium with 5% serum. Cell viability was measured using the 
alamar-blue assay at basal, 24 h, 48 h and 72 h of incubation by measuring the fluorescent 
signal exciting at 560 nm and reading at 590 nm (Flex Station 3; Molecular Devices). The 
day of each measurement, cells were incubated for 3 h in 10% alamar blue/serum free-media 
and then, alamar reduction was measured. After each measurement, medium was replaced 
immediately by fresh medium. In all cases, cells were seeded per quadruplicate and all assays 
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were repeated a minimum of four times. IGF1 and paclitaxel treatment were used as positive 
and negative controls, respectively.
Migration capacity assay
The ability BON-1 cells to migrate after 24 h of treatment with biguanides and statins was 
evaluated by wound healing technique. Briefly, cells were plated at sub-confluence in 12 well 
plates. Confluent cells were serum-starved for 24 h and after synchronization the wound was 
made using a 100 µl sterile pipette tip. Cells were incubated for 24 h in FBS free medium. 
Wound healing was calculated as the area of a rectangle centered in the picture 24 h after the 
wound vs. the area of the rectangle just after doing the wound, as previously reported [42]. 
At least three experiments per cell line were performed in independent days, in which three 
random pictures along the wound were acquired per well.
RNA isolation and reverse-transcription
Total RNA from formalin fixed paraffin-embedded (FFPE) samples was isolated using the 
RNA easy FFPE Kit (Qiagen, Limburg, The Netherlands) according to the manufacturer’s 
instructions. Quantification of the recovered RNA was assessed using NanoDrop2000 spec-
trophotometer (Thermo Scientific, Wilmington, NC, USA). One microgram of total RNA 
was retrotranscribed to cDNA with the First Strand Synthesis kit using random hexamer 
primers (Thermo Scientific) as previously reported [43, 44].
Quantitative real time PCR (qPCR)
cDNA was amplified with the Brilliant III SYBR Green Master Mix (Stratagene, La Jolla, 
CA, USA) using the Stratagene Mx3000p system and specific primers for each transcript 
of interest. Specifically, expression levels (absolute mRNA copy number/50ng of sample) of 
insulin receptor (INSR), GLUT4 genes were measured in the cells using previously validated 
primers [41], and the expression level of each transcript was adjusted by the expression of Beta 
Actin (BACT; used as housekeeping gene). Experiments were performed at least three times.
In human tumor samples, somatostatin system [i.e. somatostatin (SST), cortistatin (CORT), 
their receptors SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, sst5TMD4], and ghrelin system 
[i.e. ghrelin (GHRL), In1-ghrelin variant, ghrelin-o-acyltransferase enzyme (GOAT), and 
the receptors GHSR1a/GHSR1b] were evaluated using previously validated primers [41, 
45-48]. mRNA levels were normalized by 18S in GEP-NETs and by BACT in LCs, as previ-
ously described [45, 46]. In NET cell lines, the expression of insulin receptor (INSR) and 
glucose transporter GLUT4 was analyzed in response to biguanides and statins treatment 
using previously validated primers [49, 50].
All samples were run, in the same plate, against a standard curve to estimate mRNA copy 
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number and a No-RT sample as a negative control. Thermal profile consisted of an initial 
step at 95°C for 30 s, followed by 50 cycles of denaturation (95°C for 20s) and annealing/ 
elongation (60°C for 20s), and finally, a dissociation cycle (melting curve; 55°C to 95°C, 
increasing 0.5°C/30 s) to verify that only one product was amplified.
Serotonin assay
BON-1 and QGP-1 cells were cultured in 12-well plates. At 70% confluence, cells were 
serum starved and after a 24 h incubation period with specific treatments or with vehicle, 
media were collected and stored at −20°C until measurements. Secretion of serotonin was 
detected using a serotonin ELISA kit (ALPCO, Salem, NH, USA) following the instructions 
of the manufacturer.
Apoptosis assay
BON-1 and QGP-1 cells were cultured in 24 well plates. At 70% confluence, cells were 
serum starved and after 48 h incubation with specific treatments or with vehicle-treated 
controls in 5% FBS medium, apoptosis levels were measured using a cell death detection 
ELISA kit (Sigma Aldrich) following the manufacturer’s instructions.
Measurement of ERK1/2 and AKT signaling pathways by western blotting
500,000 cells (BON-1 and QGP-1) were cultured in 6-well plates and incubated for 8 
min with specific treatments and vehicle-treated controls. Briefly, after the corresponding 
treatment, medium was removed and cells were washed twice using PBS, detached using 
a scrapper and immediately lysed in pre-warmed SDS-DTT sample buffer at 65°C (62.5 
mM Tris-HCl, 2% SDS, 20% glycerol, 100 mM DTT and 0.005% bromophenol blue) 
followed by sonication for 10 s and boiling for 5 min at 95 °C, as previously described [51, 
52]. Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes 
(Millipore, Darmstadt, Germany), and then membranes were blocked with 5% non-fat dry 
milk in Tris-buffered saline/0.05% Tween 20 and incubated with the primary antibodies for 
total-ERK1/2, p-ERK1/2, total-AKT, p-AKT (Santa Cruz, CA, USA) and then, with the 
appropriate secondary antibodies [anti-rabbit antibody from Cell Signaling (Danvers, MA, 
USA)]. Protein analyses were developed using an enhanced chemiluminescence detection 
system (GE Healthcare, UK) with dyed molecular weight-markers. A densitometric analysis 
of the bands was carried out with the ImageJ software [53]. Relative phosphorylation of 
ERK and AKT was obtained from normalization of p-ERK1/2 or p-AKT against the total 
ERK1/2 or AKT, respectively.
Statistical analysis
In functional experiments, results are expressed as percentage vs. vehicle-control (non-treated 
cells). mRNA levels are expressed as mean ± SEM. Cell survival rate compared to control was 
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assessed by multiple comparison tests. U-Mann Whitney tests were used to evaluate clinical 
relations within LCs and GEP-NETs samples. Chi-squared test was used to compare cat-
egorical data. All statistical analyses were performed using SPSS statistical software version 
20 and Graph Pad Prism version 6. p values smaller than 0.05 were considered statistically 
significant.
RESULTS
Clinical evolution in patients with LCs and GEP-NETs and correlations with 
T2DM
In the LC group, weight loss was more frequently observed in patients with T2DM than 
in non-diabetic patients (36.4% vs. 8.6%; p<0.05; Table 1). Likewise, pleura invasion was 
also higher in T2DM patients (37.5% vs. 2.2%; p<0.05; Table 1). Despite the increased 
incidence of weight loss in diabetic patients with LC, none of the metformin-treated T2DM 
patients exhibited this symptom (p<0.05; Table 2). In this cohort, the clinical outcome did 
not differ in those patients receiving metformin or other antidiabetic treatment (Table 2). 
Mortality tended to be increased in patients with T2DM (p=0.09; Table 1).
In the GEP-NETs group, an increased incidence of a second neoplasm was observed in the 
non-diabetic group (25.7% vs. 0%; p<0.05; Table 3). Tumor diameter tended to be higher 
in patients with T2DM compared to non-diabetic patients (3.4±0.5 vs 2.5±0.2 cm, p=0.06). 
In addition, the proportion of patients with complete surgical resection was lower in T2DM 
compared with non-diabetic patients (69.2% vs. 93.8%; p<0.05; Table 3). In this cohort, 
the clinical outcome of patients treated with metformin was also similar to those treated with 
other antidiabetic drugs or insulin (Table 4).
None of the rest of clinical parameters evaluated (including functionality or incidental find-
ing), histopathological variables (including, necrosis, local invasion, presence of metastasis, 
vascular or nerve invasion), tumor grading or evolution parameters (including relapsed 
disease, disease-free survival and mortality) were associated to the presence of T2DM or the 
use of metformin in our cohorts of patients with LCs or GEP-NETs.
No clinical, histological or molecular variable was associated to the presence of hyperlip-
idemia in our cohort of LCs (Table 5) or GEP-NETs (Table 6). A higher proportion of 
patients treated with statins were free of disease during the follow up (X2 7.07; p<0.05). 
None of the other clinical, histological or evolution parameters were associated with the use 
of statins in our cohorts of patients with LCs or GEP-NETs.
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Table 1: General characteristics of the LCs patient population
General characteristic Total
(n=81)
Non-diabetic
patients (n=61)
T2DM patients
(n=14)
p
Gender 0.55
Male 51.8% (42/81) 52.5% (32/61) 50.0% (7/14)
Female 48.1% (39/81) 47.5% (29/61) 50.0% (7/14)
Age (years old) 56.4±15.6 56.1±2.7 58.3±3.7 0.75
Personal history of other tumors 18.7% (14/75) 18.3% (11/60) 21.4% (3/14) 0.52
Smoke habit (Active/ Ex-smoker) 65.5% (38/58) 68.1% (32/47) 60% (6/10) 0.44
Family history of neoplasms 55.6% (5/9) 80.0% (4/6) 20.0% (1/3) 0.40
Weight loss 14.6% (7/48) 8.6% (3/35) 36.4% (4/11) 0.046
Functionality 7.5% (4/53) 7.7% (3/39) 8.3% (1/12) 0.67
Incidental 19.2% (10/52) 21.1% (8/38) 16.7% (2/12) 0.55
Maximal tumor diameter (cm) 2.9±2.4 2.8±0.3 3.5±0.8 0.36
Multiple tumors 6.9% (5/72) 5.5% (3/55) 8.3% (1/12) 0.55
Vascular invasion 16.1% (5/50) 17.4% (4/23) 0% (0/6) 0.37
Neural invasion 11.8% (2/17) 8.3% (1/12) 25.0% (1/4) 0.45
Metastasis 25.0% (17/68) 25.0% (13/52) 25.0% (3/12) 0.65
Bronchial infiltration 75.0% (45/60) 90.0% (36/47) 50.0% (4/8) 0.13
Parenchyma infiltration 39.0% (23/59) 37.0% (17/46) 62.5% (5/8) 0.16
Pleura infiltration 6.8% (4/59) 2.2% (1/46) 37.5% (3/8) 0.008
Classification 0.17
Typical 69.4% (34/49) 65.8% (25/38) 77.8% (7/9) 0.69
Atypical 30.6% (15/49) 34.2% (13/38) 22.2% (2/9) 0.69
Relapsed disease 11.8% (6/51) 12.5% (5/40) 0% (0/9) 0.34
Disease free during follow-up 77.6% (45/58) 77.8% (35/45) 81.8% (9/11) 0.56
Mortality 19.4% (13/67) 15.4% (8/52) 35.7% (5/14) 0.09
p value refers to the comparison between non-diabetic patients and T2DM patients.
Table 2: Metformin in patients with T2DM and LCs
General characteristic Metformin
(n=6)
Other antidiabetic
treatment (n=5)
p
Weight loss 0% (0/4) 100% (4/4) 0.04
Maximal tumor diameter (cm) 2.6±0.3 cm 6.7±2.7 cm 0.38
Metastasis 0% (0/6) 60.0% (3/5) 0.12
Bronchial infiltration 50.0% (2/4) 50.0% (1/2) 0.8
Parenchyma infiltration 7.05% (3/4) 25.0% (1/4) 0.6
Pleura infiltration 50.0% (2/4) 50.0% (1/2) 0.8
Disease free during follow-up 100% (4/4) 50.0% (2/4) 0.21
Mortality 33.3% (2/6) 60.0% (3/5) 0.39
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mRNA expression of SST and ghrelin system components in LCs and GEP-NETs 
and their correlations with T2DM
The mRNA levels of several genes of interest were measured in the tumor tissue obtained 
from LCs (Figure 1A) and GEP-NET (Figure 1B) patients. In the LCs group, mRNA levels 
of SST and several receptor subtypes (SSTR1, SSTR2, SSTR4, SSTR5 and sst5TMD4), but 
not of CORT or SSTR3, were numerically, albeit non-significantly decreased in patients with 
T2DM compared to the non-diabetic patients (Figure 1A). A similar pattern of expression 
Table 3: General characteristics of the GEP-NETs patient population
General characteristic Total (n=100) Non-diabetic
patients (n=70)
T2DM patients
(n=17)
p
Gender 0.28
Male 57.0% (57/100) 58.6% (41/70) 47.1% (8/17)
Female 43.0% (43/100) 41.4% (29/70) 52.9 % (9/17)
Age (years) 55.7±17.5 57.8±3.1 55.7±2.2 0.80
Personal history of other tumors 20.7% (18/87) 25.7% (18/70) 0% (0/17) 0.012
Smoke habit 67.4% (29/43) 65.7% (23/35) 71.4% (5/7) 0.57
Family history of neoplasms 46.4% (13/28) 45.0% (9/20) 50.0% (4/8) 0.56
Weight loss 38.5% (20/52) 41.5% (17/41) 25.0% (2/8) 0.32
Incidental tumor 40.3% (29/72) 42.3% (22/52) 33.3% (4/12) 0.41
Functionality 31.5% (23/73) 32.1% (17/53) 33.3% (4/12) 0.59
Primary tumor localization
Pancreas 36.0% (36/99) 34.3% (24/70) 50.0% (8/16)
Stomach 6.0% (6/99) 4.3% (3/70) 6.3% (1/16)
Small bowel 19.0% (22/99) 16.3% (14/70) 25.1% (4/16)
Colon and rectum 36.0% (36/99) 33.4% (29/70) 0% (0/16)
Maximal tumor diameter (cm) 2.6±2.2 2.5±0.2 3.4±0.5 0.06
Free surgical border 87.3% (62/71) 93.8% (45/48) 69.2% (9/13) 0.032
Multiple tumors 7.5% (4/53) 7.5% (3/40) 0% (0/6) 0.65
Local infiltration 53.1% (43/81) 57.1% (32/56) 42.9% (6/14) 0.25
Vascular invasion 28.4% (21/74) 30.8% (16/52) 25.0% (3/12) 0.50
Neural invasion 29.6% (21/71) 32.7 % (16/49) 16.7% (2/12) 0.24
Metastasis 47.4% (45/95) 45.5% (30/66) 47.1% (8/17) 0.56
Grading (WHO 2010 criteria)
Low 46.4% (32/69) 52.2% (24/46) 23.1% (3/13) 0.08
Intermediate 39.1% (27/69) 34.8% (16/46) 69.2% (9/13) 0.08
High 14.5% (10/69) 13.0% (6/46) 7.7% (1/13) 0.27
Relapsed disease 34.2% (27/79) 36.8% (21/57) 27.3% (3/11) 0.41
Disease free during follow-up 61.4% (43/70) 60.8% (31/51) 70.0% (7/10) 0.43
p value refers to the comparison between non-diabetic patients and T2DM patients.
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Figure 1: mRNA expression of somatostatin system components in diabetic and non-diabetic 
patients with LCs (A) and GEP-NETs (B). (C) Total mRNA expression of somatostatin receptors 
in LCs and GEP-NET patients. The absolute mRNA expression of the different components of the 
SST system was determined by qPCR in tumor samples (values were normalized to BACT in LCs and 
18S in GEP-NETs). Data represent the mean±SEM (**, p<0.01).
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was observed in the GEP-NETs group, except for the mRNA levels of SSTR5 (Figure 1B). 
Interestingly, an overall decreased in the mRNA levels of all SSTRs was found in both, the 
LC and GEP-NET groups, but this difference only reached statistical significance in the 
GEP-NET group (Figure 1C).
Table 4: Metformin in patients with T2DM and GEP-NETs
General characteristic Metformin
(n=9)
Other antidiabetic
treatment (n=7)
p
Weight loss 25.0% (1/4 33.3% (1/3) 0.71
Maximal tumor diameter (cm) 3.5±0.8 cm 3.5±0.9 cm 0.95
Necrosis 25.0% (1/4) 0% (0/4) 0.50
Vascular invasion 40.0% (2/5) 16.7% (1/6) 0.42
Neural invasion 0% (0/5) 33.3% (2/6) 0. 27
Metastasis 44.4% (4/9) 57.1% (4/7) 0.50
Mortality 55.6% (5/9) 28.6% (2/7) 0.29
Table 5: Statins in patients with LCs
General characteristic No statins use (n=71) Statins (n=4) p
Previous other tumor 16.9% (12/71) 50.0% (2/4) 0.16
Weight loss 13.0% (6/46) 50.0% (1/2) 0.27
Maximal tumor diameter (cm) 2.8±0.3 4.6±2.3 0.42
Necrosis 33.3% (8/24) 0% (0/1) 0.68
Metastasis 25.0% (16/64) 25.0% (1/4) 0.74
Bronchial infiltration 74.1% (43/58) 100% (2/2) 0.55
Parenchyma infiltration 40.4% (23/57) 0% (0/2) 0.37
Pleura infiltration 7.0% (4/57) 0% (0/2) 0.87
Disease free during follow-up 78.6% (44/56) 50% (1/2) 0.40
Mortality 17.5% (11/63) 50% (2/4) 0.167
Table 6: Statins in patients with GEP-NETs
General characteristic No statins use (n=80) Statins (n=6) p
Weight loss 36.4% (16/44) 60.0% (3/5) 0.29
Maximal tumor diameter (cm) 2.6±0.2 cm 4.3±1.2 cm 0.13
Necrosis 32.0% (8/25) 0% (0/1) 0.69
Peritumoral invasion 52.3% (34/65) 75.0% (3/4) 0.36
Vascular invasion 28.3% (17/60) 33.3% (1/3) 0.64
Neural invasion 28.1% (16/57) 33.3% (1/3) 0.64
Metastasis 44.7%(34/76) 66.7% (4/6) 0.27
Mortality 28% (21/75) 66.7% (4/6) 0.07
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Similarly, mRNA levels of all the components of the ghrelin system (GHRL, In1-ghrelin, 
GOAT and the receptors GHSR1a and GHSR1b) displayed non-significant lower levels in 
diabetic LCs patients compared with non-diabetic LCs patients (Figure 2A). In GEP-NETs, 
the mRNA levels of In1-ghrelin, GOAT and GHSR1b, but not GHRL or GHSR1a, also 
tended to be lower in patients with T2DM (Figure 2B).
Interestingly, a sub-analysis showed that despite the overall expression of SSTRs was sig-
nificantly lower in the GEP-NETs group with T2DM compared to non-diabetic patients, 
these levels were not decreased in T2DM patients treated with metformin compared to 
non-diabetic patients (Figure 3A). Specifically, a non-significant increase in the mRNA levels 
of SST, CORT, SSTR1, SSTR2 and SSTR3 was observed in T2DM patients treated with 
metformin compared with T2DM patients without metformin (Figures 3B), as well as in 
the mRNA levels of GHRL, In1-ghrelin and GHSR1a (Figures 3C).
Cell survival of PNET cells after treatment with biguanides or statins
All biguanides tested clearly decreased survival rate in both BON-1 and QGP-1 cell lines, 
in a time-dependent manner (Figure 4A and 4B, respectively). The most remarkable effect 
was observed in BON-1 cells with phenformin (5x10-3 M), which decreased survival rate 
by 76.6%, 93.1% and 97.13% after 24, 48 and 72h of incubation, respectively. Metformin 
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Figure 2: mRNA expression of ghrelin system components in diabetic and non-diabetic patients 
with LCs (A) and GEP-NETs (B). The absolute mRNA expression of the different components of the 
ghrelin system was determined by qPCR in tumor samples. Data represent the mean±SEM.
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Figure 3: Effects of metformin in patients with T2DM and GEP-NETs. (A) Total mRNA expres-
sion of somatostatin receptors in GEP-NETs. Specific SST and ghrelin system components (B, C 
respectively) in GEP-NETs. The absolute mRNA expression of the different components of the SST 
system was determined by qPCR and normalized to 18S. mRNA expression was assessed in GEP-NET 
patients with and without T2DM. Among the last ones, two subgroups were analyzed: those treated 
with metformin vs those treated with other antidiabetic drugs/insulin. mRNA expression was com-
pared to control. Data represent the mean±SEM (*, p<0.05).
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(10-2 M) decreased the survival rate in these cells by 25.1%, 38.1% and 49.4%, whereas 
buformin (5x10-3 M) reduced it by 36.9%, 37.1% and 56.3% after 24, 48 and 72h of 
incubation, respectively (Figure 4A).
A similar effect was observed in QGP-1 cell line. Specifically, phenformin was also the most 
effective biguanide since survival rates decreased by 68.2%, 87.4% and 96.9% after 24, 
48 and 72h of incubation, respectively; whereas, metformin decreased the survival rate by 
24.9%, 45% and 60%, and buformin by 30.7%, 53.0% and 69.7% after 24, 48 and 72 h 
of incubation, respectively (Figure 4B).
We also analyzed the effect of different statins in cell survival in BON-1 and QGP-1 cell 
lines (Figure 4C and 4D, respectively). Specifically, a decreased survival rate was observed 
after 48 and 72h of treatment with simvastatin (10-5 M; 21.4% and 34.5%, respectively), 
and after 72h of treatment with atorvastatin (10-5 M; 15.2%) in BON-1 cells (Figure 4C), 
being the effect of simvastatin more pronounced than that of atorvastatin at 72h (p<0.05; 
Figure 4C). In QGP-1 cells, a reduction in the proliferation rate was observed after 48 and 
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Figure 4: Time-dependent effect on cell viability of biguanides in BON-1 (A) and QGP-1 (B) cell 
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72h of incubation with all the statins tested (Figure 4D). Thus, simvastatin, atorvastatin, 
lovastatin and rosuvastatin (10-5 M) decreased survival rate ranging from 14.7% to 17.2% 
after 72h.
Based on their antiproliferative effects, phenformin and simvastatin were chosen as repre-
sentative compounds of these two classes of drugs in order to perform further functional 
experiments (i.e. migration, apoptosis and serotonin secretion). Moreover, metformin was 
also included in these analyses due to its relevance in the clinical practice.
Migration capacity in PNET cells in response to metformin, phenformin and 
simvastatin treatment
Metformin and simvastatin (24h of incubation) significantly decreased the migration capac-
ity of BON-1 cells (100% and 38.6%, respectively; representative images are depicted in 
Figure 5A). In contrast, it was not possible to measure the migration capacity in response to 
phenformin in BON-1 cells, perhaps due to a treatment-related toxicity of this compound 
(see below). As previously reported [54] it was not feasible measuring this functional assay 
on QGP-1 cells since these cells form aggregates/clusters in culture, which do not allow to 
correctly measure the migration capacity under basal conditions or in response to any given 
treatment.
The effect of metformin, phenformin and simvastatin treatment on apoptosis
In BON-1 cells, phenformin caused a three-fold increase in apoptosis (Figure 5B). However, 
metformin or simvastatin treatment did not alter apoptosis in BON-1 cells. In QGP-1 cells, 
a two-fold increase in apoptosis was also observed in response to phenformin (Figure 5C). 
In addition, simvastatin increased apoptotic rate in QGP-1 cells by 58.1% (Figure 5C). 
Conversely, metformin treatment did not alter apoptosis in QGP-1 cells.
Effect of biguanides and statins on serotonin secretion in PNET cell lines
In BON-1 cells, phenformin, but not simvastatin decreased serotonin secretion after 24h 
of incubation (p<0.05; Figure 5D). Metformin treatment also tended to decrease serotonin 
release (p=0.06) (Figure 5D). In contrast, none of these treatments altered serotonin secre-
tion from QGP-1 cells (Figure 5E).
Effects of metformin, phenformin and simvastatin on ERK1/2 and AKT signaling 
pathways
To start exploring the signaling pathways affected by biguanides (metformin and phenformin) 
and simvastatin to induce their functional actions in NET cells, the levels of phosphorylation 
of AKT and ERK were evaluated. In BON-1 cells, both biguanides and simvastatin similarly 
decreased phosphorylation levels of AKT and ERK compared to controls (Figure 6A). In 
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marked contrast, in QGP-1 cells, only phenformin and simvastatin decreased phosphoryla-
tion levels of ERK without altering those of AKT (Figure 6B).
The effect of metformin, phenformin and simvastatin in the expression of key genes 
in PNET pathophysiology
In BON-1 cells, metformin and phenformin severely decreased the mRNA levels of INSR 
(p<0.001) (Figure 7A). Also, a trend to an increase in the expression GLUT-4 was observed 
in response to phenformin (Figure 6A). In QGP-1 cells, GLUT-4 expression was increased 
in response to both biguanides and simvastatin, but this difference only reached statistical 
significance in the case of phenformin (Figure 7B). Whereas, no significant changes were 
observed in the expression of INSR in QGP-1 cells in response to these compounds (Figure 
7B). Finally, metformin treatment did not significantly alter the expression of SSTRs in 
BON-1 and QGP-1 cells (data not shown).
DISCUSSION
NETs are a widely heterogeneous group of neoplasms, which are frequently diagnosed at an 
advanced stage of disease [55]. Therapeutic options for advanced metastasized NETs include 
somatostatin analogs, interferon-α, chemotherapy and peptide receptor therapy [55, 56]. In 
the last years, target-directed therapies have increased the therapeutic spectrum for progres-
sive NETs (e.g. sunitinib as tyrosine kinase inhibitor and everolimus for the mTOR pathway 
inhibition) [57-59]. However, despite the improvements in progression-free survival of these 
therapeutic options, their effect on the overall survival is still controversial [60]. Therefore, 
novel treatments are still required, especially for patients with advanced disease.
The incidence of metabolic syndrome is continuously increasing, reaching almost 35% in 
some countries, with a consequent increase in the prevalence of some types of cancer [61]. 
T2DM has been also related to an increased risk of malignancies [62, 63] and is frequently 
developed in patients using everolimus and some somatostatin analogs [64, 65]. In this con-
text, metformin is one of the most widely prescribed oral hypoglycemic agents and, in the last 
years, it has received an increased attention because of its potential antitumorigenic effects 
[5, 66]. Likewise, some publications have described that statins exert an inhibitory effect on 
tumor-induced angiogenesis and an antitumor effect in cellular/animal models of human 
cancer [22, 67]; however, other studies have also suggested a potential risk of cancer when 
statins are used [68]. In this sense, the present study, although using a limited number of 
samples, is the first that: 1) assesses the association of T2DM with clinical evolution param-
eters in patients with different NET types (LCs and GEP-NETs); 2) evaluates the expression 
levels of all the components of two key regulatory systems (SST and ghrelin) in the tumor 
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tissue of patients with these two NET types, in relation to T2DM and metformin treatment; 
and 3) analyzes and compares the effects of different biguanides and statins in key functional 
parameters in two representative models of NET cell lines, BON-1 and QGP-1 cells.
T2DM is linked to relevant defects in the INSR signaling pathway, which regulates growth 
and metabolic responses in insulin target cells and tissues [69]. Some epidemiological studies 
have described an increased risk for several types of cancer (breast, colon, rectum, liver, and 
pancreas) in insulin-resistant patients [70]. Remarkably, in our cohort of patients, a more ag-
gressive pattern in LCs (increased incidence of pleura invasion) and increased tumor size in 
GEP-NETs were observed in patients with T2DM when compared to non-diabetic patients, 
suggesting a possible association between T2DM and NET pathophysiology.
Since insulin is related to increased risk of cancer, treatment options targeting this path-
way could be effective in cancer prevention [71]. Indeed, a meta-analysis showed a 31% 
reduction in overall cancer incidence and a 34% decline in cancer mortality in patients 
with diabetes treated with metformin [72]. A retrospective study in patients with T2DM 
and NETs showed lower recurrence rate in those treated with metformin compared with 
non-metformin treated or non-diabetic patients [72]. Moreover, in a cohort of pancre-
atic NET patients receiving everolimus and octreotide LAR, progression free survival was 
higher in patients treated with metformin compared to other drugs [73]. To the best of 
our knowledge, no other specific reports in NETs have been published yet. In our cohort, 
metformin appeared to avoid weight loss in patients with LCs and T2DM. Interestingly, the 
numerical records assessed in patients with LCs receiving metformin suggested that tumor 
size were smaller, incidence of metastasis was lower and disease-free during follow-up was 
higher than in non-metformin treated patients; however, these results did not reach statisti-
cal significance, likely due to the limited size of the groups. In contrast, no association was 
observed between clinical/histological variables and the use of metformin in the GEP-NETs 
group. Obviously, we should underline that the main limitation of this work might be the 
limited number of patients with T2DM and those treated with metformin included in the 
analysis, although the size of the total cohort evaluated was large enough for making general 
comparisons. Therefore, like other studies reporting a limited cohort of samples [73], the 
results of this study should be interpreted with caution.
Novel mechanisms of action have been proposed for metformin in recent years. Among 
them, the induction of the expression of the glucagon-like peptide 1 (GLP-1) receptor on 
pancreas β-cells was described [74]. To the best of our knowledge, this is the first report 
showing that the expression of several SSTR subtypes is reduced in NETs from diabetic 
patients (LCs and GEP-NETs) compared with those from non-diabetic patients, and most 
importantly, that the overall expression of SSTR is significantly increased in LCs from 
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diabetic patients treated with metformin compared with LCs from diabetic patients without 
metformin treatment. In fact, these expression levels of SSTR in LCs from diabetic patients 
treated with metformin achieved the levels observed in LCs from patients without T2DM. 
These novel results provide suggestive evidence that metformin treatment could increase 
SSTRs expression in NETs in diabetic patients, which might be important from a clinical 
point of view, in that a previous study has suggested that metformin could have potential 
synergistic effect when combined with somatostatin analogs via the inhibition of PI3K/
AKT/mTOR axis [73]. Thus, it will be worth to elucidate in the future the mechanisms 
involved in the capacity of metformin to regulate the expression of SSTRs, as well as a 
putative synergistic effect between somatostatin analogs and metformin. In this sense, we 
analyzed the SSTR expression in BON1 and QGP1 cells after metformin treatment, but we 
did not observe changes in SSTRs mRNA expression levels, which could be in line with the 
idea that metformin could reverse the changes previously altered under diabetic conditions 
and maybe only have reduced potential to modulate basal expression of SSTRs. In addition, 
it has to be noted that pre- or co-treatment with biguanides and statins was not evaluated in 
this study, since the anti-proliferative in vitro response to somatostatin analogs is limited in 
these NET cell lines [45, 75, 76].
Biguanides increase insulin sensitivity as well as glucose use by peripheral tissues [3]. Anti-
tumoral effects of metformin and phenformin have been evaluated in in vitro and in vivo 
studies, and metformin is also being tested as an adjuvant therapy to classic chemothera-
peutic regimens [66, 77]. Specifically, an earlier study showed that metformin inhibited cell 
proliferation in pancreatic, bronchopulmonary and midgut neuroendocrine tumor cell lines 
in a dose-dependent manner, wherein this antitumoral effects appeared to be mediated via 
inhibition of mTORC1 signaling [12]. Metformin has been also shown to inhibit breast 
cancer cell growth in vitro in an AMPK-dependent manner, in association with a decreased 
mTOR activation [78]. In our study, we also observed a time-dependent antiproliferative ef-
fect of different biguanides in PNET cell lines. Similarly, our study revealed that biguanides 
were able to exert additional, beneficial effects on NET cell function by measuring other 
relevant functional endpoints (i.e. migration capacity and apoptotic rate). These results 
support and extend previous data showing that metformin exerted antitumoral actions in 
vitro by modulating cell proliferation and apoptosis in breast cancer cells [79]. However, we 
found that phenformin, but not metformin, was able to increase apoptosis in both NET cell 
lines, which is partially in agreement with previous data indicating that apoptosis induced 
by metformin would differ depending on the NET cell type [12]. We also found that met-
formin and phenformin were able to decrease serotonin secretion in BON-1, but not in 
QGP-1 cells. Although the exact mechanisms are still to be elucidated, these results could 
be clinically relevant in patients with carcinoid syndrome, since elevated serotonin levels are 
directly associated with symptoms in this pathology [79]. In this sense, we should remark 
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that this is not the first time that different results are observed in the functional response 
of BON-1 and QGP-1 cells [45, 81-83], which further emphasizes their potential distinct 
value to study the intrinsic heterogeneity of NETs. Indeed, the reason for these differences 
is still unknown, but could be related to the distinct expression pattern of key regulatory 
systems (e.g. SST, ghrelin, IGF-I, etc.) [81-84] and/or to the different activation or signaling 
of these NET cells in response to the same treatment as it has been previously observed, for 
instance, for SST analogs (i.e. octreotide and pasireotide) [81, 82].
Statins can also exert antitumoral actions. Thus, a phase II trial has reported a statin-induced 
anti-proliferative effect in breast cancer [85]. As well, the antiproliferative effect of statins has 
also been reported in several cancer cell lines including cervical [86], leukemic natural killer 
[87], cholangiocarcinoma [88] and prostate [89]. In line with these previous studies, we 
observed here, for the first time, that different statins exerted a clear antiproliferative effect 
in NET cells. Additionally, we found that simvastatin was able to significantly increased 
apoptosis levels in QGP-1 cells, an effect that has been also previously described in cervical 
cancer, leukemia, natural killer and cholangiocarcinoma cell lines [85-87].
It is well known that the PI3K/AKT/mTORC1 pathway exerts important roles in NETs 
pathogenesis [90]. In LCs, metformin inhibited AKT, ERK and mTOR pathways, suggest-
ing that its antiproliferative effects can be both AMPK-dependent and AMPK-independent 
[91]. In fact, Vlotides et al. have suggested that the functional effect of metformin is cell 
type-dependent, since they reported that AMPK and AKT phosphorylation was elevated in 
pancreatic and midgut NET-cell lines in response to metformin (48h of incubation) but this 
effect was not observed in bronchopulmonary neuroendocrine cells [12]. Interestingly, it was 
also suggested that the inhibition of the mTOR pathway was associated to the induction of 
GSK3 phosphorylation following the ERK or AKT pathway [12]. In our study, we observed 
an inhibition of phosphorylated AKT and ERK pathways after treating cells with biguanides 
(and also with simvastatin), which also reveals the AMPK-dependent and -independent ef-
fects of these drugs in NET cells. It should be mentioned that the differences between our 
results and those reported by Vlotides et al. may be related to the drug-incubation period 
(8min vs. 48h). However, as found in our study, cell inhibition of the ERK pathway has been 
also reported in non-small lung cancer and cholangiocarcinoma cell lines with concomitant 
induction of apoptosis [88, 92]. 
Nowadays, the mechanisms linking T2DM and cancer comprise a most exciting and in-
teresting research topic. It has been proposed that chronic hyperinsulinemia may promote 
the development of neoplasms via abnormal stimulation of multiple cellular signaling 
cascades by insulin, enhancing growth factor-dependent cell proliferation and/or modify-
ing cell metabolism [66]. In our results, we observed changes in the molecular expression 
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of key genes involved in tumor aggressiveness (e.g. INSR and/or GLUT-4) in response to 
metformin or phenformin, but not simvastatin, suggesting a putative modulatory effect of 
biguanides in these signaling pathways. In line with this, some studies have suggested that 
the anti-proliferative effect of statins in cancer cell lines might be associated to a cell-cycle 
regulatory effects [85], epigenetic alterations [93], or to gene expression modifications of 
cancer signaling [94]. However, the effects of simvastatin treatment on these regulatory 
endpoints, as well as whether metformin and simvastatin could play synergistic effects in 
NETs (which has been demonstrated in different tumor pathologies [95-97]) could not be 
evaluated in our study, but deserve further attention in the future. 
In sum, our study using a limited cohort of patients reveals a potential association between 
key clinical parameters of NET aggressiveness (i.e. incidence of pleura invasion or metasta-
sis, tumor size, etc.) and the presence of diabetes and/or treatment with antidiabetic drugs 
in patients with different NET types (LCs and GEP-NETs).  Moreover, this study provides 
evidence that the expression of multiple components of two key regulatory systems for the 
pathophysiology of NETs, the SST and ghrelin systems, are modulated in diabetic patients 
with LCs and GEP-NETs compared to non-diabetic patients. Finally, our results also showed 
that different biguanides and statins are capable to directly exert clear antitumoral actions 
in NET cells, probably due to their effect on cell survival, cell migration, apoptosis, gene 
expression and metabolic pathways modifications. Therefore, since metformin and statins 
are low-cost commercially available drugs, with a safe profile and large experience in their 
clinical use, our present results invite to further explore their potential value as adjuvant 
therapy for the treatment of NET patients.
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GENERAL DISCUSSION
Neuroendocrine tumors (NETs) are a very heterogeneous group of neoplasms, which can 
present with a wide range of clinical symptoms and behavior. The possibility of recurrence 
or long-term metastasis adds to the complexity to the clinical management of patients 
with NET. Moreover, heterogeneity of NETs, in terms of clinical behavior and response to 
medical treatment, emphasizes the importance of identifying new diagnostic, prognostic and 
therapeutic markers [1].
Some biomarkers for functioning and non-functioning NETs are currently available. How-
ever, despite the application of these biomarkers in clinical practice, their results should be 
interpreted with caution [2]. Considering the variable sensitivity and specificity of these 
parameters, there is an unmet need for novel biomarkers to improve diagnosis and predict 
patient outcome. Nowadays, several new biomarkers are under study, and may become 
future tools for the management of NETs. These biomarkers include: 1) peptides and growth 
factors; 2) DNA and RNA markers based on genomic and transcriptomic analysis, including 
the so-called NET test, which has been developed for analyzing gene transcripts in circulat-
ing blood; 3) circulating tumor/ endothelial/progenitor cells or cell free tumor DNA, which 
represent non-invasive methods that may provide additional information for monitoring 
treatment response and tumor recurrence; and 4) improved imaging techniques with novel 
radiolabeled somatostatin analogs or peptides. Unfortunately, nowadays there is no consen-
sus for supporting the use of these novel biomarkers as an indicator of tumor burden [3]. 
Furthermore, dysregulation of several biomarkers is not tumor specific, and the absence of 
cut-off levels for differentiating tissue and tumor subtypes, the lack of reproducibility in 
other NET cohorts and the difficulties in their interpretation, limit their clinical application. 
Thus, it is aimed to develop highly specific and sensitive circulating/tissue biomarkers using 
DNA, RNA and metabolomic approaches.
Despite the rising incidence of NETs in the last years, prognosis has improved, probably due 
to the increased detection of early stage of disease and the availability of novel therapeutic 
options. Treatment of patients with unresectable NETs is complex and aims to control 
hormone secretion and tumor growth. The development of next-generation multirecep-
tor targeting and radiolabeled somatostatin analogs, as well as target-directed therapies 
(everolimus, sunitinib) improved progression-free survival (PFS) in NET patients. However, 
only a proportion of patients responds to these therapies. Validated biomarkers that predict 
response to target-directed therapies are not yet available, whereas the expression of soma-
tostatin receptors (SSTs) in NETs can be used to select patients that are eligible for peptide 
receptor radionuclide therapy (PRRT). Therefore, there is a need to develop biomarkers that 
can be used to achieve a more personalized treatment approach in patients with NET.
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Medical treatment with somatostatin analogs (SSAs) is well-known in differentiated, locally 
advanced or metastatic NETs [4]. SSAs act through binding to G-protein-coupled SSTs 
which are broadly expressed in NETs and may modulate tumor cell proliferation and hor-
mone secretion [5, 6]. Despite their efficacy in disease stabilization and symptom control, 
SSAs cannot control hormone production and tumor growth in the long term in many 
patients. For this reason, novel therapeutic options have been developed, such as PRRT [7], 
and specific pathways involved in cell proliferation, migration and/or angiogenesis in NETs 
have been targeted [8, 9]. In addition, chemotherapy schemes have been updated [10], new 
therapeutic options for functioning NETs have been developed, and several novel treatments 
are currently under study.
Based on the above-mentioned considerations, this thesis evaluated, on the one hand, the 
putative role of somatostatin and ghrelin system components as tissue (bio-)markers in NETs, 
and on the other hand, the antitumor effect of registered drugs for other medical purposes 
(ketoconazole, biguanides and statins), as well as the effect of novel drugs for hormone re-
lease control (somatostatin-dopamine receptor chimeras and telotristat) in NETs. For these 
aims, we used clinical data and cell-based assays, which represent a valuable, simple, and 
cost-effective tool for drugs discovery and evaluation [11]. Specifically, we used traditional 
two-dimensional (2D) monolayer cell cultures, in some studies, we completed our results 
with three-dimensional (3D) cell culture models using spheroids. This last culture system is 
a novel promising method which seems to appropriately reproduce tumor cells environment 
including, cell-cell signaling, growth kinetics, extracellular matrix deposition, nutrients-
oxygen conditions, gene expression, drug resistance, cell heterogeneity and cell-cell physical 
interactions [12]. It has been described that 3D models with spheroids would allow better 
evaluation of long-term treatment [13-16], especially in NET cell lines [17]. According 
the results presented in this thesis, 3D cultures allowed studies with a reliable measure of 
hormone secretion in serum-deprived conditions, whereas an increased apoptosis, lactate 
dehydrogenase levels and decreased cell proliferation rates characterized long incubation 
periods (7 days) in 2D monolayer cell cultures. In this context, 3D culture systems with 
spheroids were especially useful in serum-deprived conditions, since they permit longer 
incubation periods with optimal (time-dependent) cell growth.
NET and somatostatin system
It has been widely described that the somatostatin system is linked to several intracellular 
signaling pathways including the regulation of cell proliferation, differentiation, and angio-
genesis, amongst others [18]. Despite the fact that the presence of the somatostatin system 
has been widely described in NETs [19, 20], a specific role in tumorigenesis has not been fully 
elucidated yet [20, 21]. This includes the use for tumoral scintigraphy [22] and as target for 
long acting SSA and peptide receptor radionuclide therapy (PRRT) [22-24]. Recent publica-
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tions have suggested that somatostatin system dysregulation may be associated with specific 
clinical features and prognosis in NETs patients [21, 25]. As such its molecular and im-
munohistochemical evaluation may represent a valuable prognostic marker in NETs [25, 26].
In the studies described in chapters 2 and 3 of this thesis, we evaluated the mRNA expression 
of specific somatostatin system components, including the ligands somatostatin, cortistatin, 
and their receptors, SST1, SST2, SST3, SST4, SST5 and SST5TMD4. Comparisons were 
made with normal (control), non-tumor adjacent (NTA) and tumor tissues. The presence of 
somatostatin system components was different between normal lung and gastroenteropan-
creatic (GEP) tissue. Specifically, in normal lung tissue, all somatostatin system components 
except somatostatin and SST3 were expressed in less than 25% of samples, whereas in GEP-
tissue, all system components (except cortistatin and SST4) were expressed in more than 
60% of cases. Additionally, the expression profile was also different among both groups: in 
lung carcinoids the mRNA expression of somatostatin and SST4 was higher in tumor tissues 
compared to normal samples, while SST5 was overexpressed in tumor samples compared to 
NTA. In contrast, in GEP-NETs, cortistatin, SST1, SST2, SST5 were clearly over- expressed 
in tumor tissues compared with NTA samples.
As described in chapters 2 and 3 of this thesis, differences in the expression of somatostatin 
system components in control (normal) and NTA tissue, as well as the correlation between 
the molecular expression of somatostatin and its receptors suggests an autocrine/paracrine 
effect that may modulate in situ tumor progression of NETs [27]. Additionally, interactions 
with other family receptors (opioids, dopamine, chemokine) have been described and may 
be associated with pathway activations [28], and even with tumor grade and malignancy 
[29].
According to our results, the different molecular expression of somatostatin system compo-
nents in NTA tissue compared to normal samples (in lung carcinoids and in GEP-NETs) 
suggest that they may exert a biologically regulatory role in proliferation/secretion of these 
tumors. Among them, in GEP-NETs the overexpression of somatostatin was associated with 
increased lymphatic invasion but not with liver metastasis, additionally, SST5 was associated 
with vascular and nerve invasion. In addition, other authors have suggested an association 
between its truncated isoform (SST5TMD4) with increased tumor aggressiveness, suggest-
ing that a dysregulation in this receptor could be related to aggressive features and patient 
outcome [21, 30]. In contrast, in lung carcinoids, no relationship between SST5 and agres-
siveness/invasion parameters was observed, while the truncated receptor SST5TMD4 was 
positively associated with disease free status during the follow-up. These results confirm the 
intrinsic variability and heterogeneity of NETs, specially in those with different localiza-
tion, suggesting that an appropiate characterization of the tumor may allow a personalized 
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clinical management. In this sense, not only the routine evaluation of SST2 provides clinical 
information, but probably in the future the determination of other receptors, specially SST5, 
may offer additional data about clinical outcome and prognosis.
As previously mentioned, SSTs expression in NETs is fundamental for the therapeutic man-
agement of these tumors. SSAs are first-line therapy in functionally active NETs, including 
those associated with the carcinoid syndrome and functional pancreatic neuroendocrine 
tumors (PNETs) [31]. Both long-acting octreotide and lanreotide, which target the SST2, 
similarly improve symptoms and quality of life in NET patients [32]. Unfortunately, some 
patients may be resistant to octreotide or lanreotide. For this reason, a novel SSA (pasire-
otide), which has high affinity to multiple SSTs, including SST2 and SST5, may represent 
a valuable therapeutic option due to its higher affinity to more SSTs [33], and is suggested 
to be of value in insulinomas resistant to other treatment options [34, 35]. In concordance 
to this, in chapter 5 and 7 a not yet described in vitro inhibitory effect of pasireotide on 
serotonin release in PNET cell lines is shown, which may be related to the SST5 expression 
in this cell line. This observation further enhances the importance of the molecular study 
of somatostatin system components in tumor samples of NETs. Importantly, the use of 
radiolabeled SSAs forms in PRRT has been shown as a successful therapeutic alternative in 
metastatic functioning NETs with SSTs expression. Specifically, therapy using peptide recep-
tor radionuclide therapy (PRRT) in GEP-NETs is associated with response rates (18-44% 
by RECIST criteria), improvement in quality of life [36, 37], reduction in risk of progres-
sion or death (79%) and increased overall response rate (ORR; 18%) [38]. Despite PRRT is 
a promising treatment in GEP-NETs, the application in lung NETs may be limited due to a 
lower expression of SSTs, especially in some atypical lung carcinoids; notwithstanding, ORR 
of 15% and disease stabilization of 47% have been reported [39, 40], which is related to the 
findings observed in our cohort, in which SST2 was expressed in NTA and tumor samples. 
Interestingly, clinical effects have been described even when tumor progression was observed 
after initial good response, suggesting that not only the antitumor effect of PRRT may be 
involved in the clinical response [41].
NETs and the Ghrelin system
Tightly associated with the somatostatin system, ghrelin system is also involved in the 
regulation of multiple (patho)-physiological functions, including hormonal secretion, β-cell 
survival or appetite and gastric motility [42-45]. Alterations in the expression of specific 
components of this system have been associated with the development/progression of vari-
ous neoplasms, but these associations are still controversial and remain unclear [46-50].
According to our results, the differences in the expression of ghrelin system components 
between normal tissue, non-tumor adjacent tissue and tumor tissue, suggest a dysregulation 
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of ghrelin system in these tumors Additionally, the concomitant expression of ghrelin, its 
activating enzyme ghrelin-O-acyl-transferase (GOAT) and the native receptor GHSR1a sug-
gests that the whole machinery of this system may modulate the development or progression 
in this pathology, and may include some splicing variants (e.g. In1-ghrelin and GHSR1b) 
[27].
In this context, ghrelin system components were expressed in < 25% of normal lung 
samples, as determined by qPCR, but ghrelin, In1-ghrelin, GHSR1a and GHSR1b were 
expressed in at least 75% of lung carcinoids and NTA tissues. Specifically, GHSR1a and 
GHSR1b were overexpressed in tumor tissue and NTA tissue compared to normal lung 
tissue. Interestingly, while the mRNA expression of ghrelin was associated with decreased 
vascular invasion capacity, the canonical receptor GHSR1a was associated with increased 
proportion of metastasis, suggesting that other unknown ligands may also bind this recep-
tor. In contrast, in GEP-NETs, ghrelin and its native receptor GHSR1a were expressed in 
more than 75% of healthy controls, additionally, their expression levels were decreased in 
NTA and tumor tissue compared with normal samples, with a slightly, but not significantly, 
increased expression in tumor compared with NTA tissue. In these tumors, GHSR1a was 
associated with functioning tumors and decreased mortality, contrasting with the clinical 
findings observed in lung carcinoids.
An important finding of this thesis is the potential role of GOAT enzyme as biomarker 
in NETs. Specifically, GOAT acylates the third serine residue of ghrelin. After this unique 
modification, acylated ghrelin represents the peptide binding and activating its canonical 
ghrelin receptor GHSR1a [45, 51]. In lung carcinoids, GOAT was virtually absent in con-
trol tissue, whereas it was present in less than 50% of the NTA samples and raised to more 
than 75% of tumor samples, despite this, it was not overexpressed in tumor tissue compared 
to NTA. In contrast, in GEP-NETs, GOAT was detected in about 20% of normal samples 
and was remarkably overexpressed in tumor tissues compared with NTA regions and normal 
tissues, especially in gastrointestinal NETs, compared to pancreatic NETs. Despite GOAT 
was not associated with any invasion/aggressiveness parameter, its remarkable overexpression 
in tumor tissue suggests a potential role in NETs, further research is required and would 
probably include its determination as circulating marker, or even more, the evaluation of 
its role as a therapeutic marker by inducing changes in its molecular expression or function.
Although clinical results presented in this thesis have been evaluated in ample, well-char-
acterized patient cohorts, the heterogeneity of the included patients and the retrospective 
analysis, may limit their reproducibility. Despite this, results presented in Part I of this thesis, 
provide a bases for future characterization and study of these system components in NETs, 
including e.g. circulating markers analysis in prospective cohorts.
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Novel targeted therapies
The availability of molecular-target therapies in NETs has increased the therapeutic alter-
natives for NETs. Sunitinib and everolimus have been described as successful treatment 
options in both functioning and non-functioning tumors, since they may control tumor 
growth, improve clinical symptoms and increase PFS [52, 53]. Unfortunately, significant 
prolongation of overall survival (OS) with these medical options is still controversial and 
novel therapeutic options, especially for hormone release control, are necessary.
Somatostatin-dopamine chimeric drugs
Multi-receptor interaction has been suggested as an efficacious and selective therapeutic 
strategy for enhancing the effects of somatostatin [28]. It has been hypothesized that this 
modulation may be achieved by the activation of different receptor systems with a common 
endpoint, an increased activation of a single/common pathway by multiple receptors, or the 
activation of multiple complimentary intracellular signal transduction systems [28]. The 
presence of hetero-dimers has been described among SSTs and between SSTs and other 
receptor families, including dopamine receptors, especially the dopamine receptor type 2 
(D2R) [54, 55]. Based on this, some structural chimeric molecules that combine elements 
of SSAs and dopamine agonists (DA) were developed [28]. The potential effect of these 
chimeras depends on the affinity for each receptor subtype, which may be modified accord-
ing to the therapeutic interest. An ideal chimeric compound would have potent SST2 and 
D2R activity, with moderate SST5 activity in order to inhibit hormone secretion without 
altering the glucose homeostasis [28, 56]. In chapter 6, the effect on cell proliferation and 
secretion of two SSTs-D2R multi receptor targeting drugs (BIM065 and BIM23A760) is 
described using two-dimensional (2D; monolayer) and three-dimensional (3D; spheroids) 
culture systems. Their inhibitory effect on serotonin and CgA secretion, which was compa-
rable to cabergoline but not to octreotide, suggests that in this PNET model, the activity 
of both chimeric drugs is probably related to their affinity for D2R. In vivo reports have 
described that BIM-23A760 acutely decreases growth hormone and prolactin secretion in 
pituitary tumors, but long-term effects disappeared due to a dopaminergic metabolite that 
may interfere with the activity of the parent molecule [28]. In our study, BIM-23A760, 
followed by cabergoline and BIM-065, were the most potent drugs for inhibiting serotonin 
and CgA secretion. In NETs, an open label, multicenter clinical trial in patients with car-
cinoid syndrome was started for evaluating the efficacy of BIM-23A760. This study was 
prematurely terminated, and unfortunately, primary/secondary outcomes were not analyzed 
(NCT01018953). Due to their putative promising effects, current research is focused in the 
improvement of chimeric molecules that could keep a long-term effect. The results described 
in chapter 6 also underline that it is important to recognize the effect of cabergoline in hor-
mone release control in NETs, in addition to that of SSA. This is further strengthened with 
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previous reports of the use of cabergoline in ectopic ACTH-producing NETs (monotherapy 
or in combination with lanreotide) when D2R expression is observed in the tumor [57-59].
Telotristat
Interestingly, the novel inhibitor of tryptophan hydroxylase, telotristat has been described as 
an effective therapeutic option for serotonin release control [60]. The use of telotristat has 
been recently approved by the European Commission and the Food and Drug Administra-
tion [61]. Decreased urinary 5-hydroxyindoleacetic acid and small bowel movements were 
reported in the TELESTAR [62] and TELECAST phase III clinical trials [63]. Surprisingly, 
despite its clinical use, to the best of our knowledge no pre-clinical data exist in which the 
in vitro effect of this novel drug in NET has been tested. In this sense, the first report of the 
in vitro effects of telotristat is presented in chapter 7 of this thesis. According to our in vitro 
model, a dose-dependent decreased serotonin release was observed. Importantly, the effects 
were achieved with clinically relevant concentrations, without concomitant cytotoxic effects 
or changes in the molecular expression of SSTs. Remarkably, serotonin has been described 
as a potent mitogen in different cell types [64]. However, in the evaluated pancreas NET 
3D culture model, no effect on cell growth was observed, whereas serotonin secretion was 
totally suppressed. These data suggest that these cells may not respond to a direct paracrine/
autocrine effect of serotonin on cell proliferation. On the other hand, serotonin might influ-
ence tumor growth via an interaction with the tumor microenvironment as well. Finally, we 
unexpectedly observed a slightly decreased effectiveness of the combination therapy with 
octreotide in BON-1 cells. This finding requires further investigation because of its implica-
tion in the clinical practice.
Importantly, in the studies presented in chapter 6 and 7 of this thesis, we used a PNET 
model for studying serotonin secretion in NETs, whereas an ideal model might be a midgut 
cell line. Unfortunately, midgut NET cell lines are not widely available. A recent study 
showed that of seven established NET cell lines, only the small intestine NET lines GOT-1, 
P-STS and the PNET lines BON-1 and QGP-1 display a neuroendocrine phenotype, as 
well as disease-characteristic mutations. Other cell lines were identified as lymphoblastoid 
(e.g. KRJ-1) [65]. Unfortunately, the GOT-1 and P-STS cell lines were not available in our 
laboratory to confirm our findings in a midgut-NET model. Finally, it will be important 
to evaluate the effects of SSTs/D2R chimeric drugs, as well as telotristat, in NET primary 
cultures.
Ketoconazole
It is important to recognize that some drugs that are prescribed for other medical purposes 
may have some direct or indirect effects for tumor control. Their combination with SSAs 
would represent a valuable method for increasing the antitumor effects or even to control 
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hormone secretion. In this sense, previous reports of the cytotoxic effect of ketoconazole in 
cancer [66] were confirmed in chapter 5 using a lung- and pancreas model of adrenocorti-
cotropin- (ACTH)-producing and non-ACTH producing NET cells, respectively. In these 
two NET models, ketoconazole may exert its action following different mechanisms includ-
ing apoptosis induction, cell toxicity and decreased cell division. The cell growth inhibitory 
effects observed in our study suggest that a direct antitumor action of ketoconazole may 
be involved in the sustained effect achieved with this drug [67]. Despite some effects of 
ketoconazole were reached with clinically relevant concentrations, its use in non-ACTH 
producing tumors is controversial and requires further studies.
Metformin and statins
It is well-known that the inflammation and insulin resistance observed in patients with 
type 2 diabetes (T2-DM) or metabolic syndrome are associated with increased incidence 
of neoplasms [68]. Thus, targeting related pathways may represent appropriate therapeutic 
options in some types of cancer. Based on this, the putative antitumor effects of biguanides 
and statins in NET were described in chapter 8. Biguanides stimulate AMP-activated protein 
kinase (AMPK), which induces cell cycle arrest, reduces the insulin/insulin growth factor 1 
(IGF-1) signaling [69, 70] and, additionally, suppresses the mammalian target of rapamycin 
(mTOR1) which is a key regulator of cell proliferation in cancer cells [71, 72]. For this 
reason, the biguanide metformin has been evaluated in multiple in vitro and in vivo studies 
[73] and is now being tested in registered clinical trials in NETs in combination with lan-
reotide (NCT02823691) in well-differentiated gastrointestinal or lung NETs. Interestingly, 
those clinical variables that in our cohort were related to metabolic syndrome were reversed 
when treated with metformin. In addition, the inverse expression of somatostatin and ghrelin 
systems when diabetic patients were treated with metformin, suggests that this drug may 
exert an additive effect for tumor control since it improves the expression of SSTs and may 
therefore potentiate the effects of SSAs. Although preliminary, these results are encouraging 
and allow to hypothesize that the effect of metformin, as an adjuvant therapy to classic thera-
peutic regimens, should be evaluated in appropriately designed prospective clinical studies.
Statins may also have additional anti-tumor effects, including induced cell-cycle arrest, 
apoptosis induction, decreased invasion/metastasis capacity and decreased Ki67 expression 
[74-78]. Our in vitro results are concordant with previous reports of the anti-proliferative 
effect of these drugs [79-81]. Despite this, in our cohort of patients, we did not observe a 
statistically significant effect of statins on clinical features of NET patients, but a higher 
proportion of disease-free patients was observed in this group. Importantly, the size of the 
cohort may have affected the significance of the results and unfortunately, there are no clini-
cal data available for comparing the effects of statins in NETs. To the best of our knowledge, 
no clinical trial for evaluating the effects of statins in NETs is currently registered.
9225
G
en
er
al
 D
isc
us
sio
n
Other future directions for diagnostic markers and treatment in NETs
Current circulating biomarkers for NETs have several limitations, especially in terms of 
sensitivity, specificity and reproducibility. To date, several prospective trials are evaluating 
the effect of novel therapeutic strategies in NETs (e.g. 90Y, 177Lu, Tyr octreotate, lenva-
tinib, palbociclib, tremelimumab, bevacizumab, temozolamide, pasireotide, PDR001), and 
most of them include the evaluation of treatment-related follow-up markers. Despite the 
advances in NET biomarkers in recent years, it is not possible yet to accurately predict 
treatment response and patient outcome. Additionally, the intrinsic heterogeneity of NETs, 
their variable behavior and prognosis complicates the identification of specific and reliable 
biomarkers to predict medical treatment response and patient prognosis.
Nowadays, several biomarkers for NETs are under study. Probably multianalyte measure-
ments based on genomics represent the most accurate system for early outcome stratification 
and decision making. The development of blood-based analysis and liquid biopsy may repre-
sent non-invasive methods for diagnosis and prognosis as well. Imaging techniques may also 
improve when combined with molecular markers, not only radiolabeled SSAs, but also pep-
tides, including the combination of glucose transporters/positron emission tomography for 
in vivo imaging. Circulating tumor cells, miRNAs, cytokines and gene transcripts represent 
putative novel biomarkers that could predict clinical outcome and response to treatment. 
Genomics will probably become the basis for developing multitranscript biomarkers, their 
combination would provide multifaceted information, may offer better medical manage-
ment and may improve the use of resources in order to improve diagnosis, treatment, quality 
of life and survival in NET patients [1].
Medical treatment options in NETs have significantly increased and improved in the last 
years. Despite this, some patients may not respond or develop treatment resistance. In these 
cases, more therapeutic options that allow a personalized management would be useful. A 
higher number of clinical trials and approved therapeutic agents facilitate the management 
of patients. As a consequence, a treatment sequence should be established taken into account 
response rate, improvements in progression-free survival and overall survival. To this aim, 
head to head studies would help to identify the best therapeutic options in specific cases. 
Importantly, overall survival in NETs has improved despite an increased incidence of these 
tumors, which may be related to the advances in tumor diagnosis and treatment. However, 
tumor heterogeneity as well as several aspects of the biologic, genetic and molecular back-
ground in NETs are still unknown and require further investigation. For this reason, it is 
needed to determine novel therapeutic targets that could improve the medical management 
of hormone-related syndromes and the antiproliferative treatment in NETs. Novel medi-
cal options and treatment combinations will be available in the upcoming years. Although 
preliminary results of clinical trials and in vitro models are encouraging, large longitudinal 
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randomized studies are still required to provide accurate evidence of their effect on survival 
and symptom control.
Targeting signaling and immune pathways involved in NETs development and progression 
has provided novel therapeutic options for these tumors. Immunotherapy is probably one 
of the most interesting fields that will be evaluated in NETs in the upcoming years. Despite 
immunotherapy has an important role in the management of other types of cancer, the effect 
on well-differentiated NETs according to preliminary data seems to be limited, but it may 
have a role in neuroendocrine carcinomas. Several clinical trials in this field are ongoing and 
hopefully in the upcoming years, some results about their real clinical applicability in NETs 
will be available.
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Neuroendocrine tumors (NETs) represent a heterogeneous group of rare, slow-growing neo-
plasms, originating from enterochromaffin cells. Their annual incidence has progressively 
increased, although it is not known whether this is a true increase in NET incidence, the 
result of increased use of (improved) diagnostic procedures, or a combination of both. While 
metastatic disease is frequently observed at diagnosis, survival in NET patients has increased, 
which may be related to the advances in diagnostic and therapeutic procedures. NETs 
require appropriate standardized diagnostic procedures to assure early diagnosis, monitor 
disease progression and guide an optimal treatment. Additionally, medical treatment options 
in NETs have significantly increased and improved in the last years. This thesis evaluates a 
number of novel diagnostic and therapeutic options for patients with NET.
Chapter 1 provides a general overview about NETs, emphasizes the applicability and limita-
tions of the current diagnostic biomarkers and summarizes some putative novel biomarkers 
in NETs. At the same time, this chapter describes current and novel therapeutic options 
for functioning a non-functioning NETs. The chapter introduces the main content of this 
thesis: novel diagnostic and therapeutic options for NETs. Chapter 1 ends with an overview 
of the main aims of this thesis.
Chapter 2 comprehensively evaluates the expression of several components of the soma-
tostatin/cortistatin and ghrelin systems in a large series of well-characterized typical and 
atypical lung carcinoids. To the best of our knowledge, this study represents the first sys-
tematic characterization of the components of these regulatory systems in samples from 
lung carcinoids (LCs), in which a comparison is made with adjacent non-tumor regions 
and normal lung tissue. In this study, we observed that the expression of somatostatin, of 
some receptor subtypes (SSTs), and of the ghrelin receptor GHSR gradually increases from 
normal to non-tumoral adjacent and tumor tissue. Moreover, the presence of the truncated 
isoforms SST5TMD4, In1-ghrelin and the ghrelin receptor GHSR1b are first reported in 
LCs. Higher expression levels of ghrelin-O-acyltransferase (GOAT) were observed in tumors 
with necrosis, which were tumors with a larger size and higher capacity of peritumoral inva-
sion and distant metastasis. These data suggest that a dysregulation of ghrelin system may be 
involved in the development/progression of these tumors.
Chapter 3 evaluates the expression of the somatostatin/cortistatin system components 
in gastroenteropancreatic- (GEP-) NETs. The observed overexpression of SST5 in tumor 
tissue compared to adjacent non-tumor and normal tissue, as well as its clinical relation 
with vascular and nerve invasion suggests the putative role of SST5 as a target for treating 
aggressive GEP-NETs. Furthermore, it emphasizes that the evaluation of SSTs profile in 
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GEP-NETs may provide additional information for clinical decision making, including the 
use of second-generation somatostatin analogs (SSAs).
The most novel and relevant finding of chapter 4 is the marked overexpression of GOAT 
in GEP-NET samples. Whereas the expression of this enzyme is almost absent in the 
corresponding normal tissues, it is present in adjacent non-tumoral tissue and notably 
overexpressed tumor tissues. Additionally, its overexpression was demonstrated using im-
munohistochemistry. Importantly, this enzyme was associated to larger tumors, especially in 
gastrointestinal-NETs. These findings, in combination with previous publications, suggest a 
putative role of GOAT as a diagnostic biomarker in GEP-NETs.
Chapter 5 evaluates the effect of ketoconazole on proliferation, cell cycle, apoptosis and 
secretion of adrenocorticotropic hormone (ACTH) or serotonin and chromogranin in an 
ACTH-producing bronchial NET and a non-ACTH producing pancreatic NET cell line, 
respectively. Ketoconazole exerted a predominant pro-apoptotic or cytotoxic effect, depend-
ing on the cell line. Additionally, ketoconazole induced changes in the cell cycle progression, 
e.g. it increases G0/G1 phase in both cell lines and an arrest in G2/M phase in the pancreatic 
NET cell line. Furthermore, a non-previously reported inhibitory effect of the SSA pasire-
otide on serotonin secretion by pancreatic NET cells was reported, which is probably related 
to the predominant SST5 expression in this cell line.
In chapter 6, a comprehensive characterization of two pancreatic NET models was per-
formed using two- (2D; monolayer) and three- dimensional (3D; spheroids) culture systems 
in different medium conditions. According to our results, NET 3D spheroid cultures 
represent a promising method for evaluating cell proliferation and secretion in NET cell 
lines, even in serum-deprived conditions. A non-previously reported dynamic expression 
of SSTs and dopamine receptor (D2R) was observed during growth of both 2D and 3D 
cultures. The effects of the somatostatin analog octreotide, the dopamine agonist cabergoline 
and of two novel SSTs-D2R multi-receptor targeting drugs (BIM-065, BIM-23A760) were 
evaluated using both culture systems. Cabergoline and SSTs-D2R multi-receptor targeting 
drugs, but not octreotide, inhibited CgA and serotonin secretion, but not NET cell growth. 
This suggests that the effect of the SSTs-D2R multi-receptor targeting drugs on secretion is 
mediated by D2R, and may indicate a putative role of dopamine agonists for treating D2R 
expressing functioning NETs, including carcinoid syndrome.
Chapter 7 shows the in vitro effects of the novel tryptophan hydoxylase inhibitor telotristat 
on pancreatic NET cells. Telotristat potently inhibited serotonin release in a dose-dependent 
manner at a clinically feasible concentration. Its combination with pasireotide, but not with 
octreotide, had an additive effect on serotonin secretion. In 3D cultured pancreatic NET 
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cells, serotonin secretion was completely blocked by telotristat, whereas this drug did not 
influence cell growth. These data suggest that serotonin has no autocrine/paracrine effect on 
cell growth in this 3D PNET model.
In chapter 8 decreased expression of SSTs was observed in tumor tissue of GEP-NET 
patients with type 2 diabetes, compared to non-diabetic GEP-NET patients. This decreased 
expression was not observed in type 2 diabetic patients that were treated with metformin. 
The in vitro experiments showed an antiproliferative effect of biguanides and statins in NET 
cell lines, with consequent increased apoptosis and decreased cell migration. Since metfor-
min and statins are low cost commercially available drugs, with a large experience in their 
clinical use, they may represent putative options for adjuvant therapy in NETs.
In chapter 9, the results and conclusions of the studies included in this thesis, are discussed 
in relation to current and possible novel future diagnostic modalities, as well as therapeutic 
options for NET patients.
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SAMENVATTING
Neuroendocriene tumoren (NET) vormen een heterogene groep van zeldzaam voorko-
mende, langzaam groeiende tumoren. NET ontstaan vanuit enterochromaffine cellen. De 
jaarlijkse incidentie van NET is progressief toegenomen in de afgelopen jaren. Het is echter 
niet duidelijk of deze toename in incidentie een werkelijke toename is, veroorzaakt wordt 
door verbeterde diagnostische procedures, of door een combinatie van beiden. Hoewel 
NET vaak al gemetastaseerd blijken te zijn bij de diagnose, is de gemiddelde overleving 
van patiënten met NET toegenomen. Dit is waarschijnlijk toe te schrijven aan verbeterde 
diagnostiek en toegenomen therapeutische mogelijkheden. Er zijn goede en gestandaardi-
seerde diagnostische procedures nodig om patiënten met een NET in een zo vroeg mogelijk 
stadium te diagnosticeren, om het beloop van de ziekte nauwlettend te vervolgen en om 
deze patiënten een optimale behandeling te kunnen geven. In de afgelopen jaren is het 
aantal medicamenteuze behandelingsmogelijkheden voor patiënten met een NET sterk 
toegenomen. In dit proefschrift worden een aantal studies beschreven die betrekking hebben 
op diagnostische en therapeutische mogelijkheden voor NET patiënten.
Hoofdstuk 1 betreft een algemene inleiding over NET en benadrukt de toepassing en 
beperkingen van de huidige diagnostische procedures voor patiënten met NET. Er wordt 
een overzicht gegeven van een aantal mogelijk nieuwe diagnostische (bio)merkers. In dit 
hoofdstuk worden tevens huidige en nieuwe behandelingsmogelijkheden voor functionele 
en niet-functionele NET besproken. Dit hoofdstuk vormt de inleiding voor het onderwerp 
van dit proefschrift, n.l. nieuwe diagnostische en therapeutische mogelijkheden voor patiën-
ten met NET. Hoofdstuk 1 wordt afgesloten met een overzicht van de doelstellingen van het 
onderzoek van het proefschrift.
In het onderzoek beschreven in hoofdstuk 2 is de expressie van verschillende componenten 
van het somatostatine/cortistatine en het ghrelin systeem onderzocht in een grote serie van 
goed gekarakteriseerde typische en atypische long carcinoiden (LC). Voor zover bekend is dit 
de eerste studie waarin beide systemen tegelijkertijd worden onderzocht in LC weefsels. Het 
onderzoek toont aan dat de expressie van somatostatine, van enkele somatostatine receptor 
subtypen (SSTs), en van de ghrelin receptor GHSR, gradueel toeneemt van normaal naar 
niet tumor-aangrenzend weefsel en tumor weefsel. Bovendien werd voor de eerste keer in 
LC expressie aangetoond van de korte iso-vormen SST5TMD4, In1-ghrelin en de ghrelin 
receptor GHSR1b. Hogere expressie van ghrelin-O-acetyltrasferase (GOAT) werd gevonden 
in tumoren met necrose, grotere tumoren met meer peritumorale invasie en metastasen op 
afstand. Deze bevindingen suggereren dat een ontregelde regulatie van het ghrelin systeem 
betrokken zou kunnen zijn bij de ontwikkeling/progressie van de tumoren.
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In hoofdstuk 3 wordt onderzoek naar de expressie van componenten van het somatostatine/
cortistatine systeem in gastroenteropancreatische- (GEP-) NET beschreven. De gevonden 
hogere expressie van SST5 in tumor weefsel in vergelijking met tumor-aangrenzend en met 
normaal weefsel, en de klinische relatie van SST5 expressie met vasculaire- en zenuw invasie, 
suggereert dat SST5 een mogelijk doelwit is om agressieve GEP-NET te behandelen. Boven-
dien kan de evaluatie van het SSTs profiel in GEP-NET aanvullende informatie opleveren 
die mogelijk gebruikt kan worden bij klinische besluitvorming, waaronder het gebruik van 
een tweede generatie somatostatine analogen (SSA).
De meest nieuwe en relevante bevinding van het onderzoek beschreven in hoofdstuk 4 is de 
duidelijke overexpressie van GOAT in GEP-NET weefsel. Terwijl de expressie van dit enzym 
vrijwel afwezig is in bijbehorend normaal weefsel, wordt expressie gevonden in aangrenzend 
niet-tumor weefsel en is expressie van GOAT met name aanwezig in tumor weefsel. De 
hogere expressie van GOAT in GEP-NET weefsel werd tevens aangetoond met behulp van 
immunohistochemie. Hoge expressie van dit enzym was geassocieerd met grotere tumoren 
en voornamelijk in gastro-intestinale NET. Deze bevindingen, tezamen met eerdere publica-
ties, suggereren dat GOAT een mogelijke diagnostische biomerker is in GEP-NET.
Hoofdstuk 5 beschrijft onderzoek naar de effecten van het geneesmiddel ketoconazol op 
de groei, cel cyclus, apoptose en afgifte van ACTH of serotonine en chromogranine in 
respectievelijk een ACTH-producerende long NET cellijn en een niet-ACTH producerende 
pancreas NET cellijn. Ketoconazol heeft een voornamelijk pro-apoptotisch of cytotoxisch 
effect, afhankelijk van het type cellijn. Bovendien zorgt behandeling met ketoconazol voor 
veranderingen in celcyclus, namelijk een toename in G0/G1 fase in beide cellijnen en een af-
name in G2/M fase in de pancreas NET cellijn. Bovendien tonen de resultaten in hoofdstuk 
5 een niet eerder gerapporteerd remmend effect aan van het SSA pasireotide op serotonine 
afgifte van de pancreas NET cellijn. Dit effect wordt waarschijnlijk gemedieerd via de hoge 
SST5 expressie in deze cellijn.
Het onderzoek in hoofdstuk 6 beschrijft een uitgebreide karakterisering van twee pan-
creas NET modellen in tweedimensionale (monolayer) en driedimensionale (sferoïden) 
kweeksystemen, in verschillende kweekmedium condities. Op basis van de resultaten van 
dit onderzoek wordt geconcludeerd dat een driedimensionaal (sferoïde) kweeksysteem een 
veelbelovend systeem is om groei en hormoon secretie van NET cellijnen te bestuderen, zelfs 
onder serum arme kweekcondities. In dit onderzoek wordt tevens aangetoond dat de expres-
sie van SSTs en de dopamine D2 receptor (D2R) verandert tijdens de groei van cellen, zowel 
in twee- als driedimensionale kweken. De effecten van het somatostatine analoog octreotide, 
de dopamine agonist cabergoline en van twee nieuwe SSTs-D2R bindende geneesmiddelen 
(BIM-065 en BIM-23A760) werden onderzocht in de twee kweeksystemen. Cabergoline en 
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de twee SSTs-D2R multi-receptor bindende geneesmiddelen, en niet octreotide, hadden een 
remmend effect op de afgifte van chromogranine en serotonine, maar niet op de celgroei. De 
bevindingen suggereren dat het effect van de twee SSTs-D2R bindende geneesmiddelen op 
de afgifte van hormonen in dit pancreas NET model verloopt via de D2R, en een mogelijke 
rol voor dopamine agonisten bij de behandeling van D2R-bevattende functionele NET, 
waaronder het carcinoid syndroom.
Hoofdstuk 7 beschrijft onderzoek naar de in vitro effecten van de nieuwe tryptofaan 
hydroxylase remmer telotristat op pancreas NET cellen. Telotristat remt krachtig en dosis-
afhankelijk de serotonine afgifte, bij klinisch relevante concentraties. De combinatie met 
pasireotide, maar niet met octreotide, had een aanvullend remmend effect op de serotonine 
afgifte. In driedimensionaal gekweekte pancreas NET cellen kon de serotonine afgifte vol-
ledig worden geremd door telotristat, maar was er geen effect op de celgroei. Deze resultaten 
tonen aan dat serotonine in dit pancreas NET model geen autocrien/paracrien effect heeft 
op de celgroei.
Het onderzoek in hoofdstuk 8 toont dat de SSTs expressie in GEP-NET weefsel van patiën-
ten met type 2 diabetes verlaagd is ten opzichte van GEP-NET weefsel van patiënten zonder 
diabetes. In type 2 diabetes patiënten die behandeld werden met metformine werd deze 
verlaging in SSTs expressie niet gevonden. In vitro experimenten toonden groei remmende 
effecten van biguanides en statines aan op NET cellijnen, met een toegenomen apoptose en 
afgenomen migratie van de cellen. Aangezien metformine en statines commercieel verkrijg-
bare en relatief goedkope geneesmiddelen zijn en er een langdurige ervaring is in het gebruik 
ervan, kunnen deze geneesmiddelen mogelijk van aanvullende waarde zijn bij de adjuvante 
behandeling van patiënten met NET.
In hoofdstuk 9 worden de resultaten en conclusies van de studies uit dit proefschrift 
bediscussieerd in relatie tot huidige en mogelijk nieuwe toekomstige diagnostische en thera-
peutische mogelijkheden voor patiënten met een NET.
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RESUMEN
Los tumores neuroendocrinos (NETs) son un grupo heterogéneo de neoplasias poco co-
munes, caracterizadas por un lento crecimiento y que se originan a partir de las células 
enterocromafines. Su incidencia anual viene aumentando progresivamente, aunque se des-
conoce si éste incremento es real, el reflejo de mayor uso de (mejores) técnicas diagnosticas 
o una combinación de ambas. A pesar de que frecuentemente los NETs tienen metástasis al 
diagnóstico, la supervivencia en estos pacientes ha aumentado, lo cual puede relacionarse con 
mejoras en las opciones diagnósticas y terapéuticas disponibles. Los NETs requieren métodos 
diagnósticos estandarizados para asegurar un diagnóstico precoz, así como para monitorizar 
la progresión de la enfermedad y orientar un tratamiento óptimo. Adicionalmente, el núme-
ro y la calidad de las opciones terapéuticas se ha incrementado en los últimos años. En este 
sentido, esta tesis evalúa algunas nuevas opciones diagnósticas y terapéuticas para pacientes 
con NETs. El capítulo 1 ofrece una visión general sobre los NETs, y se centra en la utilidad/
limitaciones de los biomarcadores actualmente disponibles, así como en la descripción de 
algunos nuevos (posibles) marcadores en NETs. Además, resume opciones terapéuticas para 
tumores neuroendocrinos funcionantes y no funcionantes, tanto aquellas nuevas como las 
actualmente disponibles. Este capítulo representa la introducción al contenido fundamental 
de esta tesis: nuevos marcadores diagnósticos y opciones terapéuticas en NETs. El capítulo 1 
termina con una visión general de los objetivos generales de esta tesis.
El capítulo 2 evalúa detalladamente la expresión de algunos componentes de los sistemas 
somatostatina/cortistatina y ghrelina en una seria amplia, bien caracterizada, de carcinoides 
pulmonares típicos y atípicos. Hasta donde sabemos, este estudio representa la primera ca-
racterización sistemática de los componentes de estos sistemas reguladores en muestras de 
carcinoides pulmonares (LCs), tejido adyacente no tumoral y pulmón sano. En este estudio, 
la expresión de somatostatina, de algunos de sus receptores (SSTs) y del receptor de ghrelina se 
incrementó gradualmente en el tejido no tumoral adyacente y en el tejido tumoral en compara-
ción a pulmón normal. Además, la presencia de isoformas truncadas SST5TMD4, In1-ghrelin 
y el receptor de ghrelina GHSR1b fue reportada por primeras vez en LCs. Asimismo, una 
expresión aumentada de la enzima ghrelin-O-aciltransferasa (GOAT) se observó en tumores 
con necrosis, los cuales (a su vez) fueron aquellos con mayor tamaño, mayor capacidad de 
invasión y de producir metástasis a distancia. Estos datos sugieren que una desregulación del 
sistema ghrelina puede estar involucrada en el desarrollo/progresión de estos tumores.
El capítulo 3 discute específicamente la expresión de componentes de los sistemas somatos-
tatina/cortistatina en tumorres gastroenteropancreáticos (GEP-NETs). La sobre-expresión 
observada de SST5 en el tejido tumoral comparado con el tejido adyacente no tumoral y 
el control sano, así como su relación clínica con la invasión vascular y nerviosa del tumor, 
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sugieren un probable rol del SST5 como diana terapéutica en GEP-NETs agresivos, además, 
enfatiza la importancia de evaluar el perfil de SSTs en GEP-NETs, el cual aportaría informa-
ción adicional para la toma de decisiones terapéuticas, incluida la utilización de análogos de 
somatostatina (SSAs) de segunda generación.
El hallazgo más novedoso y relevante del capítulo 4 es la marcada sobre-expresión de la enzi-
ma GOAT en muestras de GEP-NETs. Específicamente, cuando la expresión de esta enzima 
es prácticamente ausente en tejido normal, ésta se observó en tejido adyacente no tumoral 
y se sobre-expresó en tejido tumoral, una sobre-expresión que fue confirmada utilizando 
inmunohistoquímica. Asimismo, esta enzima se asoció con tumores de mayor tamaño, 
especialmente en NETs gastrointestinales. Estos hallazgos, combinados con publicaciones 
previas, sugieren el posible papel de la enzima GOAT como un biomarcador en NETs.
El capítulo 5 describe los efectos de ketoconazol en la proliferación, ciclo celular, apoptosis, 
secreción de adrenocorticotropina (ACTH) o serotonina y cromogranina en una línea celular 
de NET bronquial productora de ACTH y una línea celular de NET pancreático no pro-
ductora de ACTH. Específicamente, ketoconazol mostró características predominantemente 
pro-apoptóticas o citotóxicas dependiendo de la línea celular; estos efectos se mantuvieron a 
pesar de la combinación con SSAs. Además, ketoconazol fue capaz de inducir cambios en el 
ciclo celular, específicamente el aumento de las fases G0/G1 en ambas líneas celulares y una 
disminución de las fases G2/M en la línea celular pancreática. Incluso se observó un efecto 
inhibitorio en la secreción de serotonina del análogo de somatostatina pasireotide en la línea 
celular pancreática, el cual no había sido previamente descrito y que probablemente se debe 
a la expresión de SST5 en esta línea celular.
En el capítulo 6 se caracteriza de forma detallada un modelo de líneas celulares pancreáticas 
utilizando sistemas de cultivo en dos- (2D; monolayer) y tres- dimensiones (3D; esferoides) 
en diferentes condiciones de nutrientes. Al analizar los resultados, se observa que los cultivos 
en 3D con esferoides representan un método valioso para evaluar la secreción y proliferación 
celular en líneas celulares de NETs, incluso en condiciones con deprivación de suero. Se 
observó una expresión dinámica de los SSTs y receptor de dopamina (D2R) en los sistemas 
de cultivo en 2D y 3D, lo cual no se había descrito previamente. En este capítulo, los efectos 
del análogo de somatostatina octreotide y el agonista de dopamina cabergolina, así como de 
los nuevos fármacos quimera SSTs-D2R (BIM-065, BIM-23A760) se evaluaron en ambos 
modelos de cultivo. El tratamiento con cabergolina y ambas quimeras inhibió la secreción de 
cromogranina A y serotonina, pero no la proliferación celular. Esto sugiere que el efecto de 
las quimeras en la secreción parece estar mediado por el D2R, sugiriendo un posible papel de 
los agonistas de cabergolina para el tratamiento de NETs funcionantes, incluido el síndrome 
carcinoide, siempre y cuando expresen D2R.
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El capítulo 7 muestra los efectos in vitro de telotristat etiprate, un nuevo inhibidor de la 
enzima hidroxilasa de triptófano en líneas celulares pancreáticas. Este fármaco mostró un 
potente efecto en la inhibición de la secreción de serotonina, el cual fue dependiente de 
dosis en un modelo de células pancreáticas de NETs. Su combinación con pasireotide, pero 
no con octreotide, tuvo un efecto aditivo en el control de la secreción de serotonina. En el 
modelo 3D de NET pancreático, la secreción de serotonina fue totalmente inhibida por 
telotristat, sin embargo, este bloqueo no produjo cambios en el crecimiento celular. Estos 
datos sugieren que la serotonina no ejerce un efecto autocrino/paracrino en la proliferación 
celular en este modelo 3D de NET pancreático.
En el capítulo 8 se observó una expresión disminuida de SSTs en pacientes con diabetes tipo 
2 y GEP-NETs comparado con pacientes con GEP-NETs pero sin diabetes. Esta expresión 
disminuida no se observó cuando los pacientes diabéticos fueron tratados con metformina. 
Los estudios in vitro demostraron el efecto anti-proliferativo de las biguanidas y estatinas en 
líneas celulares de NETs, con el consiguiente incremento de la apoptosis y disminución de 
la migración celular. Puesto que la metformina y las estatinas son fármacos comercialmente 
disponibles, económicos y con una amplia experiencia en su uso, nuestros resultados sugie-
ren que estos fármacos podrían representar una opción terapéutica factible como terapia 
adyuvante en NETs.
Finalmente, en el capítulo 9 se discuten los resultados y conclusiones de los estudios pre-
sentados en esta tesis, especialmente en relación a las modalidades diagnósticas y opciones 
terapéuticas, tanto actuales como futuras, para los pacientes con NETs.

Appendices
PhD Portfolio
List of publications
About the author
Acknowledgements

247
Ph
D
 P
or
tfo
lio
PhD PORTFOLIO
Erasmus MC Department Internal Medicine- Section of Endocrinology
Reina Sofia UH Department Endocrinology and Nutrition Unit
Research School Molmed
 Maimonides Institute of Biomedical research
Research Period 2014-2018
Promotors Leo J. Hofland/Justo P. Castaño
Co-promotors Richard A. Feelders/María Angeles Gálvez
Erasmus General Academic Courses year Workload
(ECTS)
The Introduction in GraphPad Prism Version 6 2018 0.3
Workshop on Microsoft Access 2010: Advanced 2018 0.3
Workshop on Microsoft Access 2010: Basic 2018 0.3
Course Bayesians statistics and JASP 2018 0.3
Biomedical English Writing Course for MSc and PhD-students 2018 2.0
Microscopic Image Analysis: From Theory to Practice 2018 0.8
Workshop Writing Successful Grant Proposals 2017 0.5
Research Integrity 2017 0.3
Clinical Courses and meetings year Workload 
(ECTS)
Post-graduate course 15th Annual Conference for diagnosis and treatment of 
neuroendocrine tumor disease. European Neuroendocrine Tumor Society
2018 5
Course in systematic reviews and metaanalysis. Reina Sofia University Hospital. 
Maimonides Institute of Biomedical Research
2017 4.5
Problems and solutions for treating osteoporosis. Spanish Society of the Bone and 
Mineral Research
2017
Clinical scenarios for type 2 diabetes. Córdoba Medical College 2017 0.4
Pre-conference course 14th Annual Conference for diagnosis and treatment of 
neuroendocrine tumor disease. European Neuroendocrine Tumor Society
2017 3
Course in Clinical Nutrition. Andalusian Society of Endocrinology, Diabetes and 
Nutrition
I meeting for heart and diabetes. Andalusian Society of Endocrinology, Diabetes and 
Nutrition
2017 0.6
IX meeting in neuroendocrinology. Spanish Society of Endocrinology and Nutrition 2017
Update course in diabetes. Andalusian Health Board 2016 2
Pre-conference course in neuroendocrinology. Andalusian Society of Endocrinology, 
Diabetes and Nutrition
2016
Mellanby centre Training Course in osteoporosis. Spanish Society of the Bone and 
Mineral Research
2016 0.8
248
Ph
D
 P
or
tfo
lio
Actuality in Osteoporosis Spanish Society of the Bone and Mineral Research 2016 0.6
XXI update course in neuroendocrinology and nutrition. Spanish Society of 
Endocrinology and Nutrition
2016 2
XVII advanced course in diabetes. Spanish Society of Endocrinology and Nutrition 2016
Appropriate use of antimicrobials. Andalusian Health Board 2015 1
Update in enteral nutrition. Reina Sofia University Hospital 2015
Translational research in rare diseases. Maimonides Institute of Biomedical Research 2015 0.8
Pre-conference course in thyroid cancer. Andalusian Society of Endocrinology, Diabetes 
and Nutrition
2015
XXI update in clinical nutrition. Spanish Society of Endocrinology and Nutrition 2015
Diabetes Live. Attention to the patient with diabetes 0.5
Cardiovascu.ar health in diabetic patients with enteral nutrition 2015 0.8
Course of thyroid ultrasound for endocrinologists. Reina Sofia University Hospital 2015 0.6
Course of diagnostic and therapeutic neck ultrasound. Reina Sofia University 
Hospital. Andalusian Health Board
2015 1
Diabetes live! Patients with Diabetes. Andalusian Health Board 2015 6.88
III course in scientific divulgation. University of Córdoba 2015 1
Pre-conference course in thyroid ultrasound. Andalusian Society of Endocrinology, 
Diabetes and Nutrition
Nutritional support in elderly. Spanish Society of Enteral and Parenteral Nutrition 2014 4.2
III course in neuroendocrinology. Andalusian Society of Endocrinology, Diabetes and 
Nutrition
2014 1.82
Management of the diabetic patient in the hospital and after the delivery. Andalusian 
Health Board
2014 0.57
8th update course in Diabetes. Reina Sofia University Hospital 2014 2
Update in Osteoporosis. Reina Sofia University Hospital 2014 0.4
Conferences oral/poster presentations year
Type 2 diabetes in neuroendocrine tumors: are biguanides and statins part of the 
solution?
18th Congress of the European Neuroendocrine Association.
2018
Hyperlipidemia during gestational diabetes: maternal and offspring complications.
20th European Congress of Endocrinology.
2018
Utility of 3D cell culture systems with spheroids in neuroendocrine tumors.
20th European Congress of Endocrinology.
2018
Effects of multi-receptor targeting drugs in neuroendocrine tumors using 3D cell 
culture.
15th congress of the European Neuroendocrine Tumor Society
2018
Potential effects of ketoconazole on ACTH-producing and non- ACTH-producing 
neuroendocrine tumors.
15th congress of the European Neuroendocrine Tumor Society.
2018
249
Ph
D
 P
or
tfo
lio
Ghrelin O-acyltransferase (GOAT) enzyme and ghrelin receptor GHSR1a as putative 
prognosis markers and therapeutic targets in gastroenteropancreatic neuroendocrine 
tumors.
15th congress of the European Neuroendocrine Tumor Society.
2018
Effects of ketoconazole on ACTH-producing and non ACTH-producing 
neuroendocrine tumor cells.
19th European Congress of Endocrinology.
2017
Potential anti-tumor activity of biguanides and statins in neuroendocrine tumor cells.
14th European Neuroendocrine Tumor Society Conference.
2017
Planning for pregnancy in type 1 diabetes
XXVIII conference of the Spanish Diabetes Society
2017
Muscular area by computed tomography in liver transplant patients
IX National Conference for the Clinical Assistance of the Chronic Patient of the Spanish 
Society of Internal Medicine
2017
Role of the computed tomography in the evaluation of the body composition in liver 
transplant patients
XIX conference of the Spanish Society of Musculoskeletal Radiology
2017
Components of Splicing Machinery are Drastically Dysregulated on Neuroendocrine 
Tumors and Associated with Malignancy.
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Radiation and chemotherapy side effects in patients with head-neck tumors receiving 
early nutrition support therapy.
38th Conference of the European Society of Parenteral and Enteral Nutrition
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